Mechanisms of exercise intolerance in chronic heart failure

and type 2 diabetes mellitus by Garnham, Jack Oliver
 
 
Mechanisms of exercise intolerance in chronic heart failure 
and type 2 diabetes mellitus 
 
 
Jack Oliver Garnham 
 
 
 
Submitted in accordance with the requirements for the degree of 
Doctor of Philosophy 
 
 
The University of Leeds 
Faculty of Medicine and Health 
School of Medicine 
Leeds Institute of Cardiovascular and Metabolic Medicine 
 
 
 
 
September 2018 
ii 
 
The candidate confirms that the work submitted is his own, except where work 
which has formed part of jointly-authored publications has been included. The 
contribution of the candidate and the other authors to this work has been 
explicitly indicated below. The candidate confirms that appropriate credit has 
been given within the thesis where reference has been made to the work of 
others.  
 
Manuscripts arising from this thesis: 
Gierula J, Paton MF, Lowry JE, Jamil HA, Byrom R, Drozd M, Garnham JO, 
Cubbon RM, Cairns DA, Kearney MT & Witte KK (2018). Rate-response 
programming tailored to the force-frequency relationship improves exercise 
tolerance in chronic heart failure. JACC Heart Fail, 6(2), 105-113.  
 
Ferguson C, Birch KM, Garnham JO & Witte KK (2017). Exercise training: The 
under developed elixir vitae of chronic disease? Diab Vasc Dis Res, 14(2), 113-
115.  
 
Abstracts arising from this thesis: 
Garnham JO, Boyle JP, Roberts LD, Peers C, Kearney MT, Bowen TS & Witte 
KK (2018). Diabetic heart failure patients demonstrate a mitochondrial complex 
I dependent impairment in skeletal muscle. FASEB J, 32(S1): 903.10.  
 
iii 
 
Allen L, Jamil HA, Gierula J, Paton MF, Garnham JO, Kearney MT, Bowen TS 
& Witte KK (2015). Factors affecting exercise capacity in diabetic heart failure 
patients. Circulation, 132(S3): A19397.  
 
 
 
This copy has been supplied on the understanding that it is copyright material 
and that no quotation from the thesis may be published without proper 
acknowledgement. 
 
 
 
The right of Jack Oliver Garnham to be identified as Author of this work has been 
asserted by him in accordance with the Copyright, Designs and Patents Act 
1988.  
 
 
 
 
© 2018 The University of Leeds and Jack Garnham 
 
 
 
 
 
iv 
 
Acknowledgements 
First and foremost I wish to thank my primary supervisor Dr Klaus Witte for his 
unrelenting passion, enthusiasm, and commitment to both myself and this 
project. His inimitable ebullience has both inspired and motivated me throughout 
this PhD and I shall always be grateful for his persistent belief in my potential, 
which has flourished under his careful support and guidance. Furthermore his 
aphoristic musings on life have left an indelible mark on me and I believe that 
adopting a similar philosophy will allow me to successfully progress my career 
and develop further as an individual. I will always retain many fond memories of 
our times together in the “cath lab” and hope to maintain a close personal and 
professional relationship with him in the future.  
 
I wish to extend this gratitude to my three co-supervisors, Dr John Boyle, 
Professor Stuart Egginton, and Dr Scott Bowen, all of whom provided invaluable 
scientific insight throughout this project. Their input has successfully developed 
my research acumen, critical thinking skills, and scientific writing. I am 
particularly grateful for their patience, allowing me the time and freedom to 
develop my laboratory techniques at my own pace.  
 
Additionally, I wish to thank Professor David Beech and the Multidisciplinary 
Cardiovascular Research Centre (MCRC) within the Leeds Institute of 
Cardiovascular and Metabolic Medicine (LICAMM) for giving me the opportunity 
to undertake this PhD and funding me for four years. I wish to also thank both Dr 
Carrie Ferguson and Dr Lee Roberts, who have provided timely and appropriate 
feedback throughout this PhD. Furthermore I also acknowledge the support of 
v 
 
my fellow PhD students and colleagues, including Dr Roger Kissane, Dr John 
Gierula, Maria Paton, Judith Lowry, Dr Haqeel Jamil, and Dr Matthew Davies, 
amongst many others.  
 
I also sincerely thank the numerous staff working at Leeds General Infirmary 
(LGI) and within the Leeds Teaching Hospital Trust, including those in the 
Cardiovascular Clinical Research Facility. I would particularly like to thank those 
individuals that supervised the cardiopulmonary exercise tests and performed 
echocardiography assessments. I must also thank the ward sisters on LGI ward 
14, particularly Jennifer Leach, Val Wallis, and Alison Romaniw, who willingly 
assisted throughout this project. This thanks must also be extended to the 
numerous surgeons that assisted with biopsy sampling, including Dr Peter 
Swoboda, Dr Andrew Hogarth, Dr Alex Simms, and Dr Chris Pepper. A particular 
thanks must also be offered to Dr Richard Ferguson of Loughborough University, 
who guided us on sampling leg muscle biopsies from patients. Finally, I must 
also thank all of the patients, who bravely and willingly volunteered to participate 
in these studies. 
 
Last, but certainly not least, I wish to thank the endless support and 
encouragement from my parents, to whom I dedicate this thesis. Their unfaltering 
love has, and always will be, the impetus for my success.  
 
  
vi 
 
Abstract 
Chronic heart failure (CHF) and type 2 diabetes mellitus (DM) remain primary 
causes of mortality. Furthermore ~25-30% of CHF patients have DM, and these 
diabetic heart failure (D-HF) patients have an adverse prognosis. However, as 
yet, very few studies have examined the D-HF population in comparison to 
matching CHF, DM, and control patients. Therefore the current thesis described 
four experimental studies examining exercise intolerance and skeletal muscle 
abnormalities in these patient populations.  
 
The first study of this thesis employed a novel exercise test (RISE-95) to better 
evaluate exercise intolerance in CHF and D-HF patients. This study confirmed 
previous clinical findings indicating that D-HF patients have a lower peak 
pulmonary oxygen uptake (V̇O2peak). Furthermore this study also demonstrated 
that nearly half of the cohort acutely increased V̇O2peak, the mechanism of which 
may elucidate potential therapeutic targets.  
 
To examine potential mechanisms contributing to exercise intolerance, the 
second study investigated skeletal muscle mitochondrial function in chest muscle 
biopsies obtained from control, DM, CHF and D-HF patients. This study identified 
that D-HF patients exhibit both quantitative and qualitative mitochondrial 
impairments, with the latter residing at complex I. The next study corroborated 
these findings in leg biopsies from the same patients.  
 
vii 
 
The final study uncovered potential mechanisms possibly contributing to skeletal 
muscle mitochondrial impairments, including an increased mitochondrial reactive 
oxygen species (ROS) production and downregulated expression of key 
mitochondrial genes. Furthermore this study revealed that D-HF patients exhibit 
a type II fibre-specific atrophy and capillary rarefaction.  
 
Collectively, these studies expand our current knowledge regarding exercise 
intolerance in D-HF patients and how skeletal muscle impairments may 
contribute to the worse symptoms and outcomes seen in this growing population. 
The findings from this thesis are expected to guide future research endeavours, 
which may identify potential therapeutic targets by which exercise intolerance 
may be ameliorated in these patients.  
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Chapter 1 Introduction 
1.1 Prologue 
Chronic heart failure (CHF) and type 2 diabetes mellitus (DM) remain primary 
causes of morbidity and mortality despite recent advances in management and 
treatment. Aside from the debilitating human consequences, these conditions 
also impose a substantial burden on healthcare resources (estimated to be 
~$108 billion USD and ~$673 billion USD for CHF and DM, respectively) (Ziaeian 
& Fonarow, 2016; Zheng et al., 2018). A concerning trend to recently emerge is 
the increasing prevalence of DM within CHF patients (Lehrke & Marx, 2017), that 
shall henceforth be termed diabetic heart failure (D-HF). Several recent 
epidemiological studies have shown that ~25-30% of CHF patients secondary to 
left ventricular systolic dysfunction (LVSD) present with coexisting DM 
(MacDonald et al., 2008a; MacDonald et al., 2008b; Cubbon et al., 2013; van 
Deursen et al., 2014; Dei Cas et al., 2015; Seferovic et al., 2018). Importantly, 
D-HF an adverse prognosis characterised by an increased risk of CHF 
hospitalization, as well as all-cause and cardiovascular mortality (Shindler et al., 
1996; de Groote et al., 2004; Gustafsson et al., 2004; Cubbon et al., 2013; Dauriz 
et al., 2017; Seferovic et al., 2018).  
 
Given that exercise intolerance is the most powerful predictor of mortality (Myers 
et al., 2002), there is much interest as to what mechanisms contribute towards 
exercise intolerance in CHF, DM and D-HF. In the context of CHF, there is 
substantial evidence to indicate that peripheral perturbations within the skeletal 
muscle system influence the archetypal symptoms of exercise intolerance 
2 
 
observed in these patients (Mettauer et al., 2006; Middlekauff, 2010; Okita et al., 
2013). DM is also characterised by compromised skeletal muscle metabolism, 
one outcome of which is insulin resistance (Abdul-Ghani & DeFronzo, 2010). 
Thus, it may be postulated that the lower exercise capacity previously described 
in D-HF patients (Guazzi et al., 2002; Tibb et al., 2005; Ingle et al., 2006) may 
be attributed to aberrant skeletal muscle abnormalities resulting from the 
presence of both conditions. However, as yet, very few studies have assessed 
skeletal muscle alterations in D-HF patients. Therefore, it is still unclear as to 
how the additional comorbidity of DM may influence skeletal muscle and 
potentially worsen symptoms of exercise intolerance in the context of CHF.  
 
The current thesis aimed to identify and establish the cellular mechanisms within 
the skeletal muscle system underpinning exercise intolerance in the context of 
both CHF and DM, and how these factors may contribute to the worse prognosis 
observed in D-HF patients. This study has also focused on measuring skeletal 
muscle alterations in both locomotor and postural muscle groups to discriminate 
the systemic effects of these two conditions from the potentially confounding 
influence of detraining/disuse that frequently occurs in these clinical conditions 
(Olsen et al., 2005; Reynolds et al., 2007; Rehn et al., 2012).  
 
1.2 Chronic heart failure 
1.2.1 Aetiology 
Chronic heart failure (CHF) secondary to left ventricular systolic dysfunction 
(LVSD) is a complex and progressive clinical condition (Metra & Teerlink, 2017). 
Heart failure with reduced ejection fraction (HFrEF) accounts for ~50% of all CHF 
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cases (Bloom et al., 2017), and is characterised by a reduced capacity to provide 
sufficient blood flow, and hence oxygen (O2) delivery, to bodily tissues 
commensurate with metabolic demands (Mudd & Kass, 2008; Kemp & Conte, 
2012). Heart failure with preserved ejection fraction (HFpEF) accounts for the 
remaining 50% of CHF cases; however, as the aetiology, progression, and 
treatment for these patients remains poorly understood, the current thesis is 
focused purely on patients with HFrEF, henceforth termed as CHF for simplicity.  
 
CHF arises from congenital or acquired alterations that deleteriously affect the 
structure and/or function of the heart such that there is a reduction in ventricular 
filling or ejection (Shah & Mann, 2011; Bloom et al., 2017). While multiple 
divergent aetiologies may contribute to this final common syndrome - including 
hypertension, coronary artery disease, cardiomyopathies, myocardial infarction, 
myocarditis, and valvular disease - they are each underscored by an adverse left 
ventricular remodelling (McMurray et al., 2012; Bloom et al., 2017). Specifically, 
this left ventricular remodelling occurs due to a loss of myocyte cells and 
increased myocardial strain, which lead to left ventricular hypertrophy and 
dilatation as well as fibrosis and functional mitral regurgitation (Metra & Teerlink, 
2017). Consequently, these increase myocardial O2 consumption and decrease 
myocardial contractile efficiency, which cause LVSD and a reduction in left 
ventricular ejection fraction (LVEF) (Moss, 2010; Metra & Teerlink, 2017). Thus, 
LVSD in CHF occurs as a maladaptive compensatory response to myocardial 
injury. However, the symptomatic progression to overt CHF occurs due to 
systemic overactivation of the neurohormonal systems, the renin-angiotensin-
aldosterone system (RAAS) and the sympathetic nervous system (SNS) 
(Hartupee & Mann, 2017). These systems result in numerous cardiovascular, 
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renal and neurohormonal adaptive responses that initially aim to preserve 
cardiovascular homeostasis but ultimately progress the condition to a whole-
body syndrome by chronically exerting deleterious effects (Kemp & Conte, 2012; 
Hartupee & Mann, 2017). Therefore, CHF is considered a multifaceted 
syndrome, which originates as a result of a central haemodynamic disorder, but 
propagates a multitude of maladaptive consequences and symptoms due to 
altered haemodynamic, neural, hormonal and renal responses.  
 
CHF patients typically present with a constellation of signs and symptoms which 
impair quality of life primarily by inducing symptoms of exercise intolerance, 
including breathlessness (dyspnoea) and skeletal muscle fatigue (Ziaeian & 
Fonarow, 2016). However, as many of these symptoms are common in other 
conditions, such chronic obstructive pulmonary disease, CHF can only be 
diagnosed from an echocardiogram combined with measurements of the serum 
concentrations of brain natriuretic peptide (BNP) and/or the N-terminal 
prohormone of BNP (NT-proBNP) (Cowie, 2017; Metra & Teerlink, 2017). A BNP 
level > 100 pg·mL⁻1 and a NT-proBNP level > 400 pg·mL⁻1 is considered 
indicative of CHF (Cowie, 2017; Metra & Teerlink, 2017). Symptomatic status is 
often assessed subjectively in CHF patients using the New York Heart 
Association (NYHA) functional classification system (Ponikowski et al., 2016). 
This groups patients into one of four groups (classes I-IV) based on the severity 
of their symptoms during daily activities. Those in class I have no symptoms 
whereas classes II, III, and IV correspond to mild, moderate, and severe 
symptoms, respectively (McMurray et al., 2012). Despite being a subjective 
measure, this classification system has been shown to be a good predictor of 
mortality (Scrutinio et al., 1994).  
5 
 
1.2.2 Epidemiology 
CHF currently afflicts about 2% of the world’s adult population (Metra & Teerlink, 
2017) with over half a million of these individuals currently living in the UK 
(Townsend et al., 2014). CHF prevalence increases with age and is more 
common in males (Ho et al., 1993). Although the incidence of CHF has been 
stable or even decreased in recent years (Conrad et al., 2018), the prevalence 
has increased and is forecast to rise due to an expanding and ageing 
demographic as well as improvements in survival and treatment of individuals 
suffering from acute coronary events (Heidenreich et al., 2013; Kearney, 2015; 
Bloom et al., 2017; Conrad et al., 2018). Importantly, CHF confers a poor 
prognosis with frequent hospitalizations and readmissions as well as a high 
mortality (Krum & Abraham, 2009; Bui et al., 2011; Metra & Teerlink, 2017). 
Indeed, 6-7% of patients with stable CHF will die within 1-year (Metra & Teerlink, 
2017). Additionally, treatment costs contribute to ~2% of healthcare expenditure 
(Cowie, 2017; Metra & Teerlink, 2017). Although several developments in recent 
years, such as evidence-based pharmacotherapy and device implantations, 
have improved outcomes (Mudd & Kass, 2008; Ziaeian & Fonarow, 2016), CHF 
continues to remain a major global concern.  
 
1.2.3 Treatment 
Neurohormonal antagonists, diuretics and implantable devices are the mainstay 
of CHF treatment (Metra & Teerlink, 2017). Neurohormonal antagonists block 
the RAAS and SNS systems to prevent adverse remodelling from overactivation 
(Krum & Abraham, 2009). Several CHF drugs that specifically target each of 
these systems have proven effective in improving morbidity and mortality rates 
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(Krum & Teerlink, 2011). These drugs include angiotensin converting enzyme 
inhibitors (ACEis), angiotensin receptor blockers or antagonists (ARBs), 
aldosterone antagonists, mineralocorticoid receptor antagonists, and beta-
blockers (Bristow, 2012; Metra & Teerlink, 2017). CHF patients are also often 
afflicted with oedema, or fluid retention, in the lower extremities (peripheral 
oedema), or the lungs (pulmonary oedema), which often exacerbate symptoms 
of exercise intolerance, particularly breathlessness (Clark & Cleland, 2013). 
Therefore diuretic treatment aims to achieve and maintain euvolaemia by 
ameliorating congestion associated with CHF (Krum & Abraham, 2009). 
 
Although left ventricular assist devices have recently emerged as a novel therapy 
(Fang, 2009; Abraham & Smith, 2013), implantable devices, including both 
implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation 
therapy (CRT) devices, remain the cornerstone of surgical treatment options for 
CHF patients (Holzmeister & Leclercq, 2011). ICDs prevent sudden cardiac 
death by terminating arrhythmias, such as ventricular tachycardia and ventricular 
fibrillation (DiMarco, 2003; Betts & de Bono, 2010). ICD therapy effectively 
reduces mortality risk in CHF patients compared to conventional medical therapy 
alone (Moss, 2010). CRT devices improve symptoms and prognosis by 
overcoming intraventricular dyssynchrony, which most commonly manifests as 
left bundle branch block (Jarcho, 2005; Betts & de Bono, 2010; Abraham & 
Smith, 2013). CRT devices simultaneously pace both the right and left ventricles 
(biventricular pacing), and have been shown to reduce the interventricular delay, 
improving functional haemodynamic indices, including an increase in LVEF 
(Abraham et al., 2002; Cleland et al., 2005). Furthermore, CRT device therapy 
has been shown to improve symptomatic status (NYHA classification), exercise 
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capacity, and quality of life, as well as reduce hospitalizations and decrease 
mortality, above conventional medical therapy alone (Abraham et al., 2002; 
Cleland et al., 2005; Abraham & Smith, 2013). Additionally, the combination of a 
CRT-ICD device has been shown to improve quality of live, functional status, and 
exercise capacity in moderate to severe CHF patients (Young et al., 2003) as 
well as reduce the risk of CHF events in patients with a low LVEF (Moss et al., 
2009).  
 
1.3 Type 2 diabetes mellitus 
1.3.1 Aetiology 
Type 2 diabetes mellitus (DM) is characterised by elevated plasma glucose, or 
hyperglycaemia, in both the fasting and postprandial states. This condition 
develops due to dysregulation in the action and production of insulin, one of two 
hormonal homeostatic peptides that regulate plasma glucose concentrations. In 
healthy individuals, insulin and glucagon both tightly control plasma glucose 
concentrations by encouraging glucose disposal in peripheral tissues in the 
postprandial state and releasing glucose in relation to energetic demand, such 
as during exercise or fasting (Muoio, 2014). However, in DM, overt 
hyperglycaemia occurs as a result of a reduction in insulin sensitivity in peripheral 
target tissues (insulin resistance), which precedes the decrease in insulin 
secretion from pancreatic β cells (Kahn et al., 2014). Clinically, DM is diagnosed 
as a fasting plasma glucose concentration ≥ 7 mmol·L⁻1 or a 2-hour postprandial 
plasma glucose concentration ≥ 11.1 mmol·L⁻1. Glycated haemoglobin (HbA1c) 
is also used as a marker of longitudinal glycaemic control with an HbA1c 
concentration ≥ 6.5% (≥ 48 mmol·L⁻1) being indicative of DM.  
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Insulin resistance in peripheral tissues is evident several years before the 
development of overt hyperglycaemia and is also present in both obese and lean 
offspring of DM patients and in obese non-DM individuals (Abdul-Ghani & 
DeFronzo, 2010). Insulin resistance is a relative impairment in the ability of 
insulin to exert its effects on glucose and lipid metabolism in target tissues 
(Turner & Heilbronn, 2008), as measured by a euglycaemic-hyperinsulinaemic 
clamp test to assess insulin sensitivity and glucose uptake (Kim, 2009). These 
target tissues primarily include the liver, adipose tissue (adipocytes) and skeletal 
muscle. In skeletal muscle, insulin resistance is evident from a reduction in 
insulin-stimulated glucose uptake and glycogen synthesis during postprandial 
hyperinsulinemia (Szendroedi et al., 2011). Indeed, as skeletal muscle accounts 
for ~80% of postprandial insulin-stimulated glucose uptake (Shulman et al., 
1990), it is considered to be the primary site of insulin resistance in DM (Abdul-
Ghani & DeFronzo, 2010). Insulin resistance also reduces fatty acid metabolism 
in the fasting state and promotes ‘metabolic inflexibility’, which refers to the 
inability to adjust between the oxidation of different nutrient fuel substrates within 
the prevailing extracellular milieu (Kelley & Mandarino, 2000). The persistent 
hyperglycaemic environment associated with DM promotes the development of 
several macro- and microvascular complications that increase morbidity and 
mortality (Stratton et al., 2000). The macrovascular complications include an 
increased risk of intermittent claudication, stroke, heart failure, and coronary 
heart disease (Kannel & McGee, 1979). The microvascular complications of DM 
include retinopathy (eye damage), neuropathy (nerve damage) and nephropathy 
(renal failure). Additionally, DM patients often present with high blood pressure 
(hypertension) and hyperlipidaemia. Given these complications, it is perhaps 
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unsurprising that DM patients suffer greatly from cardiovascular morbidity and 
mortality, with cardiovascular disease being the primary cause of death in DM 
patients (Abdul-Ghani et al., 2017). Furthermore, the treatment and management 
of DM and its associated complications is a substantial burden on national 
healthcare costs and resources.  
 
1.3.2 Epidemiology 
The global prevalence of DM has quadrupled in the last 30 years and will soon 
effect half a billion people (Chatterjee et al., 2017; Zheng et al., 2018). Although 
a genetic predisposition is associated with an increased risk of DM (Fuchsberger 
et al., 2016), the predominant factors promoting this dramatic increase in 
prevalence include an ageing population and obesity, the latter of which has 
been fuelled by metabolic derangements owing to modern lifestyle changes in 
physical activity and diet (Zheng et al., 2018). These lifestyle alterations have 
partially been fostered by changes in the environments of industrialised and 
economically-developed societies, such as urbanisation, mechanised 
transportation, and sedentary occupations, all of which have fostered an 
increasingly inactive population. Simultaneously, there has been an increase in 
excessive energy intake, particularly as a result of the increased consumption of 
energy-dense calorific foods high in sugar and fat content (Zheng et al., 2018). 
Although obesity is the best predictor of DM development, there is evidence that 
DM incidence is greater in normal weight individuals presenting with insulin 
resistance than overweight individuals without insulin resistance (Chen et al., 
2012). Therefore metabolic perturbations may be of more clinical significance for 
predicting DM risk than body weight per se. Aside from these modifiable lifestyle 
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factors, unmodifiable risk factors, such as ethnicity and familial history, have 
combined to contribute to the recent upsurge in these disorders. Although 
originally believed to only develop in adults, evidence now indicates that DM is 
becoming increasingly common in young adults, adolescents and, in some 
instances, children (Chen et al., 2012). Owing to the chronic nature of the 
disease and its associated comorbidities, this reduction in the age of onset is 
likely to result in considerable burden both for the individual and healthcare 
resources.  
 
1.3.3 Treatment 
The primary aim of DM treatments is to optimally maintain plasma glucose 
concentrations within the normal range whilst still accounting for diurnal and 
postprandial fluctuations (Kahn et al., 2014). Metformin, which reduces hepatic 
glucose output and increases peripheral insulin sensitivity, remains the primary 
treatment for DM patients as it is effective at reducing HbA1c concentrations as 
well as cardiovascular disease risk without increasing the likelihood of a 
potentially adverse episode of hypoglycaemia (Chatterjee et al., 2017). 
Treatment with short- and long-acting insulin analogues are most effective at 
improving glycaemic control but increase the risk of hypoglycaemia (Chatterjee 
et al., 2017). Often these treatments are combined with sulfonylureas and 
meglitinides, both of which act to increase insulin secretion from pancreatic β-
cells (Chatterjee et al., 2017). 
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1.4 Diabetic heart failure 
Several recent epidemiological studies have shown that ~25-30% of CHF 
patients present with coexisting DM (MacDonald et al., 2008a; MacDonald et al., 
2008b; Cubbon et al., 2013; van Deursen et al., 2014; Dei Cas et al., 2015; 
Seferovic et al., 2018). This prevalence is higher when prediabetic individuals 
are included (Suskin et al., 2000) and may even be underestimated given that 
DM frequently goes undiagnosed (Beagley et al., 2014). This prevalence of DM 
in CHF is substantially higher than the non-CHF population and is expected to 
rise with an ageing population and improved survival rates after myocardial 
infarction (MacDonald et al., 2008a; Dei Cas et al., 2015; Kearney, 2015). This 
high prevalence is driven by a bidirectional relationship between DM and CHF 
whereby either condition increases the risk of developing the other (MacDonald 
et al., 2008a). Indeed, a recent prospective cohort study with over 1.9 m people 
indicated that the presentation of heart failure was one of the most common initial 
manifestations of cardiovascular disease in DM patients (Shah et al., 2015). 
Similarly, follow-up studies on CHF patients have also shown that the prevalence 
of DM increases over time (Vermes et al., 2003), particularly in older individuals 
(From et al., 2006).  
 
Insulin resistance and poor glycaemic regulation in both DM (Iribarren et al., 
2001) and non-DM (Ingelsson et al., 2005) individuals is associated with a 
greater propensity of CHF incidence. Indeed, every 1% increase in HbA1c 
concentrations is associated with an 8% increased risk of developing CHF 
(Iribarren et al., 2001). Similarly, higher fasting plasma glucose (Khan et al., 
2014) and HbA1c concentrations (Matsushita et al., 2010) have both been 
associated with the development of CHF even in non-DM individuals. Indeed, a 
12 
 
recent meta-analyses discovered that higher HbA1c and fasting plasma glucose 
concentrations as well as insulin use were all independently associated with the 
incidence of CHF (Wang et al., 2015). Significantly, higher HbA1c concentrations 
are associated with worse outcomes in D-HF patients (Iribarren et al., 2001; 
Shah et al., 2012; Dauriz et al., 2017) and, even in non-DM CHF patients, insulin 
resistance is independently associated with a worse prognosis (Doehner et al., 
2005). Furthermore, insulin resistance is associated with a reduced exercise 
capacity in CHF patients (Swan et al., 1997) and patients with a higher NYHA 
functional classification present with higher glucose and insulin concentrations 
(Suskin et al., 2000). Collectively, these findings suggest that insulin resistance 
and glycaemic control may play a pathophysiological role in the development 
and severity of CHF.  
 
Compared to CHF patients, D-HF patients have an adverse prognosis 
characterised by an increase in CHF hospitalization, as well as all-cause and 
cardiovascular mortality (Shindler et al., 1996; de Groote et al., 2004; Gustafsson 
et al., 2004; Cubbon et al., 2013; Dauriz et al., 2017; Seferovic et al., 2018). 
Indeed, one-third of D-HF patients will die within 1-year and 50% within 3 years 
(Gustafsson et al., 2004). Furthermore, D-HF patients have worse NYHA 
symptomatic status and exercise capacity despite comparable cardiac function 
(Suskin et al., 2000; Cubbon et al., 2013). Similarly, adverse left ventricular 
remodelling following myocardial infarction does not explain the increased 
incidence of CHF in DM patients (Solomon et al., 2002). Therefore, given these 
findings, it is plausible to suggest that peripheral, non-cardiac factors, such as 
skeletal muscle abnormalities, may promote the increased incidence and poor 
prognosis of D-HF patients.  
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As yet, little is known regarding the underlying, and likely complex, 
pathophysiological pathways mediating the intrinsic relationship between CHF 
and DM. Given that exercise capacity is lower in D-HF (Guazzi et al., 2002; Tibb 
et al., 2005; Ingle et al., 2006), and this is closely associated with mortality (Myers 
et al., 2002), it is likely that the mechanisms mediating exercise intolerance in D-
HF contribute to the worse prognosis in these patients. Therefore a greater 
understanding of the mechanisms contributing to exercise intolerance in D-HF 
patients may uncover potential therapeutic targets to ameliorate symptoms and 
improve outcomes in this population.  
 
1.5 Exercise intolerance in CHF and D-HF 
Compared to CHF patients, exercise intolerance is exacerbated in D-HF patients 
(Guazzi et al., 2002; Tibb et al., 2005; Ingle et al., 2006), despite comparable left 
ventricular ejection fraction (Cubbon et al., 2013). Importantly, exercise 
intolerance is associated with an increased risk of premature mortality in both 
CHF (Swank et al., 2012; Keteyian et al., 2016) and DM patients (Wei et al., 
1999; McAuley et al., 2007; Nylen et al., 2010). Furthermore the physical 
symptoms of exercise intolerance are of clinical significance as they reduce 
quality of life (Bekelman et al., 2007) and are associated with a decline in 
functional capacity resulting in an inability to fulfil daily activities (McMurray et al., 
2012). Therefore this produces a vicious cycle in which reduced exercise 
capacity decreases physical activity levels which further exacerbate exercise 
intolerance.  
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1.5.1 Assessment of exercise intolerance 
To provide an objective assessment of exercise intolerance, it is most common 
for patients to undertake a non-invasive symptom-limited incremental 
cardiopulmonary exercise (CPX) test, performed with continuous breath-by-
breath measurements. The latter provide data relating to individual symptoms of 
breathlessness and fatigue and are considered more valuable in the clinical 
evaluation of exercise intolerance in CHF patients (Piepoli et al., 2006; Corra et 
al., 2014; Malhotra et al., 2016). Indeed, the prognostic significance of the 
measurements obtained from incremental CPX tests with metabolic gas 
exchange lies in the ability to identify and discriminate the pathophysiological 
origins potentially contributing to the symptoms of exercise intolerance (Corra et 
al., 2014; Malhotra et al., 2016). CPX tests are often conducted on either a 
treadmill or cycle ergometer and consist of patients exercising from a relatively 
low-intensity before the workload is incrementally increased until the patient 
achieves volitional exhaustion at the limit of tolerance.  
 
The peak pulmonary oxygen uptake (V̇O2peak) measured at the limit of tolerance 
is one of the most clinically significant variables obtained from CPX tests. This 
measure reflects the integrative whole-body capacity of the pulmonary, 
cardiovascular, and neuromuscular systems to uptake, transport, extract, and 
utilise atmospheric O2 for the cellular respiration that provides the necessary 
energy for contractile activity. V̇O2peak is dictated by the products of the Fick 
equation, cardiac output (Q̇) and skeletal muscle O2 extraction. Compared to 
age-matched controls, V̇O2peak is reduced by ~40% in CHF patients (Clark et al., 
2000; Witte et al., 2003) and ~20% in DM patients (Regensteiner et al., 1995). 
Importantly, V̇O2peak is prognostically predictive of all-cause (Keteyian et al., 
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2016) and cardiac-related mortality and hospitalisations in CHF patients (Arena 
et al., 2004). Furthermore, V̇O2peak is also used to guide clinical interventions in 
CHF patients, such as cardiac transplantation in those patients with a V̇O2peak ≤ 
14 mL·kg⁻1·min⁻1 (Mancini et al., 1991; Mehra et al., 2016). In DM patients, a 
lower V̇O2peak is associated with an increased risk of cardiovascular events 
(Seyoum et al., 2006), as well as cardiovascular (Church et al., 2005) and all-
cause mortality (Wei et al., 1999; McAuley et al., 2007; Nylen et al., 2010). 
Furthermore, prospective studies show that a low V̇O2peak is an independent risk 
factor for the development of DM (Wei et al., 1999). The reduction in V̇O2peak in 
DM patients is also independently associated with the microvascular 
complications associated with DM, including retinopathy and neuropathy 
(Estacio et al., 1998). Additionally, exercise capacity is inversely correlated with 
DM duration, HbA1c concentrations and body mass index (BMI) (Fang et al., 
2005) as well as insulin sensitivity (Seibæk et al., 2003).  
 
Despite the clinical and prognostic utility of a CPX test to volitional exhaustion, 
CHF patients invariably terminate tests prematurely due to symptoms of 
breathlessness and fatigue (Piepoli et al., 2006). Therefore the term symptom-
limited V̇O2peak is most commonly used, rather than the term maximal pulmonary 
oxygen uptake (V̇O2max), which is evidenced by a plateau in the V̇O2 response at 
maximal exercise, thus providing evidence that the upper limit of aerobic function 
has been attained (Hill & Lupton, 1923). As such, verification phases at the end 
of a peak exercise test have been advocated to overcome any confusion 
between V̇O2peak and V̇O2max, rather than using poorly discriminate secondary 
criteria such as predictive maximal heart rate, respiratory exchange ratio (RER), 
blood lactate levels and ratings of perceived exertion (Bowen et al., 2012a; Poole 
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& Jones, 2017). One such alternative protocol is the RISE-95 protocol, which 
involves a ramp-incremental (RI) phase followed by a constant-load step-
exercise (SE) phase at 95% of the peak work rate achieved during RI (Rossiter 
et al., 2006). A non-significant difference in V̇O2peak between RI and SE can 
confirm V̇O2max attainment by satisfying the traditional criterion plateau (Rossiter 
et al., 2006). This protocol recently demonstrated, albeit in a small cohort of CHF 
patients, that V̇O2max is often underestimated, with a significant proportion able 
to acutely increase V̇O2peak between the RI and SE phases by ~20% (Bowen et 
al., 2012a). However, it is not known whether these findings translate to a large 
clinical CHF cohort, what mechanisms may facilitate this increase in V̇O2, and 
why certain patients are able to access this so called “aerobic reserve”. A better 
understanding of the mechanisms allowing the increase in V̇O2 with prior 
exercise warrants further investigation as this may uncover potential therapeutic 
targets by which V̇O2peak can be pharmacologically increased and thus improve 
symptoms, prognosis and outcomes in exercise intolerant patients. 
 
1.5.2 Assessing mechanisms of exercise intolerance 
Historically, given that CHF is characterised by LVSD, it was intuitively presumed 
that the severity of cardiac dysfunction would relate to the degree of exercise 
intolerance in patients. Therefore, many early studies hypothesised that central 
cardiovascular factors mediated exercise intolerance in CHF. Indeed, two 
studies concluded that reduced skeletal muscle blood flow to the legs resulted in 
muscular fatigue and exercise termination during incremental maximal cycle 
exercise (Wilson et al., 1984a; Wilson et al., 1984b). Thus, it was presumed that 
a reduction in Q̇ resulted in an underperfusion of the exercising skeletal 
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musculature and an earlier onset of intramuscular acidosis, which subsequently 
induced volitional exhaustion (Okita et al., 2013).  
 
Subsequent experimental study designs sought to increase Q̇ and improve 
skeletal muscle blood flow. However, several studies showed that inotropic 
agents were unable to improve exercise capacity despite improving Q̇ and 
peripheral O2 delivery (Maskin et al., 1983; Wilson et al., 1984a; Mancini et al., 
1990). This led to the conclusion that impaired O2 extraction or utilisation within 
the muscle was the primary cause of exercise intolerance in CHF patients. In 
addition to these interventional studies, correlational studies have failed to 
demonstrate a significant relationship between resting cardiac function and 
exercise capacity in CHF patients (Franciosa et al., 1981). Furthermore, 
symptom severity does not correlate with the degree of LVSD in CHF patients 
(McMurray et al., 2012). This lack of correlation suggests that therapeutic 
strategies targeted towards improving cardiac function may not necessarily 
ameliorate exercise intolerance symptoms (Middlekauff, 2010). Collectively, 
these findings suggest that cardiac dysfunction may not be the primary cause of 
exercise intolerance in CHF patients. Consequently, it has been proposed that 
peripheral factors, particularly skeletal muscle abnormalities, may represent a 
common underlying pathology contributing to the aetiology of exercise 
intolerance. Therefore a better understanding of the underlying skeletal muscle 
physiology that mediates exercise intolerance has the potential to elucidate 
therapeutic targets in the context of CHF and also D-HF.  
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Given that both CHF and DM contribute to exercise intolerance, it is perhaps 
unsurprising that several studies have sought to determine exercise intolerance 
in D-HF patients. Indeed, it has been shown that the additional comorbidity of 
DM exacerbates exercise intolerance in CHF with several studies indicating that 
D-HF patients have a lower exercise capacity than those presenting with CHF 
alone (Guazzi et al., 2002; Tibb et al., 2005; Ingle et al., 2006). One of the earliest 
studies to investigate the additional comorbidity of DM in CHF showed that D-HF 
patients exhibited a lower V̇O2peak and a steeper increase in ventilation for a given 
carbon dioxide output (V̇E/V̇CO2) during ramp incremental exercise tests 
compared to CHF alone (Guazzi et al., 2002). Follow-up studies expanded on 
these findings by demonstrating, in a larger equally matched cohort of 78 D-HF 
and 78 CHF patients, that V̇O2peak prospectively measured during a symptom-
limited treadmill exercise test was significantly lower in the D-HF cohort (Tibb et 
al., 2005). This finding persisted even after accounting for several confounding 
baseline characteristics, such as LVEF, physical activity, hypertension and 
HbA1c. Furthermore, there were no significant between group differences in 
peak heart rate or ventilatory threshold in this cohort. Based on these findings, 
the authors concluded that the additional comorbidity of DM further exacerbated 
skeletal muscle metabolic perturbations that ultimately reduced V̇O2peak (Tibb et 
al., 2005). 
 
Comparable results have also been demonstrated in patients undertaking the 6-
minute walk test (6-MWT), with D-HF patients covering less distance compared 
to CHF (Ingle et al., 2006). Interestingly, there is also evidence that D-HF patients 
have reduced peripheral skeletal muscle strength as measured by a handgrip 
dynamometer and isokinetic dynamometry of the knee extensors and flexors 
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(Izawa et al., 2013). Furthermore, even in non-DM CHF patients, insulin 
resistance is highly prevalent (79 out of 129 patients) and this correlated with a 
higher symptomatic status, as determined by NYHA functional classification, as 
well as a reduced exercise capacity and V̇O2peak (AlZadjali et al., 2009). This 
study is supported by the finding that acute insulin infusion can increase V̇O2peak 
and time to anaerobic threshold as well as lower the V̇E/V̇CO2 slope (Guazzi et 
al., 2003). Therefore these studies suggest that DM lower exercises capacity and 
this is associated with poor glycaemic control. Thus, it is of increasing clinical 
interest to determine the pathophysiology of exercise intolerance in the context 
of D-HF.  
 
1.6 Skeletal muscle structure, function and metabolism 
1.6.1 Structure 
Skeletal muscle makes up ~40-50% of body mass in normal weight individuals 
and is composed of long multinucleated cells bound tightly together within 
fascicles that attach to bones via ligaments and tendons. During skeletal muscle 
contractions, these attachments transfer force generation from the muscles to 
the bones and thereby facilitate locomotion. Individual muscle fibres consist of 
cylindrical strands of proteins known as myofibrils, which are segmented into 
sarcomeres, and consist of thick myosin filaments and thin actin filaments. 
Myosin filaments consist of a heavy chain, which is the most abundant protein 
within the muscle, while actin contains myosin binding sites that are covered by 
tropomyosin at rest.  
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Human skeletal muscle contains three different myosin heavy chain (MHC) 
isoforms, which are used to differentiate individual muscle fibres into type I, type 
IIa and type IIx in humans (Schiaffino & Reggiani, 2011). The consequence of 
the different isoform phenotypes expressed in skeletal muscle is a preferential 
shift in the metabolic substrate pathway and underlying differences in contractile 
properties. At one end of the spectrum, the slow-twitch type I fibres have fatigue-
resistant characteristics underpinned by a greater reliance upon aerobic 
metabolism and low force but sustainable contractions. At the other end of the 
spectrum, the fast-twitch type IIx fibres rely heavily on anaerobic pathways to 
rapidly generate high force contractions but are easily fatigued. Oxidative type I 
fibres have a smaller diameter, appear red due to the higher concentration of 
iron-containing myoglobin, and contain more mitochondria and oxidative 
enzymes. Type II fibres are characterised by an increased glycogen content and 
greater myosin adenosine triphosphatase (ATPase) activity. The type IIa “fast 
oxidative” glycolytic fibres may be considered a hybrid isoform containing 
elements of both type I and IIx isoforms. Human skeletal muscle may be 
composed of various proportions of these three isoforms depending on several 
factors, such as contractile activity, gender and age. Capillaries are interspersed 
throughout the skeletal musculature to facilitate O2 delivery and removal of 
metabolites and other waste products, which helps sustain repeated 
contractions. 
 
1.6.2 Function 
Skeletal muscle primarily functions by coordinating metabolic processes and 
neuronal inputs to facilitate force generation and contractions. Contractions 
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occur when the individual myofilaments, actin and myosin, interact to produce 
cross-bridges within skeletal muscle sarcomeres. Downstream of the 
neuromuscular junction, this process is reliant upon two processes: 1) the 
release (and reuptake) of calcium (Ca2+) from the sarcoplasmic reticulum (SR) 
via ryanodine receptors in response to action potential propagation from efferent 
neurons; and 2) the resynthesis of adenosine triphosphate (ATP), which is used 
as an “energy currency”, facilitating the conversion of stored chemical energy in 
the form of metabolic substrates to the mechanical energy required for 
myofilament cross-bridge formation. The released Ca2+ from the SR binds to 
troponin C, which shifts tropomyosin from the actin molecule, thus allowing actin-
myosin binding and cross-bridge cycling. Therefore the binding of actin to myosin 
results in the contractile process of the individual sarcomere, which collectively 
results in the coordinated contraction of the muscle. During relaxation of the 
muscle, SR reuptake of Ca2+ is facilitated by sarco(endo)plasmic reticulum Ca2+ 
ATPase (SERCA).  
 
1.6.3 Metabolism 
The hydrolysis of ATP to inorganic phosphate (Pi) and adenosine diphosphate 
(ADP) by the enzyme myosin ATPase releases the free energy (Δ) required for 
the actin-myosin interaction. Given that the concentration of muscle ATP is finite 
(~8 mM) (Kemp et al., 2007), repeated muscular contractions for exercise 
continuation are reliant upon ATP resynthesis, predominantly via the 
phosphorylation of ADP with Pi. This resynthesis can occur via several different 
metabolic pathways and substrates throughout the myocyte depending on the 
rate and capacity of ATP required. Specifically, the metabolic pathways for ATP 
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resynthesis rely upon the oxidation of both stored and circulating carbohydrates 
and fats. The intrinsic differences in the molecular structure of these different 
substrates dictate the rate and capacity at which ATP can be resynthesized. ATP 
resynthesis generally occurs via three metabolic pathways in skeletal muscle: 1) 
the phosphocreatine (PCr) system; 2) cytosolic glycolysis; and 3) mitochondrial 
oxidative phosphorylation (OXPHOS). The PCr pathway is capable of providing 
an immediate and instantaneous source of ATP from the catalytic breakdown by 
creatine kinase of PCr to creatine and Pi, which is used to phosphorylate ADP. 
However, given that intramuscular PCr stores are limited (~33 mM) (Kemp et al., 
2007), this pathway is only able to sustain ATP resynthesis for a few seconds. 
Glycolysis occurs in the cytosol and this pathway facilitates the conversion of 
glucose to pyruvate. This process releases free energy to resynthesise ATP and 
the pyruvate formed is then transported into the mitochondrial matrix via pyruvate 
dehydrogenase to produce acetyl-coenzyme A (CoA), which initiates the Krebs 
cycle. However, the predominant source of ATP resynthesis during daily 
activities performed at a relatively low intensity is from mitochondrial OXPHOS. 
Thus, the oxidative phosphorylation substrate pathway is of most clinical 
significance as it provides the majority of ATP required for daily living. 
 
1.6.3.1 Mitochondrial oxidative phosphorylation 
The ability to resynthesise ATP by mitochondrial OXPHOS is underpinned by: 1) 
the supply of metabolic substrates; 2) the delivery of atmospheric O2 to myocyte 
mitochondria; and 3) adequate mitochondrial content and function. The delivery 
of O2 to skeletal muscle mitochondria is reliant on several integrative pathways 
that may provide a limitation. Firstly, in normoxic conditions, O2 uptake is 
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dependent upon the capacity of the lungs and pulmonary capillaries to facilitate 
gaseous exchange; secondly, the capacity of the cardiovascular system to 
effectively deliver oxygen-rich blood to the skeletal muscles; and finally, the 
successful diffusion of O2 from capillary to skeletal muscle mitochondria.  
 
Mitochondria are organelles found in the majority of eukaryotic cells that primarily 
function to resynthesise ATP via oxidative phosphorylation. Within skeletal 
muscles, mitochondria are organized in a reticular network throughout the 
sarcoplasm and are structurally distinct within different muscle fibre types to 
facilitate energy distribution (Ogata & Yamasaki, 1997; Glancy et al., 2015). 
Mitochondria comprise ~6% of deep oxidative muscles and only 2-3% of 
superficial glycolytic muscles (Garnier et al., 2003). Mitochondria contain both an 
inner and outer mitochondrial membrane, owing to their evolutionary origin from 
an endosymbiotic relationship formed between a host archaebacterium engulfing 
an α-proteobacterium (Gray et al., 1999). The inner mitochondrial membrane 
encloses the mitochondrial matrix and is separated from the outer membrane by 
the intermembrane space. The mitochondrial matrix is the primary site of 
substrate metabolism (via β-oxidation and the Krebs cycle) and the inner 
mitochondrial membrane is embedded with five multi-subunit respiratory enzyme 
complexes along a series of invaginations, or folds in the membrane, termed 
cristae. These five enzyme complexes (denoted complexes I-V) – 
NADH:ubiquinone oxidoreductase (Complex I), succinate dehydrogenase 
(Complex II), cytochrome bc1 complex (Complex III), cytochrome c oxidase 
(Complex IV), and ATP synthase (Complex V) - resynthesise ATP from the 
chemical energy of reduced substrates and the acceptance of electrons by O2.  
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Mitochondrial OXPHOS involves the coupling of substrates derived from the 
Krebs cycle for entry into the electron transfer system (ETS) that allow 
subsequent ATP resynthesis at complex V. Initially, glycolysis and β-oxidation 
produce substrates derived from carbohydrates and fats that enter the Krebs 
cycle as acetyl-CoA. The enzymatic reactions of the Krebs cycle produce two 
high-energy reducing equivalents, reduced nicotinamide adenine dinucleotide 
(NADH) and reduced flavin adenine dinucleotide (FADH2), which donate 
electrons to complexes I and II, respectively. These electrons are then 
sequentially transferred along to complexes III and IV via a series of redox 
reactions that are facilitated by the electron carriers, ubiquinone/co-enzyme Q10 
and cytochrome c, respectively. At complex IV, O2 acts as the final electron 
acceptor and is reduced to water, as a metabolic by-product. Coupled with this 
electron transfer is the translocation of H+ protons from the mitochondrial matrix 
to the intermembrane space at complexes I, III and IV, respectively. Specifically, 
complexes I and III translocate 4 protons for each pair of electrons whilst complex 
IV transfers 2 protons per pair.  
 
This proton translocation creates an electrochemical gradient across the inner 
mitochondrial membrane. The gradient provides the necessary proton-motive 
force to facilitate ATP resynthesis via a process known as chemiosmotic coupling 
(Mitchell, 1961). More specifically, the free energy released for every 4 protons 
that dissipate back down their chemical gradient through ATP synthase (complex 
V) is coupled with the phosphorylation of 1 ADP molecule to ATP. This proton-
motive force, or electrochemical potential (ΔPmt), has both an electrical 
25 
 
component, determined by the inner mitochondrial membrane potential (ΔΨmt), 
and a chemical component, governed by the pH difference (ΔpH) across the 
membrane. Matrix-formed ATP is then exchanged for cytosolic ADP by adenine 
nucleotide translocators that are also situated within the inner mitochondrial 
membrane. Similarly, the mitochondrial isoform of creatine kinase is coupled to 
oxidative phosphorylation by controlling the transfer of matrix-formed ATP to the 
myosin cross-bridge heads. Given the close coupling of these processes, 
skeletal muscle O2 consumption closely reflects ATP resynthesis via 
mitochondrial OXPHOS. As such, skeletal muscle O2 consumption is dependent 
on both mitochondrial density as well as the functional capacity of mitochondria 
to successfully couple the transport of electrons with the phosphorylation of ADP 
to ATP.  
 
1.7 Skeletal muscle abnormalities in CHF and DM 
Although CHF is initiated by cardiac dysfunction, it is now recognised as a 
multifactorial condition affecting several physiological systems, including the 
renal and vascular systems. Numerous studies now indicate that the skeletal 
muscle system is also perturbed in CHF patients (Table 1.1), which include: 
muscle fibre atrophy; a phenotypic shift from type I oxidative fibres to type II 
glycolytic fibres in limb muscle; reduced capillarisation; impaired Ca2+ dynamics; 
and mitochondrial dysfunction. Many of these factors are also evident in skeletal 
muscle samples from DM patients (Table 1.1). In this context, these 
abnormalities contribute to the reduced insulin-stimulated glucose uptake that 
characterise insulin-resistance. However, as yet, there is limited research on how 
D-HF per se impacts the skeletal muscle system (Table 1.1).  
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Table 1.1. Summary of studies assessing skeletal muscle function in DM, CHF 
and D-HF patients. Appropriate references are included in the text. 
 DM CHF D-HF 
Fibre cross-sectional area ↓ ↓ ? 
Proportion of type II to type I fibres (phenotype) ↑ ↑ ? 
Capillarisation ↑, ↓ and ↔ ↑, ↓ and ↔ ? 
Ca2+ dynamics ↓ ↓ ? 
In vivo skeletal muscle metabolism ↓ ↓ ? 
Mitochondrial enzyme activity levels ↓ ↓ and ↔ ? 
Mitochondrial content ↓ ↓ ↓ 
Mitochondrial function ↓ and ↔ ↓ and ↔ ? 
Mitochondrial ROS production and oxidative stress ↑ ↑ ↑ 
↑, increase; ↓, decrease; ↔ unchanged; ?, unknown  
 
1.7.1 Skeletal muscle structure 
1.7.1.1 Atrophy 
Both CHF (Anker et al., 1997; Harrington et al., 1997; Anker et al., 2003; Fulster 
et al., 2013; von Haehling et al., 2017) and DM (Park et al., 2007; Park et al., 
2009; Kim et al., 2010; Leenders et al., 2013; Kim et al., 2014) patients exhibit a 
loss of muscle mass (atrophy) that is greater than what is observed naturally with 
the ageing process. In CHF, this loss of muscle mass is termed cardiac cachexia 
and is estimated to effect ~10% of all patients, equating to ~1.2 million people 
within Europe alone (von Haehling & Anker, 2014). In DM, ~16% of patients 
present with atrophy (Kim et al., 2010) and the risk of low muscle mass is ~2-4-
fold higher in elderly patients with DM compared to age-matched controls (Kim 
et al., 2014). Importantly, muscle wasting is independently associated with 
reduced V̇O2peak (Fulster et al., 2013) and is also an independent risk factor for 
hospitalisations and mortality (Anker et al., 1997; Anker et al., 2003; Rossignol 
et al., 2015). Furthermore this loss of muscle mass reduces muscle strength 
(dynapenia) (Cetinus et al., 2005; Park et al., 2006; Park et al., 2007; Fulster et 
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al., 2013; Almurdhi et al., 2016; Almurdhi et al., 2017), endurance (Minotti et al., 
1993) and impairs the ability to perform routine activities (Leenders et al., 2013), 
thus contributing to a vicious cycle of inactivity and exercise intolerance in 
patients. Studies have also shown that muscle size is a correlate and predictor 
of V̇O2peak (Mancini et al., 1992; Harrington et al., 1997; Fulster et al., 2013) and 
altered skeletal muscle metabolism (Mancini et al., 1992). Furthermore, reduced 
muscle mass and strength has been associated with insulin resistance, poor 
glycaemic control, and increased intramuscular fat accumulation in CHF 
(Doehner et al., 2015), DM (Park et al., 2006; Almurdhi et al., 2016) and impaired 
glucose tolerant patients (Almurdhi et al., 2016). Collectively, these studies 
indicate that the reduced muscle mass and strength seen in CHF and DM 
contribute to insulin resistance, exercise intolerance and mortality.  
 
Many studies in both CHF (Lipkin et al., 1988; Mancini et al., 1989; Sullivan et 
al., 1990; Massie et al., 1996; Delp et al., 1997; Xu et al., 1998; Larsen et al., 
2002; Li et al., 2007; Yu et al., 2008) and DM (Almond & Enser, 1984; Kemp et 
al., 2009) have corroborated that this loss of muscle mass is the result of 
individual fibre atrophy by demonstrating a reduction in fibre cross-sectional area 
(FCSA) in histological samples of skeletal muscle biopsies. Interestingly, the 
majority of these studies have shown that atrophy selectively occurs in type II 
fibres (Almond & Enser, 1984; Mancini et al., 1989; Sullivan et al., 1990; Massie 
et al., 1996; Xu et al., 1998; Larsen et al., 2002; Li et al., 2007; Yu et al., 2008; 
Kemp et al., 2009). However, the exact mechanisms behind this selective 
atrophy remain to be elucidated. Furthermore the reduction in FCSA has been 
strongly correlated with reduced V̇O2peak and muscle strength (Massie et al., 
1996). Muscle fibre atrophy occurs when catabolic protein degradation 
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(proteolysis) pathways exceed anabolic protein synthesis pathways (Perry et al., 
2016). In both CHF and DM, it has been postulated that chronically elevated 
concentrations of circulating pro-inflammatory cytokines, such as tumour 
necrosis factor-α (TNF-α) and interleukin-6 (IL-6), may induce oxidative stress 
and upregulate proteolysis via the ubiquitin-proteasome and autophagy-
lysosome pathways as well as apoptosis (Fulster et al., 2013; Bowen et al., 
2015b; Perry et al., 2016; von Haehling et al., 2017). However, as yet, it is 
unknown whether D-HF patients exhibit greater muscle fibre atrophy.  
 
1.7.1.2 Phenotype 
In locomotor skeletal muscle, several previous studies have documented a fibre 
type shift from type I oxidative to type II glycolytic fibres in both CHF (Lipkin et 
al., 1988; Mancini et al., 1989; Sullivan et al., 1990; Drexler et al., 1992; 
Schaufelberger et al., 1995; Massie et al., 1996; Simonini et al., 1996; 
Schaufelberger et al., 1997; Sullivan et al., 1997; Middlekauff et al., 2013) and 
DM patients (Marin et al., 1994; Nyholm et al., 1997; Gaster et al., 2001; 
Oberbach et al., 2006; Mogensen et al., 2007). Furthermore, these findings have 
been corroborated in well controlled animal models of CHF (De Sousa et al., 
2000) and DM (Eshima et al., 2017). Although the magnitude of this phenotypic 
shift as well as the predominant type II isoform (IIa or IIx) are not consistent 
amongst these studies, given that type II fibres contain fewer mitochondria 
(Schiaffino & Reggiani, 2011), these findings have been interpreted as evidence 
of a reduction in oxidative capacity in both CHF and DM. Indeed, some of these 
studies have demonstrated an inverse correlation between the percentage of II 
fibres and V̇O2peak and a positive correlation between V̇O2peak and the percentage 
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of type I fibres (Mancini et al., 1989; Schaufelberger et al., 1995), thereby 
suggesting that a shift in muscle phenotype may contribute to exercise 
intolerance in these patients. Furthermore some studies have shown that the 
proportion of type IIx fibres is strongly correlated with circulating free fatty acids 
and insulin resistance in obese DM and non-DM subjects (Mogensen et al., 
2007). Therefore, collectively, these studies indicate that a shift in muscle fibre 
type may contribute to exercise intolerance and insulin resistance in CHF and 
DM patients. However, the effect of D-HF on muscle phenotype has yet to be 
elucidated.  
 
1.7.1.3 Capillarisation 
Measures of skeletal muscle capillarisation in CHF and DM studies have 
identified a reduction in microvascular O2 perfusion may contribute to exercise 
intolerance. One of the most frequently reported indices of capillarisation is 
capillary density (CD), which is the number of capillaries within a region of 
interest obtained from a histological stain (Egginton, 1990b). CD is reduced in 
animal models of CHF (Nusz et al., 2003) as well as some (Drexler et al., 1992) 
but not all (Mancini et al., 1989) patient studies. Similarly, CD is reduced in DM 
patients (Marin et al., 1994; Groen et al., 2014) and strongly correlates with 
insulin resistance (Lillioja et al., 1987; Marin et al., 1994). 
 
One of the issues with CD is that it is highly sensitive to changes in FCSA, as 
seen with atrophy, which often accompany pathophysiological conditions such 
as CHF and DM (Ahmed et al., 1997). Therefore many studies also cite the 
numerical capillary-to-fibre ratio (C:F), which is relatively independent of changes 
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in FCSA (Egginton, 1990b). Interestingly, some of these studies have then 
shown that CD is not changed whereas C:F is reduced in both CHF patients 
(Schaufelberger et al., 1995; Schaufelberger et al., 1997; Williams et al., 2004) 
and animals (De Sousa et al., 2000). Additionally, others have reported equivocal 
findings in terms of how C:F is changed with respect to the individual fibre 
isoforms in CHF, with some suggesting that both type I and II are affected 
(Sullivan et al., 1990; Williams et al., 2004) and others demonstrating that only 
type II fibres exhibit a reduced capillarisation (Xu et al., 1998). Furthermore, CHF 
patient studies have shown that the reduced C:F is inversely correlated with 
V̇O2peak (Duscha et al., 1999). C:F has also been reported to be reduced in DM 
patients (Andreassen et al., 2014; Groen et al., 2014) and animals (Machado et 
al., 2016), with the latter study showing that this difference could be ameliorated 
through exercise training. Collectively, these studies suggest that CHF and DM 
appear to have a reduced skeletal muscle capillarisation, and this may impact 
upon both insulin sensitivity and exercise intolerance due to a reduced area of 
tissue being supplied by the microvasculature.  
 
1.7.2 Skeletal muscle function 
Studies in both CHF (Buller et al., 1991; Minotti et al., 1991; Minotti et al., 1992; 
Harrington et al., 1997; Toth et al., 2010) and DM (Sayer et al., 2005; Park et al., 
2006; Park et al., 2007; Volpato et al., 2012; Leenders et al., 2013; Almurdhi et 
al., 2016; Bianchi & Volpato, 2016) patients have demonstrated impairments to 
muscle strength and endurance, which impair physical functional capacity. 
Specifically, these studies have shown that patients experience skeletal muscle 
fatigue due to a reduced force generating capacity, as shown by lower torques 
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and power outputs during isometric, eccentric and isokinetic contractions of 
single muscle groups (Buller et al., 1991; Minotti et al., 1991; Minotti et al., 1992; 
Harrington et al., 1997; Sayer et al., 2005; Park et al., 2006; Park et al., 2007; 
Toth et al., 2010; Volpato et al., 2012; Leenders et al., 2013; Almurdhi et al., 
2016). The use of nerve-stimulation to augment voluntary contractions has 
demonstrated that this fatigue is the result of an intrinsic impairment within the 
muscle rather than a reduction in central motor drive or neuromuscular junction 
transmission (Minotti et al., 1992). Furthermore, even when these measures are 
adjusted to account for differences in muscle size and mass, the reduction in 
contractile performance persists (Harrington et al., 1997; Park et al., 2006; Park 
et al., 2007; Toth et al., 2010). This therefore suggests that, in addition to atrophy, 
intrinsic qualitative abnormalities, a process termed contractile dysfunction, 
contribute to loss of muscle strength and endurance in CHF and DM patients.  
 
To corroborate these findings and elucidate the mechanisms behind these 
impairments, several studies have measured contractile activity and Ca2+ 
handling in single muscle fibres isolated from CHF patients (Szentesi et al., 2005; 
Miller et al., 2010; Middlekauff et al., 2012; Rullman et al., 2013; DiFranco et al., 
2014) and animal models of DM (Bayley et al., 2016; Rodriguez-Reyes et al., 
2016; Eshima et al., 2017). Collectively, these studies have shown: reduced 
tetanic force production (Eshima et al., 2017); reduced maximal isometric force 
production (Bayley et al., 2016; Rodriguez-Reyes et al., 2016); impaired Ca2+-
activated acto-myosin ATPase activity (Szentesi et al., 2005); decreased cross-
bridge kinetics and Ca2+ sensitivity (Miller et al., 2010); decreased SERCA 
protein content (Middlekauff et al., 2012; Bayley et al., 2016); increased oxidative 
damage to ryanodine receptors (Rullman et al., 2013); and impaired action 
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potential-evoked Ca2+ release (DiFranco et al., 2014). Many of these findings 
have also been documented in animal models of CHF (Simonini et al., 1999; 
Lunde et al., 2001; Lunde et al., 2006; Gillis et al., 2016). Collectively these 
studies indicate that Ca2+ may play a role in exercise intolerance in CHF and DM.  
  
1.7.3 Skeletal muscle metabolism 
1.7.3.1 In vivo skeletal muscle mitochondrial function 
Evidence of aberrant skeletal muscle metabolism in CHF and DM patients was 
first derived from 31phosphorous magnetic resonance spectroscopy (31P MRS) 
studies. This technique permits continuous and non-invasive in vivo 
measurements of intracellular concentrations of Pi, PCr, ATP and pH during 
exercise as a means to evaluate intracellular acidosis (decreased pH) and 
skeletal muscle metabolism (Kemp et al., 2015). Importantly, measures of 
oxidative capacity determined from the 31P MRS method have been validated 
against invasive muscle biopsy methods that measure in situ skeletal muscle 
mitochondrial function using respirometry (Lanza et al., 2011; Ryan et al., 2014). 
Using 31P MRS, several studies have shown that CHF patients exhibit 
intramuscular metabolic abnormalities during exercise (Wilson et al., 1985; 
Wiener et al., 1986; Massie et al., 1987a; Massie et al., 1987b; Rajagopalan et 
al., 1988; Mancini et al., 1989; Mancini et al., 1990; Kemp et al., 1996; van der 
Ent et al., 1998; Okita et al., 2001; Nakae et al., 2005) with these effects 
persisting even after cardiac transplantation (Stratton et al., 1994). Collectively, 
these studies showed that CHF patients exhibit greater skeletal muscle fatigue 
at lower exercise intensities, which was accompanied by lower PCr 
concentrations, an elevated Pi:PCr ratio and an earlier onset of intracellular 
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acidosis, many of which correlated with the reduced exercise capacity (Wilson et 
al., 1985; Wiener et al., 1986; Massie et al., 1987a; Massie et al., 1987b; 
Rajagopalan et al., 1988; Mancini et al., 1989; Mancini et al., 1990; Stratton et 
al., 1994; Kemp et al., 1996; van der Ent et al., 1998; Okita et al., 2001; Nakae 
et al., 2005). Interestingly, some of these studies failed to show that these 
metabolic perturbations were the result of compromised muscle blood flow, 
thereby indicating impairments with skeletal muscle utilization rather than 
perfusion (Wiener et al., 1986; Massie et al., 1987a; Massie et al., 1987b; 
Mancini et al., 1990). More recently, studies in DM patients have also shown 
similar in vivo impairments using 31P MRS, as reflected by a slower rate of PCr 
recovery following exercise, which is an alternative method for determining 
mitochondrial oxidative phosphorylation (Petersen et al., 2004; Schrauwen-
Hinderling et al., 2007; Phielix et al., 2008; Bajpeyi et al., 2011; Tecilazich et al., 
2013). Furthermore, these studies also showed that this impaired in vivo 
mitochondrial function strongly correlated with measures of glycaemic control, 
including HbA1c and fasting plasma glucose concentrations (Schrauwen-
Hinderling et al., 2007) as well as glucose disposal (Bajpeyi et al., 2011). Taken 
together, these studies show that in vivo impairments of mitochondrial oxidative 
phosphorylation contribute to exercise intolerance and likely impact insulin 
resistance in CHF and DM patients.  
 
1.7.3.2 Mitochondrial content 
These initial 31P MRS data prompted investigators to assess skeletal muscle 
mitochondrial content in biopsies from CHF and DM patients using transmission 
electron microscopy (Drexler et al., 1992; Hambrecht et al., 1995; Kelley et al., 
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2002; Morino et al., 2005; Ritov et al., 2005; Chomentowski et al., 2011; Guzman 
Mentesana et al., 2014). Early studies showed that mitochondrial volume density 
and surface density of cristae were reduced by ~20% in the vastus lateralis 
muscle of severe CHF patients (NYHA II-IV) and these measures correlated with 
V̇O2peak and the lactate threshold (Drexler et al., 1992). Similarly, training studies 
in CHF patients indicated that 6 months of regular physical activity increased the 
mitochondrial volume density in the vastus lateralis muscle, and this matched 
improvements in exercise tolerance and leg O2 consumption (Hambrecht et al., 
1995). Transmission electron microscopy has also identified a reduced 
mitochondrial density in DM patients and insulin-resistant offspring of DM 
parents compared to control subjects (Kelley et al., 2002; Morino et al., 2005; 
Ritov et al., 2005; Chomentowski et al., 2011). Interestingly, two of these studies 
also showed a significant correlation between mitochondrial density and insulin 
sensitivity, as measured by the euglycaemic clamp method (Kelley et al., 2002; 
Chomentowski et al., 2011). Similarly, the decrease in mitochondrial content in 
insulin-resistant offspring has been associated with impairments in insulin 
signalling (Morino et al., 2005). Collectively, these studies indicate that the 
reduced mitochondrial content in CHF and DM may contribute to exercise 
intolerance and insulin resistance.  
 
1.7.3.3 Ex vivo skeletal muscle mitochondrial function 
Aside from changes in mitochondrial morphometry, studies have also shown that 
CHF and DM are associated with reductions in mitochondrial oxidative enzyme 
activity levels which likely impair mitochondrial O2 consumption. Specifically, 
these studies have shown reduced activity levels of: β-hydroxyacyl CoA 
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dehydrogenase (β-HAD), a key mitochondrial enzyme involved in β-oxidation of 
fatty acids (Mancini et al., 1989; Schaufelberger et al., 1996; Larsen et al., 2009); 
succinate dehydrogenase, a key enzyme involved in both the Krebs cycle and 
the electron transport system (Massie et al., 1996; He et al., 2001); citrate 
synthase, a Krebs cycle enzyme which is often used as a marker of mitochondrial 
content (Vondra et al., 1977; De Sousa et al., 2000; Mettauer et al., 2001; Kelley 
et al., 2002; Larsen et al., 2011); and mitochondrial complex IV, where O2 
accepts electrons (Drexler et al., 1992). Importantly, succinate dehydrogenase 
activity (Massie et al., 1996) as well as β-HAD and citrate synthase activity 
(Brassard et al., 2006) have been strongly correlated with measures of exercise 
intolerance in these studies. Taken together, these consistent findings of 
reduced oxidative enzyme activity levels indicate that reduced skeletal muscle 
mitochondrial content and function may play a contributory role to exercise 
intolerance in CHF patients.  
 
Although isolated measurements of muscle enzyme activity provide insight into 
mitochondrial abnormalities, it remains unclear how such findings translate to the 
in vivo setting, where several rate-limiting enzymes are simultaneously operating 
within the mitochondria to resynthesise ATP. More recently, the advent of high-
resolution respirometers capable of measuring in situ O2 consumption in small 
permeabilized muscle biopsies has advanced the field of muscle biology 
(Kuznetsov et al., 2008). Key to this method is the capacity to use multiple 
substrates, uncouplers, and inhibitors to measure mitochondrial O2 consumption 
in several different ex vivo respiratory states, thus allowing for functional 
characterization (i.e. quality) of the individual complexes involved in 
mitochondrial OXPHOS (Kuznetsov et al., 2008). Furthermore, this method has 
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the advantage of measuring mitochondrial function in relation to the extracellular 
milieu, such as the cytoskeleton, nucleus and endoplasmic reticulum, which is 
not possible when mitochondria are isolated or homogenized (Picard et al., 
2011b; Picard et al., 2011c; Larsen et al., 2014). This technique is only viable 
after incubating dissected skeletal muscle samples in saponin, which has a high 
affinity for cholesterol-containing membranes, and therefore selectively 
permeabilizes the sarcolemma whilst maintaining the structural integrity of both 
the inner and outer mitochondrial membranes for ex vivo analysis (Kuznetsov et 
al., 2008).  
 
Using high-resolution respirometry methods, several studies have demonstrated 
evidence of mitochondrial dysfunction in animal models of CHF (De Sousa et al., 
2000; Garnier et al., 2003; Zoll et al., 2006). These studies have shown that in 
situ mitochondrial respiration is reduced by ~30-40% in limb skeletal muscles, 
with this effect being most apparent using substrates for complex I (Zoll et al., 
2006). Importantly, these effects were only observed over a longer duration of 
CHF, suggesting that skeletal muscle mitochondrial dysfunction only manifests 
after prolonged exposure to the condition (Zoll et al., 2006). However, despite 
these findings in animal models, studies in CHF patients have failed to detect 
differences in skeletal muscle mitochondrial ATP production rate, oxidative 
enzyme activity, and mitochondrial function, including both complex I and III 
activity, when compared to age- and sedentary-matched controls (Mettauer et 
al., 2001; Williams et al., 2004; Garnier et al., 2005; Toth et al., 2012; Middlekauff 
et al., 2013; Guzman Mentesana et al., 2014). Nevertheless, one of these studies 
did demonstrate a correlation between mitochondrial function and both V̇O2peak 
and V̇O2 at the lactate threshold (LT) in both the control and CHF populations 
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(Mettauer et al., 2001), thereby suggesting a strong association between muscle 
mitochondrial function and exercise tolerance. The discrepancies between the 
human and animal studies may be explained by the large variability inherent with 
human studies coupled with the relatively small sample sizes studied. 
Furthermore, these human studies included patients on optimized drug therapy, 
which may also explain the differences between these modern studies and those 
initially conducted in the 1980’s and 1990’s.  
 
Using similar methods, several previous studies have assessed skeletal muscle 
mitochondrial respiration in biopsies from DM patients. Collectively, these 
studies have demonstrated that DM patients exhibit a lower O2 flux with 
substrates supporting complex I, complex I+II, and uncoupled respiration (Kelley 
et al., 2002; Ritov et al., 2005; Boushel et al., 2007; Mogensen et al., 2007; 
Phielix et al., 2008; Larsen et al., 2009; Rabøl et al., 2009; Rabøl et al., 2010; 
Ritov et al., 2010; Larsen et al., 2011). Interestingly, however, these studies have 
produced equivocal results, with some (Boushel et al., 2007; Larsen et al., 2009; 
Rabøl et al., 2009; Rabøl et al., 2010; Larsen et al., 2011) but not all (Kelley et 
al., 2002; Ritov et al., 2005; Mogensen et al., 2007; Phielix et al., 2008; Ritov et 
al., 2010), reporting that these differences in mitochondrial respiration are 
eradicated after adjusting the data to a marker of mitochondrial content, such as 
citrate synthase activity or mitochondrial DNA copy number. Therefore, although 
reduced mitochondrial content may be a primary mechanism contributing to 
mitochondrial deficits in DM patients, associated qualitative functional 
impairments also likely play a key role.  
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With regards to D-HF patients, there have only been a limited number of muscle 
biopsy studies conducted in this population so far (Taub et al., 2012; Ramirez-
Sanchez et al., 2013). Despite relatively small sample sizes and the absence of 
DM, CHF and control groups, these studies have generally demonstrated that D-
HF patients could increase mitochondrial protein expression, cristae abundance 
and volume density following a dietary intervention (Taub et al., 2012; Ramirez-
Sanchez et al., 2013). However, they did not measure mitochondrial function in 
situ using high-resolution respirometry so were unable to specifically identify 
what the functional consequences of these aberrations were in terms of oxidative 
phosphorylation.  
 
1.7.4 Putative mechanisms of skeletal muscle abnormalities in CHF 
and DM 
In CHF and DM, chronically elevated concentrations of pro-inflammatory 
cytokines and angiotensin II, as well as mitochondrial substrate overload, are all 
considered to contribute to oxidative stress, which subsequently induces fibre 
atrophy and mitochondrial dysfunction. Oxidative stress is often caused by an 
increase in reactive oxygen species (ROS) and decreased antioxidant defences 
(Tsutsui et al., 2011). Furthermore, oxidative stress has been implicated in 
numerous pathologies, including cardiovascular and metabolic diseases 
(Johannsen & Ravussin, 2009), as well as ageing (Harper et al., 2004). Indeed, 
animal models of CHF (Tsutsui et al., 2001; Rush et al., 2005; Supinski & 
Callahan, 2005; Coirault et al., 2007; Okutsu et al., 2014; Martinez et al., 2015; 
Gomes et al., 2016; Laitano et al., 2016; Mangner et al., 2016) and CHF patients 
(Linke et al., 2005; Cunha et al., 2012; Guzman Mentesana et al., 2014) exhibit 
oxidative stress and increased ROS production, which have been associated 
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with decreased mitochondrial function and exercise intolerance. Similarly, diet-
induced hyperlipidaemia and hyperglycaemia animal models of DM demonstrate 
increased skeletal muscle ROS production and oxidative stress, which result in 
mitochondrial dysfunction, insulin resistance and exercise intolerance (Bonnard 
et al., 2008; Anderson et al., 2009; Yokota et al., 2009). Recent studies in D-HF 
patients have demonstrated that low mitochondrial antioxidant enzyme activity 
levels are accompanied with increased markers of oxidative stress, including 
protein carbonylation and nitrotyrosine residue formation (Ramirez-Sanchez et 
al., 2013). However, further research is required to determine whether oxidative 
stress and increased ROS production are evident in D-HF patients compared to 
CHF and DM patients alone.  
 
1.8 Overall aims and objectives of thesis 
The overall aim of this thesis was to determine how the specific combination of 
both CHF and DM, as seen in D-HF patients, impacts upon whole-body exercise 
tolerance and skeletal muscle structure and metabolism, with a particular 
emphasis on mitochondrial dysfunction. The rationale for this was based on 
evidence showing that D-HF patients have exacerbated exercise intolerance 
compared to CHF patients alone despite comparable cardiac function. Therefore 
we hypothesised that peripheral skeletal muscle abnormalities may present a 
key mechanism that contribute, in part, to exercise intolerance in D-HF patients. 
To answer this question, the present studies in this thesis first aimed to provide 
a more in-depth evaluation of measuring exercise intolerance in D-HF patients. 
Thereafter muscle biopsies from the upper (i.e. chest) and lower body (i.e. leg) 
were sampled to directly assess in situ mitochondrial function in D-HF patients. 
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Finally, this thesis ended by examining further muscle-specific mechanistic 
changes that likely contribute to the worse exercise intolerance D-HF patients.  
 
Therefore the present thesis performed the following studies to achieve these 
aims: 
1. A novel CPX test in a large clinical setting to better evaluate exercise 
tolerance in CHF patients, that would also provide important mechanistic 
insight into why D-HF patients suffer worse limiting symptoms on exertion;  
2. Assessment of skeletal muscle mitochondrial function using high-
resolution respirometry in pectoralis major biopsies from control, DM, 
CHF, and D-HF patients; 
3. Assessment of skeletal muscle mitochondrial function using high-
resolution respirometry in both vastus lateralis and pectoralis major 
biopsies from control, DM, CHF, and D-HF patients. This is to provide 
insight into the systemic effects of the clinical conditions (which we 
hypothesise to be more discernible in the pectoralis major muscle) and 
the potential confounding effects of physical activity and detraining, which 
likely have more of an impact on the vastus lateralis, a muscle which is 
frequently recruited during locomotor activities.  
4. Identification of general underlying muscle-specific mechanisms 
contributing to the muscle pathology in D-HF including gene expression, 
fibre atrophy, capillarisation, and mitochondrial ROS production.  
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Chapter 2 General methods 
2.1 Research participants  
A total of 329 patients were recruited for the current thesis. Figure 2.1 details 
how these patients were included in each of the Results chapters included.  
These patients were grouped into four cohorts based on the presence of CHF 
and/or DM, including: 1) control (CON) patients selected for pacemaker 
intervention with a LVEF > 50% and no previous diagnosis of LVSD or DM; 2) 
DM patients with a previous diagnosis > 3 months as defined by a documented 
history of DM, fasting plasma glucose ≥ 7.0 mmol·L⁻1, plasma glucose ≥ 11.1 
mmol·L⁻1 two hours after the oral glucose tolerance test, and/or an HbA1c ≥ 6.5% 
(≥ 48 mmol·L⁻1); 3) CHF patients, with symptomatic (NYHA class I-III) and stable 
CHF with no changes in medical therapy > 3 months and a LVEF < 50 % 
secondary to LVSD, as confirmed by echocardiography, with indications for a 
pacemaker implant procedure of either an ICD, permanent pacemaker (PPM) or 
CRT device; and 4) diabetic heart failure (D-HF) patients, that met criteria for 
both CHF and DM outlined above. The physical, demographic, clinical and 
treatment characteristics of these patients are included in the four individual 
results chapters.  
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Figure 2.1. Summary of all the patients recruited to each of the Results chapters 
included in this thesis.  
 
CON and DM patients were prospectively recruited after being referred for device 
implantation by a consultant cardiologist. CHF and D-HF patients were initially 
approached about the study after being listed for implant device therapy by a 
consultant cardiologist at the Heart Failure Clinic at Leeds General Infirmary. 
Most of the CHF and D-HF patients had previously attended a clinically-indicated 
symptom-limited peak CPX test. This test was used as evidence of exercise 
intolerance as demonstrated by a V̇O2peak < 20 mL·kg⁻1·min⁻1. This threshold 
was applied as patients with a V̇O2peak > 20 mL·kg⁻1·min⁻1 are asymptomatic 
during exercise and have a better prognosis (Mancini et al., 1991; Myers et al., 
2002). Patients were screened and excluded if they were unable to provide 
informed consent (i.e. those with cognitive dysfunction e.g. dementia). Additional 
exclusion criteria included those who had previously been diagnosed with other 
potentially confounding comorbidities, such as chronic obstructive pulmonary 
disease, cachexia or cancer. If patients satisfied these criteria, they were 
progressed to the informed consent stage of the study.  
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2.1.1 Sample size 
The sample size for the skeletal muscle biopsy studies was determined from a 
power calculation on data previously collected from a pilot study. This calculation 
suggested that a sample size of at least 22 patients in each of the four cohorts 
would be required to detect a significant difference in a two-sided test with an 
alpha of 0.05 and 80% statistical power. Therefore we aimed to enrol 50 patients 
with CHF and 50 control subjects (25 patients with DM in each group). To 
account for participant drop-outs and experimental failures, we reasoned that 25 
in each group would be a suitable sample target. 
 
2.2 Ethics and informed consent 
The studies performed were all approved by the Leeds West Research Ethics 
Committee (11/YH/0291; Appendix A) and the Leeds Teaching Hospitals R+D 
committee (CD11/10015) and all procedures were conducted in accordance with 
the Declaration of Helsinki (Appendix B). All prospective patients were provided 
with a participant information sheet (Appendix C) which detailed the outline of 
the study, including any potential risks. Prospective patients were then allowed 
sufficient time to read the information sheet and ask any questions they may 
have before deciding whether they wished to participate in the study. 
Participation was voluntary and patients were not required to provide an 
explanation for not wishing to participate. Non-participation in the study had no 
effect on any future treatment(s). Eligible patients elected for pacemaker surgery 
whom volunteered to participate then provided written informed consent 
(Appendix D). I took informed consent from the majority of patients after acquiring 
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certification in Good Clinical Practice (Appendix E) and attending an NIHR 
informed consent workshop (Appendix F).  
 
All patients were assigned a numerical study identification code, which was used 
for recording all experimental data. A record linking the study ID to the 
participant’s name was stored on a password-protected spreadsheet within a 
secure restricted access folder on the Leeds Teaching Hospitals Trust (LTHT) 
servers. Therefore all patient-identifiable information (e.g. name, NHS number, 
and date of birth) could not be determined from the experimental data 
spreadsheets. The data collected in this thesis will remain securely stored for the 
foreseeable future until no longer required.  
 
2.3 Demographic, clinical and pharmacotherapy treatment 
factors 
Age, sex, and body mass were recorded on the day that patients attended their 
appointment for an implantable device. Exercise capacity (V̇O2peak) was 
determined from a CPX test performed prior to the implant procedure (details 
provided in 2.4). NYHA functional classification was determined by a cardiologist 
based on the symptomatic status of the patient. Documented medical history 
records were accessed to determine the aetiology of LVSD (i.e. ischaemic or 
dilated cardiomyopathy (DCM)). These records were also accessed to record 
any additional comorbidities and/or treatments, including atrial fibrillation (AF), 
previous coronary artery bypass graft (CABG), and hypertension. Prior to the 
implant procedure, an accredited sonographer determined LVEF and the left 
ventricular internal diameter at end diastole (LVIDd) from 2-dimensional 
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transthoracic echocardiography according to European Society of Cardiology 
criteria using the Simpson’s biplane method (Lang et al., 2015). Blood samples 
were taken from patients on the day of the implant procedure to measure 
concentrations of haemoglobin, sodium, potassium, and creatinine. Renal 
function was determined using the estimated glomerular filtration rate (eGFR) 
method. Fasting plasma glucose and HbA1c concentrations were also recorded 
to determine DM status and confirm that non-DM patients (i.e. CON and CHF 
cohorts) did not show evidence of undiagnosed DM.  
 
All relevant pharmacological treatments were recorded based on previous 
documented medical history. These included the use of angiotensin converting 
enzyme inhibitors (ACEi), beta-blockers, loop diuretics, angiotensin receptor 
blockers (ARB), aldosterone antagonists, statins, aspirin, metformin and insulin. 
Equivalent daily dosages for each treatment were also recorded. An equivalent 
dosage of furosemide was recorded for patients receiving bumetanide treatment 
by assuming 1 mg of bumetanide equates to 40 mg furosemide (Cubbon et al., 
2013).  
 
2.4 Exercise testing 
All ambulatory CHF and D-HF patients undertook a peak symptom-limited CPX test 
to volitional exhaustion prior to the implant procedure. These tests were performed 
under the supervision of trained cardiac physiologists at Leeds General Infirmary. 
CPX tests were performed on a computer-controlled stationary 
electromagnetically-braked cycle ergometer that continuously recorded cadence 
and power output (Excalibur Sport, Lode BV, Groningen, NL). A 12-lead 
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electrocardiogram (ECG) was used to monitor patients throughout the test and 
heart rate (HR) was determined beat-by-beat from the R-R interval. Pulse 
oximetry (Biox 3745, Ohmeda, Louisville, KY) was used to measure arterial 
oxygen saturation (SpO2) from the finger. Patients wore a nose clip and a 
mouthpiece, which was connected to a pneumotach and a sampling tube that 
enabled continuous breath-by-breath measurements of pulmonary gas exchange 
(V̇O2, V̇CO2, RER) and ventilatory variables (ventilation, V̇E; tidal volume, VT; 
breathing frequency, Bf) to be recorded throughout the protocol (MedGraphics 
Ultima™ CardiO2®, Medical Graphics UK Limited, Gloucester, UK). This 
measurement system was recalibrated prior to each experiment using 
manufacturer-recommended volume and gas calibration methods.  
 
All tests were started with a 5 minute baseline warm-up period at a work rate of 5 
W. Thereafter patients completed a RI test to exhaustion. The RI protocol 
consisted of a continuous increase in power output over the duration of the test, 
typically between 5-20 W·min⁻1 depending on the patients’ symptomatic status. 
This ramp rate was selected to induce intolerance within ~8-12 minutes 
(Buchfuhrer et al., 1983). Exercise was terminated voluntarily by the patient or 
when a pedal cadence > 50 rpm could no longer be maintained despite strong 
verbal encouragement, thereby indicating the limit of tolerance. The test was 
then preceded by a cool-down period at 10 W. Peak pulmonary variables were 
determined by averaging the final 12 breaths of exercise (~20 s) prior to exercise 
termination, as previously described (Bowen et al., 2012a).  
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A selection of patients (Results I) completed a modified protocol, which included 
RI followed by a SE phase at 95% of the max work rate attained during RI (RISE-
95) (Rossiter et al., 2006; Bowen et al., 2012a) to determine if V̇O2max had been 
attained (Figure 2.2). During this test, patients completed the RI protocol outlined 
above and then exercised at 10 W for 5 minutes before completing the SE 
component of the test. The SE phase consisted of an immediate increase in 
power output, which patients were encouraged to maintain until the limit of 
tolerance, as defined above. Patients selected for the RISE-95 test were 
encouraged to attend the test in a postprandial (2-3 hr) state, having refrained 
from strenuous activity (24 hr), caffeine (3 hr) and alcohol consumption (48 hr) 
prior to testing.  
 
Figure 2.2. Schematic of RISE-95 protocol employed in the current study. 
Following a warm-up period, patients exercised to volitional exhaustion (RI). 
They were then allowed to recover for 5 minutes before completing the SE 
component of the test, which was performed at 95% of the peak work rate 
achieved during RI.  
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2.5 Pacemaker implantation and muscle biopsy sampling 
2.5.1 Pectoralis major sampling 
Fresh human skeletal muscle biopsies of the pectoralis major muscle were 
obtained from eligible patients undergoing pacemaker procedures at Leeds 
General Infirmary (Leeds Teaching Hospitals Trust) (Figure 2.3A). This muscle 
was chosen as a suitable candidate for analysis for two reasons. Firstly, as we 
hypothesised that the clinical impact of both CHF and DM have systemic effects 
on skeletal muscle, the pectoralis major muscle was considered a suitable 
candidate to discriminate these effects from any potentially confounding training 
effects, which are more prominent in the locomotor muscles of the lower body. 
Secondly, this muscle can be easily and painlessly accessed during routine 
pacemaker procedures due to the position of the pacemaker generator in a pre-
pectoral pocket. Therefore samples may be procured from this site without 
burdening patients with additional invasive biopsies from a different muscle. This 
was considered to be a more ethically sound procedure for obtaining muscle 
biopsies for research purposes.  
 
In each case, the pacemaker procedure was carried out routinely. Lidocaine was 
initially injected to anaesthetize the area and a small incision was made under 
the left clavicle. A pre-pectoral pocket for the pacemaker generator above 
pectoralis major provided a suitable position for the extraction of ~4 small 
biopsies weighing ~50 mg each (Figure 2.3B). Previous studies have shown that 
local anaesthetics have no effect on subsequent measures of skeletal muscle 
mitochondrial respiration (Cardinale et al., 2018).  
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Figure 2.3. Sampling pectoralis major muscle from the pre-pectoral pocket during 
routine device implantations (A). Using this sampling method, we extracted ~4 
small biopsies weighing ~50 mg each (B).  
 
 
2.5.2 Vastus lateralis sampling 
Percutaneous skeletal muscle biopsies from the vastus lateralis muscle of the 
right thigh were obtained from patients using the Bergström needle method 
(Bergström, 1962), modified to allow for suction (Evans et al., 1982; Hennessey 
et al., 1997; Shanely et al., 2014). This suction-modified Bergström needle 
biopsy method is known to be safe and has a low complication rate (Tarnopolsky 
et al., 2011). The biopsy was taken from the lateral part of the thigh muscle belly 
approximately one-third of the distance between the mid-patella of the knee and 
the femoral greater trochanter (Cardinale et al., 2018). In cases where excessive 
subcutaneous adipose tissue and/or muscle atrophy made it difficult to identify 
the vastus lateralis muscle, patients were asked to tense their thigh muscles to 
allow for accurate determination of the sample site. After scrubbing the sample 
region with iodine, local anaesthetic (1% lidocaine) was injected intradermally in 
to the incision area and a sterile scalpel was used to make a ≤ 10 mm piercing 
in the skin and puncture through the subcutaneous adipose tissue and fascia of 
the muscle. After clearing of blood with sterile swabs, a 6 mm Bergström biopsy 
needle (Dixons 11420-06, UK) was introduced progressively through the incised 
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fascia to a depth of 2-3 cm and rotated to match the pennation angle of the 
muscle (Figure 2.4C). This was included to extract transverse samples for later 
histological analyses. The end of the needle was attached to a suction catheter, 
which was appended to a 50 mL syringe that was used to apply the necessary 
suction to extract samples (Figure 2.4D). Where necessary, several passes were 
made with the needle to extract sufficient muscle tissue (~4 samples totalling 
~100 mg) for all future analyses. Following the procedure, the biopsy wound was 
closed with surgical tape strips and a soft adhesive sterile dressing (Figure 2.4E).  
 
Figure 2.4. Sampling vastus lateralis muscle. Sterilised table set up prior to 
sampling vastus lateralis biopsies (A). Bergström biopsy needle attached to a 
suction catheter and syringe (B). Biopsy sampling method of inserting needle 
through a small incision of the thigh (C) and applying suction to extract samples 
(D). The biopsy wound was closed with surgical strips immediately following the 
procedure (E). Six months after the procedure, there was no visible scarring from 
the site where the biopsy was extracted (F).  
 
51 
 
2.5.3 Preparing muscle samples 
Of the 4 samples extracted from the pectoralis major and vastus lateralis, 1 was 
immediately immersed in a 1.5 mL Eppendorf tube containing 1 mL of ice-cold 
relaxing and biopsy preservation solution (BIOPS) (Table 2.1). This sample was 
transported back to the laboratory on ice for high-resolution respirometry and, in some 
cases, for simultaneous fluorometric analysis. Skeletal muscle samples may be kept 
in BIOPS solution on ice for up to 5 hours without any impairment on respirometry 
measures (Cardinale et al., 2018). A second sample was slightly stretched above 
its slack length and mounted on a pinned cork disc. This sample was orientated 
with the fibres parallel to the pin and perpendicular to the cork before being 
embedded in optimum cutting temperature medium (Thermo Fisher Scientific, 
Waltham, MA) (Figure 2.5A). This sample was snap-frozen in isopentane (2-
Methylbutane; Sigma-Aldrich, St Louis, MO) cooled in liquid nitrogen and stored 
at -80 °C until later analysis. However, in some cases, samples were too big to 
be pinned up and so were embedded in the optimum cutting temperature 
medium in a cut-off pipette tip (Figures 2.5B & 2.5C) before being snap-frozen 
as described above. This sample was used for quantifying MHC isoform 
composition, fibre cross-sectional area and indices of capillarity. The remaining 
two samples were immediately snap-frozen in liquid nitrogen and stored at -80 
°C for additional molecular biology analyses, including enzyme activity 
measurements and gene expression analysis. 
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Figure 2.5. Preparing muscle samples for histological staining. Muscle biopsy 
sample pinned on cork prior to being frozen for later histological staining (A). 
Bigger samples from both vastus lateralis (B) and pectoralis major (C) were 
frozen in cut-off pipette tips.  
 
2.6 Mitochondrial function in saponin-permeabilized fibres 
Mitochondrial function was assessed in saponin-permeabilized skeletal muscle 
fibres using high-resolution respirometry (Oxygraph-2K; Oroboros Instruments, 
Innsbruck, Austria). High-resolution respirometry is considered the gold standard 
for assessing mitochondrial function by measuring in situ O2 consumption in 
different mitochondrial respiratory states (Kuznetsov et al., 2008). Furthermore, 
the permeabilized fibre method has the advantage of measuring mitochondrial 
function in relation to the extracellular milieu, such as the cytoskeleton, nucleus 
and endoplasmic reticulum, which is not possible when mitochondria are isolated 
(Picard et al., 2011b; Picard et al., 2011c; Larsen et al., 2014).  
 
2.6.1 Stock solutions for respirometry protocol 
The relaxing and biopsy preservation solution (BIOPS) for transporting and 
preparation of permeabilized muscle fibres was made according to previously 
outlined protocols (Veksler et al., 1987; Letellier et al., 1992; Fontana-Ayoub et 
al., 2014), and is outlined in Table 2.1 below. The pH was adjusted to 7.1 using 
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5 M KOH and the final solution was aliquoted into 20 ml universal tubes and 
stored at -20 °C until required. BIOPS has an ionic strength of 160 mM and 
contains the following ion concentrations: 0.1 μM free Ca2+, 1 mM free 
magnesium (Mg2+), and 5 mM MgATP.  
 
Table 2.1. Solutions and compounds used to make BIOPS. 
*See below 
 
The CaK2EGTA and K2EGTA stock solutions were made up according to the 
below concentrations and stored at -20 °C until required: 
 
1. CaK2EGTA was made by dissolving 2.002 g CaCO3 (C4830, Sigma-
Aldrich, St Louis, MO) in a 100 mM solution of EGTA (E4378, Sigma-
Aldrich, St Louis, MO; 7.608 g/200 mL) while stirring continuously and 
adding 2.3 g KOH (P 1767, Sigma-Aldrich, St Louis, MO) to adjust the pH 
to 7.0.  
Solution/Compound 
Final 
Con. 
Molecular 
weight 
Stock 
solution 
Addition 
to 1 Litre 
Source and 
product code 
CaK2EGTA* 2.77 mM  100 mM 27.7 ml  
K2EGTA* 7.23 mM  100 mM 72.3 ml  
Na2ATP  5.77 mM 551.1  3.141 g Sigma A2383 
MgCl2·6 H2O  6.56 mM 203.3  1.334 g Sigma M9272 
Taurine  20 mM 125.1  2.502 g Sigma T0625 
Na2Phosphocreatine  15 mM 255.1  4.097 g Sigma P7936 
Imidazole  20 mM 68.1  1.362 g Sigma S6750 
Dithiothreitol  0.5 mM 154.2  0.077 g Sigma D0632 
MES hydrate  50 mM 195.2  9.76 g Sigma M0895 
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2. K2EGTA was made by dissolving 100 mM EGTA (7.608 g E4378, Sigma-
Aldrich, St Louis, MO) and 200 mM KOH (2.3 g; P 1767, Sigma-Aldrich, 
St Louis, MO) in 200 ml water (H2O), and adjusting the pH to 7.0 with 
KOH.  
 
The mitochondrial respiration medium (MiR05) for respirometry experiments was 
made according to previously outlined protocols (Fasching et al., 2014a), and is 
outlined in Table 2.2 below. The pH was adjusted to 7.1 using 5 M KOH (P 1767, 
Sigma-Aldrich, St Louis, MO) and the final solution was aliquoted into 20 ml 
universal tubes and stored at -20 °C until required. MiR05 has an ionic strength 
of 95 mM and contains the following ion concentrations: 2.1 mM free magnesium 
(Mg2+), 90 mM K+, and 0.46 mM free EGTA. 
 
Table 2.2. Solutions and compounds used to make MiR05.
 Solution/ 
Compound 
Final 
con. 
Molecular 
weight 
Stock 
solution 
Addition 
to 1 Litre 
Source and 
product code 
K-lactobionate* 60 mM  0.5 M 120 mL  
EGTA  0.5 mM 380.4  0.190 g Sigma E4378 
MgCl2·6 H2O 3 mM 203.3  0.610 g Sigma, M9272 
Taurine  20 mM 125.1  2.502 g Sigma T0625 
KH2PO4  10 mM 136.1  1.361 g 
BDH Laboratory 
Supplies 
HEPES  20 mM 238.3  4.77 g Sigma H3375 
D-Sucrose  110 mM 342.3  37.65 g Acros Organics 
Bovine serum 
albumin (BSA) 
1 g·L⁻1 66.5  1 g Sigma A6003 
*See below 
 
55 
 
The K-lactobionate stock solution was made by dissolving 35.83 g lactobionic acid 
(L2398, Sigma-Aldrich, St Louis, MO) in 200 ml H2O and adjusting the pH to 7.0 
with KOH. 
 
2.6.2 Preparation of muscle fibres 
Permeabilized skeletal muscle fibres for high-resolution respirometry were 
prepared as previously described (Pesta & Gnaiger, 2011; Pesta & Gnaiger, 
2012; Lemieux et al., 2014). Initially samples were mechanically permeabilized 
under a microscope (Meiji EMT, Tokyo, Japan), in a petri dish on ice containing 
BIOPS solution (Figure 2.6A). Connective tissue, blood and fat were removed 
from samples with sharp forceps and individual muscle fibre bundles (containing 
~6-8 muscle fibres each) were gently dissected along their longitudinal axis 
(Figure 2.6B). This mechanical permeabilization allows for increased 
mitochondrial exposure to exogenous titrations during the respirometry 
experiment. These fibre bundles were then immediately placed into a new 1.5 
mL Eppendorf containing 1 mL BIOPS solution and 50 μg·mL⁻1 freshly prepared 
saponin. Saponin selectively permeabilizes the cholesterol-containing 
sarcolemma whilst retaining the structural integrity of the inner and outer 
mitochondrial membranes as well as other extracellular components (Veksler et 
al., 1987; Letellier et al., 1992; Saks et al., 1998; Kuznetsov et al., 2008; Picard 
et al., 2011c). This method consequently provides uninhibited access to the 
mitochondria for subsequent titrations of substrates, uncouplers and inhibitors 
added to the respiration medium (Kuznetsov et al., 2008). To allow sufficient time 
for saponin to exert its effects, samples were left on ice for a 30 minute chemical 
permeabilization period. These saponin-permeabilized fibre bundles were 
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subsequently rinsed twice for 10 minutes each on ice in MiR05 (Table 2.2) to 
remove excess saponin. 
 
Figure 2.6. Mechanical permeabilization of muscle samples. Samples were 
initially mechanically permeabilized on ice under a microscope using sharp 
forceps (A) to gently dissect out individual muscle fibre bundles (containing ~6-8 
muscle fibres each) along their longitudinal axis (B). 
 
Samples were thereafter dry blotted on filter paper and carefully weighed (wet 
weight, WW) on calibrated digital scales (Mettler Toledo, Greifensee, 
Switzerland), which measure samples in mg to 2 decimal places (Figure 2.7A). 
In each case, the sample was split in to two pieces (each weighing the 
recommended ~2-6 mg (Kuznetsov et al., 2008). Small differences in sample 
weight within this range do not effect respirometry measures in permeabilized 
fibres (Cardinale et al., 2018). Fibres were then then immediately transferred to 
the two internally lit sealed chambers of the high-resolution respirometer, where 
each chamber contained 2 mL MiR05 (Figure 2.7B).  
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Figure 2.7. Preparing samples for high-resolution respirometry. After samples 
had been mechanically and chemically permeabilized, they were washed, dried 
and weighed on digital scales (A – sample circled in red). The Oxygraph-2k 
contains two internally lit chambers connected to polarographic O2 sensors (B). 
Stoppers inserted at the top were used to seal the chambers.  
 
 
2.6.3 Oxygraph-2k and DatLab software 
The two chambers of the Oxygraph-2k are contained within a copper block that 
maintains a constant temperature of 37 °C and samples are suspended in MiR05 
by electromagnetic stirrers rotating at 750 rpm. The dual chamber design of the 
O2K respirometer allowed each sample to be measured in duplicate on the same 
machine. Polarographic O2 sensors are attached to each chamber and 
continuously measure the O2 concentration within the sealed chambers over the 
time course of the experiment. The decline in the O2 concentration within the 
chambers was measured over 2-second intervals by the sensors and recorded within 
specialised software (DatLab5 and DatLab6; Oroboros Instruments, Innsbruck, 
Austria) connected to the respirometer. These sensors measure partial O2 
pressure, which is then converted to O2 concentration by accounting for the 
barometric pressure and an O2 solubility factor of the respiration medium relative to 
pure water of 0.92 at 37 °C (Rasmussen & Rasmussen, 2003; Fasching & Gnaiger, 
2014). The derivative of the decline in O2 concentration within the chambers over 
time was calculated as the O2 flux of the permeabilized muscle fibres throughout 
58 
 
the duration of the protocol, corrected for Ww of the sample. Therefore all O2 flux 
measurements are expressed as O2 flux per mass, in pmol O2·s⁻1·mg⁻1 Ww. On the 
day of each experiment, a standard air calibration of the high-resolution 
respirometer was performed prior to adding samples (Fasching & Gnaiger, 
2014). 
 
2.6.4 SUIT protocol using high-resolution respirometry 
Mitochondrial respiration was measured using a standard previously described 
substrate, uncoupler, and inhibitor titration (SUIT) protocol (Holmstrom et al., 
2012; Wüst et al., 2012; Distefano et al., 2017; Grassi et al., 2017) to assess 
mitochondrial function in several different respiratory states. This SUIT protocol 
reconstitutes physiological conditions which allows functional ex vivo evaluation 
of the mitochondrial complexes in isolation. Each exogenous titration of the SUIT 
protocol was suitably separated to allow for stabilization of the O2 flux signal 
recorded by the DatLab software. These titrations were performed using 10 μL, 
25 μL, and 50 μL Hamilton syringes (Hamilton Co., Reno, NV), which are 
designed to fit the small opening in the stopper used to seal the chambers. 
Hamilton syringes were cleaned with 70% EtOH and distilled water between 
titrations (Fasching & Gnaiger, 2014). All the solutions used in the respirometry 
protocol, including stock and final concentrations, titration volume and dilution, 
as well as manufacturer’s names and product codes are detailed in Table 2.3 
below. Aside from saponin and pyruvate, which were always made fresh daily, 
all solutions were prepared in advanced according to recommended protocols 
and stored at -20 °C, except ADP (stored at –80 °C) (Saks et al., 1998; Fontana-
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Ayoub et al., 2014; Gnaiger, 2014). These solutions were kept on ice for the 
duration of the experiment.
 
6
0
 
Table 2.3. Compounds used in the SUIT protocol in order of use.
 Compound Molecular weight Stock concentration 
Titration 
volume (µL) 
Dilution Final concentration Source and product code 
Saponin 929.1 20 mg·mL⁻1 N/A 1:400 50 μg·mL⁻1 S4521, Sigma-Aldrich 
Blebbistatin  25 mM 2 1:1000 25 µM 13186, Cayman Chemical 
Glutamate 169.1 2 M 10 1:200 10 mM G1626, Sigma-Aldrich 
Malate 134.1 0.4 M 2.5 1:800 0.5 mM M1000, Sigma-Aldrich 
Pyruvate 110.0 2 M 5 1:400 5 mM P2256, Sigma-Aldrich 
ADP 501.3 0.5 M 10 1:200 2.5 mM A5285, Sigma-Aldrich 
Cytochrome c 12.4 4 mM 5 1:400 10 µM C7752, Sigma-Aldrich 
Succinate 270.1 1 M 20 1:100 10 mM S2378, Sigma-Aldrich 
FCCP 254.2 10 mM 1 1:2000 5 µM C2920, Sigma-Aldrich 
Rotenone 394.4 0.1 mM 5 1:400 0.25 µM R8875, Sigma-Aldrich 
Antimycin A 540.0 5 mM 5 1:400 12.5 µM A8674, Sigma-Aldrich 
Ascorbate 198.1 0.8 M 5 1:400 2 mM A4034, Sigma-Aldrich 
TMPD 237.2 0.2 M 5 1:400 0.5 mM T3134, Sigma-Aldrich 
Sodium Azide 65.0 4 M 10 1:200 20 mM BDH Laboratory Supplies 
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Each chamber contained 5 μM of the myosin II ATPase inhibitor, blebbistatin, 
which encourages fibre relaxation in order to limit the inhibition of respiration, 
which can occur in contracting fibres (Perry et al., 2011). After the samples were 
added to the chambers but prior to any exogenous titrations, pure O2 (BOC 
Healthcare, Manchester, UK) was injected in to the chambers with a 50 mL 
syringe to increase O2 concentration > 400 nmol·mL⁻1 (µM) and overcome the 
known O2 diffusion limitation within the mitochondria of permeabilized skeletal 
muscle fibres (Gnaiger et al., 1998). Additional O2 injections were performed during 
the experiment where necessary to prevent the concentration from decreasing to < 
270 nmol·mL⁻1 (µM) (Wüst et al., 2012).  
 
The first respiratory state to be measured in the SUIT protocol was complex I 
Leak respiration (LI). This state was measured by titrating in the Krebs cycle 
intermediates, glutamate (10 mM), malate (0.5 mM) and pyruvate (5 mM), which 
generate the complex I substrate NADH. This provides a measure of non-
phosphorylated O2 consumption that may be attributed to proton leak across the 
inner mitochondrial membrane. A bolus saturating concentration of 2.5 mM ADP 
was subsequently titrated to provide a measure of maximal complex I-supported 
OXPHOS (PI). The permeability of the outer mitochondrial membrane was 
assessed by the addition of 10 μM cytochrome c; samples were excluded from 
the final analysis if this increased respiration > 15% as this is deemed indicative 
of outer mitochondrial membrane damage (Kuznetsov et al., 2004). In such 
cases the increase in respiration demonstrates that cytochrome c can easily 
penetrate across the outer mitochondrial membrane. Such damage is 
considered to not accurately represent in vivo function, in which the outer 
mitochondrial membrane contains numerous ion channels and membrane-
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bound co-transporters required for cellular respiration. The addition of 10 mM 
succinate provided a measure of maximal coupled electron flow with substrates 
providing convergent electron flow to the Q-junction supported by complex I+II-
supported OXPHOS (PI+II). The stepwise titration of 5 μM carbonyl cyanide 4-
(trifluoromethoxy)-phenylhydrazone (FCCP) yielded an uncoupled state of 
maximal ETS capacity with complex I+II substrates (EI+II). The addition of the 
complex I inhibitor rotenone (0.25 μM) provided a measure of complex II-
supported ETS capacity in isolation (EII). Finally, 2.5 μM antimycin A, a complex 
III inhibitor, provided a measure of residual oxygen consumption (ROX) as an 
estimate of non-mitochondrial (background) respiration, which was subtracted 
as a correcting factor from all respiratory measurements.  
 
2.6.5 Complex IV activity assay 
After the addition of antimycin A, a 2 mM titration of ascorbate in combination 
with 0.5 mM N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD) was used as a 
measure of complex IV activity. TMPD is an artificial electron donor to complex 
IV and ascorbate maintains TMPD in a reduced state (Kuznetsov & Gnaiger, 
2010). Following this, 20 mM sodium azide was added to completely inhibit 
mitochondrial respiration (Bowler et al., 2006) and therefore correct for the 
chemical background O2 consumption that occurs due to autoxidation of TMPD 
in the presence of cytochrome c (Kuznetsov & Gnaiger, 2010). The difference in 
O2 flux between the TMPD+ascorbate titration and that obtained following 
sodium azide was used as a measure of complex IV activity (Figure 2.9), which 
has been previously described as a surrogate measure of mitochondrial content 
(Larsen et al., 2012a). To confirm the validity of this method as a marker of 
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mitochondrial content, we measured citrate synthase activity in 27 samples and 
observed that this was significantly correlated with the corresponding measures 
obtained using this complex IV assay (Figure 2.8). For respirometry analysis, this 
method has the advantage of being easily incorporated at the end of the protocol 
using the same sample of tissue. This therefore circumvents the need to do 
alternative methods on a separate tissue sample, which may have a slightly 
different mitochondrial content to that used in the respirometry experiment.  
 
Figure 2.8. Validating complex IV assay against citrate synthase activity. The 
assay for complex IV activity was validated by a significant correlation with citrate 
synthase activity, which is a more common and well established method for 
determining mitochondrial content.  
 
Figure 2.9 shows a typical trace obtained from the Datlab software for the SUIT 
and complex IV activity protocols outlined above. This trace shows both the O2 
concentration signal and the derived O2 flux signal as well as the portions of data 
from which O2 flux measures were obtained for each of the respective respiratory 
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states. After correcting for ROX, the recorded measures from each duplicate 
simultaneous experiment were averaged prior to statistical analysis. Previous 
studies have shown that measurements from each chamber are in close 
agreement with each other and there is no difference in measures on the same 
biopsy sample when conducted by two different investigators (Cardinale et al., 
2018). When consecutive experiments were carried out on the same day, the 
chambers were cleaned for 30 minutes in 100% EtOH and rinsed out with 
distilled water, otherwise they were left overnight in 70% EtOH (Fasching & 
Gnaiger, 2014).  
 
Figure 2.9. Screenshot showing traces obtained from a standard SUIT protocol 
on the Oxygraph-2k. The blue trace corresponds to the O2 concentration within 
the chambers (left y-axis) and the red trace represents the O2 flux of the muscle 
fibres, corrected for wet weight of the tissue (right y-axis), plotted against time 
(x-axis). The light blue shaded boxes show the areas of the red trace which were 
used to extract O2 flux data for the corresponding respiratory states identified 
beneath the graph.  
 
2.6.6 Respiratory and flux control ratios 
Respiratory and flux control ratios were calculated to explore limitations within 
intrinsic mitochondrial respiratory capacity. The respiratory control ratio (RCR), 
which provides the degree of coupling between the O2 consumed and the ATP 
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resynthesized by complex I, was calculated as the ratio of PI to LI respiration. 
Thus, a low RCR would suggest that a greater proportion of electrons leak across 
the inner mitochondrial membrane without contributing to ATP resynthesis via 
OXPHOS. Flux control ratios (FCR), which express the O2 flux of each 
respiratory state (LI, CI, CI+II, EII) as a proportion of the maximal O2 flux in the 
uncoupled state (EI+II), were also calculated. These provide an estimate of how 
limiting complexes I and II are to maximal ETS capacity and therefore may be 
used as evidence of qualitative abnormalities within the individual complexes. 
Therefore a low FCR would indicate that there is an intrinsic abnormality within 
a complex which is limiting electron flow from being the maximal that may be 
sustained for ATP resynthesis. To relate changes back to a recommended 
measure of mitochondrial content (Szendroedi et al., 2011), the raw O2 flux 
results for each respiratory state were corrected to complex IV activity. 
 
2.7 Citrate synthase enzyme activity levels 
2.7.1 Muscle homogenization 
Snap-frozen muscle tissue was thawed on ice and roughly minced with scissors 
in T-PER™ Tissue Protein Extraction Reagent (78510, Thermo Fisher Scientific, 
Waltham, MA) buffer containing a protease inhibitor tablet (1 tablet per 10 mL) 
(05892970001, cOmplete™ ULTRA Tablets, Mini, EASYpack Protease Inhibitor 
Cocktail, Roche, Mannheim, Germany). Each ~50 mg sample was homogenized 
in ~1 mL of homogenization buffer. Roughly chopped tissue was transferred to 
a Falcon tube stored on crushed ice and homogenized using a handheld 
homogenizer (IKA® T10 basic Ultra-Turrax®, Oxford, UK), set to maximum 
speed. Samples were sequentially homogenized for 20 seconds each to avoid 
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overheating and potentially denaturing enzymes. Each 20 second 
homogenization was repeated until no visible chunks remained and the handheld 
homogenizer was washed in distilled water between uses. Thereafter 
homogenate was transferred to a 1.5 mL Eppendorff and sonicated briefly using 
a handheld sonicator (Misonix XL-2000, Misonix Inc., Farmingdale, NY). 
Samples were then centrifuged at 12000 rpm (~12000 × g) for 10 minutes at 4 
°C. The supernatant was then aliquot in to a new 1.5 mL Eppendorff, snap-frozen 
in liquid nitrogen and stored at -80 °C until later analysis.  
 
2.7.2 Bicinchoninic acid protein assay 
A bicinchoninic acid (BCA) assay was performed on homogenate samples to 
quantify total protein content and therefore calculate specific activity 
measurements for the citrate synthase assay. The BCA assay works on the 
premise that proteins reduce Cu2+ to Cu+ under alkaline conditions (biuret 
reaction), producing a colour change from green to purple from the chelation of 
Cu+ by bicinchoninic acid that is linearly proportional to the protein content of the 
sample across a broad range of concentrations (Smith et al., 1985). Homogenate 
samples were thawed, vortexed and centrifuged for 20 seconds at 6000 rpm 
before being diluted 1:5 in the homogenization buffer and loaded onto a 96-well 
plate (3599, Costar, Corning Inc., Corning, NY) in 10 µL triplicates. Eight BSA 
standards, with a protein concentration range between 0-2000 µg·mL⁻1, were 
loaded on to the plate in 10 µL duplicates. The homogenization buffer and 
distilled water (10 µL each) were loaded in duplicates as reference controls. A 
200 µL working reagent buffer from a commercially available kit (23225, Pierce™ 
BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham, MA) was added to 
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each well. The plate was then incubated at 37 °C for 30 minutes and then 
absorbance was read at 562 nm using colorimetry (Promega GloMax®-Multi+ 
Detection System, Madison, WI). The BSA standards were used to produce a 
standard curve from which the protein content of the homogenate samples could 
be determined based on their absorbance. Protein concentrations were typically 
within the range of 1-4 mg·mL⁻1.  
 
2.7.3 Stock solutions for citrate synthase assay 
All stock solutions used in the citrate synthase assay are detailed below in Table 
2.4. Acetyl-CoA was made up in advance by dissolving a 10 mg vial of acetyl-
CoA in 1.235 mL distilled water and aliquoting 300 µL into 0.5 mL tubes that were 
stored at -20 °C or kept on ice during the experiment. 5,5’-Dithiobis-(2-
Nitrobenzoic acid) (DTNB) was made fresh each day in a bijou tube by dissolving 
2 mg DTNB with 5 mL of a 1M Tris-HCl buffer at pH 8.1. Oxaloacetic acid was 
made fresh each day in a bijou tube by dissolving 6.6 mg oxaloacetic acid in 4.5 
mL distilled water and 0.5 mL 1M Tris-HCl buffer at pH 8.1. A citrate synthase 
standard was always made fresh each day by diluting 2 µL citrate synthase 
(C3260, citrate synthase from porcine heart, Sigma-Aldrich, St Louis, MO) in 998 
µL (1:500) 0.1 M Tris-HCL buffer at pH 7.0. 
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Table 2.4. Stock solutions used in citrate synthase assay. 
 Name 
Molecular 
weight 
Stock 
Solution 
Volume 
per well  
Final 
concentration 
Source and 
product 
code 
Acetyl-CoA 809.57 10 mM 5 µL 0.25 mM Sigma A2181 
DTNB 396.35 1 mM 20 µL 0.1 mM Sigma D8130 
Tris-HCL 157.6 1 M N/A N/A Sigma T3253 
Oxaloacetic acid 132.07 10 mM 10 µL 0.5 mM Sigma O4126 
 
2.7.4 Spectrophotometry assay 
Citrate synthase activity was measured spectrophotometrically in a plate reader 
(Thermo Fisher Scientific Varioskan® Flash, Waltham, MA) at 412 nm using a 
previously described method (Srere, 1969; Eigentler et al., 2015). All samples 
were measured in triplicate with each well of the clear 96-well plate (3599, 
Costar, Corning Inc., Corning, NY) containing 1 µL diluted (1:10) homogenate 
and a 200 µL working buffer containing 0.25 mM acetyl-CoA and 0.1 mM DTNB. 
The linear change in absorbance following the addition of 0.5 mM oxaloacetic 
acid was measured every 30 seconds over 10 minutes at 37 °C to give the rate 
of absorption change (rA = dA/dt). Each plate contained a commercially available 
citrate synthase standard as a reference control, one blank (no sample) control, 
and one internal control sample, which was used to correct for inter-assay 
variability. Specific enzyme activity was quantified by normalising to protein 
content to give a measure as international units (IU) per mg protein (IU/mg). All 
data were then expressed as a fold change relative to the control patient cohort.  
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2.8 Simultaneous high-resolution respirometry with H2O2 
production 
High-resolution respirometry was performed simultaneously with fluorometric 
measures of hydrogen peroxide (H2O2) formation. H2O2 is the stable ROS 
product formed by the dismutation of superoxide anion (O2·-) by manganese 
superoxide dismutase (MnSOD/SOD2) in the mitochondrial matrix. Measuring 
H2O2 emission is the preferred method for determining mitochondrial ROS 
production for three reasons: 1) it is a lot more stable than O2·-; 2) the majority of 
mitochondrial superoxide production is immediately dismutated to H2O2 by 
MnSOD; and 3) H2O2 can permeate across the two mitochondrial membranes 
and react with exogenous fluorogenic probes used to accurately quantify H2O2 
production (Starkov, 2010). H2O2 production was determined using the 
established Amplex Red assay method (Zhou et al., 1997), which has recently 
been incorporated to detect H2O2 production simultaneously with measurements 
of O2 flux using high-resolution respirometry (Eigentler et al., 2013; Fasching et 
al., 2013; Krumschnabel et al., 2015b; Makrecka-Kuka et al., 2015).  
 
2.8.1 O2K-Fluorescence LED2-Module 
Mitochondrial H2O2 production and O2 flux were simultaneously measured in 
different respiratory states using the Oxygraph-2K (Oroboros Instruments, 
Innsbruck, Austria) high-resolution respirometer fitted with the O2K-
Fluorescence LED2-Module (Oroboros Instruments, Innsbruck, Austria). This 
module contains two fluorometric sensors, each of which consist of a light-
emitting diode, a photodiode, a filter-cap, and a filter set-up specific for detecting 
the fluorophore resorufin (Fasching et al., 2014b). The filter set-up consists of a 
green short pass excitation filter (Fluorescence Sensor Green; excitation 
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wavelength = 520 nm) covering the light-emitting diode and a red long pass 
emission filter (emission wavelength = 590 nm) covering the photodiode. The 
fluorometric sensors were fitted in to the two front windows of the O2K chambers 
and connected to the amperometric O2K-Multisensor channels, which allows for 
the signals and corresponding H2O2 fluxes to be measured simultaneously with 
O2 flux measurements and recorded within specialised software (DatLab5 and 
DatLab6; Oroboros Instruments, Innsbruck, Austria).  
 
2.8.2 Amplex Red assay 
The Amplex Red assay measures the production of the red fluorescent 
compound resorufin, which is the reaction product formed in a 1:1 stoichiometric 
ratio by the H2O2-dependent oxidation of Amplex® UltraRed (excitation maxima 
= 568 nm; emission maxima = 581 nm) catalysed by the enzyme horseradish 
peroxidase (HRP). Resorufin is extremely stable once formed and is detected at 
emission/excitation wavelengths of 563 nm/587 nm, respectively (Anderson & 
Neufer, 2006). Although the manufacturers of the commercially available 
Amplex® UltraRed (A36006, Invitrogen™ Molecular Probes®, Eugene, OR) do 
not stipulate how it differs from 10-acetyl-3, 7-dihydroxyphenoxazine, commonly 
referred to as Amplex® Red, the reaction is assumed to work the same way. As 
a result of this enzymatic reaction, there is an increased concentration of 
resorufin formed within the chambers with a concurrent decrease in Amplex® 
UltraRed (Krumschnabel et al., 2015b). The concentration of H2O2 within the 
chambers remains at (or close to) zero as all mitochondrial-derived H2O2 
immediately reacts with the Amplex® UltraRed in the presence of HRP 
(Krumschnabel et al., 2015b). 
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2.8.3 H2O2 calibrations 
Up until 3 µM, there is a linear relationship between the concentration of the 
accumulated resorufin and the fluorescence signal emitted (Krumschnabel et al., 
2015b). Thus, the slope in the fluorescence signal over time (ΔF/s) generated by 
the accumulation of resorufin is directly proportional to the production and 
release of mitochondrial H2O2. However, when the accumulated resorufin 
concentration is expected to exceed 3 µM, such as in prolonged SUIT protocols 
described in this study, the non-linearity of the relationship has to be corrected 
by repeated calibrations of external H2O2 to account for the change in sensitivity 
(V/µM) between the raw voltage recorded by the fluorometric sensors and the 
actual concentration of resorufin formed within the chambers (Krumschnabel et 
al., 2015b). Using the previously described SUIT protocol, these calibrations 
were performed at the start of the experiment without the sample added, and 
then once in the Leak, OXPHOS, and uncoupled maximal ETS states. In each 
instance, 3 titrations of 0.1 µM freshly prepared H2O2 (Table 2.5) were added, 
which resulted in a step-wise increase in the amp raw signal with respect to time 
that was used to determine the signal change (V) in relation to concentration 
(µM). The regression equation of these titrations provided a measure of 
sensitivity (V/µM) that was used as a correction factor when calculating H2O2 
production. Low concentrations of H2O2 were used for two reasons: firstly, to 
prevent excessive consumption of Amplex® UltraRed, which can be depleted 
during prolonged SUIT protocols; and secondly, to limit unnecessary resorufin 
formation, which may exceed the capacity of detection by the photodiode, which 
is within the range of 1-9 V (Fasching et al., 2014b).  
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2.8.4 Stock solutions for fluorometric measurements 
Table 2.5 details the stock and final concentrations, titration volumes and 
dilutions, plus manufacturer’s names and product codes of the additional 
compounds included in this protocol for measuring H2O2 production. Superoxide 
dismutase (SOD) was optionally included to ensure that all mitochondrial-derived 
superoxide was dismutated to H2O2 (Krumschnabel et al., 2015b). In each case, 
Amplex® UltraRed, HRP, and SOD were titrated in prior to the sample being 
added so that the machine could be calibrated in the absence of biological 
material, as recommended (Krumschnabel et al., 2014). A 40 µM H2O2 stock 
solution was prepared fresh prior to each experiment in order to perform the 
necessary calibrations during the experiment. Once prepared, the stock solution 
was immediately aliquoted into 4 (one for each calibration step) 0.5 mL 
Eppendorf tubes and kept on ice for the duration of the experiment. Aliquots of 
Amplex® UltraRed, HRP, and SOD were prepared in advance of experiments 
and stored in the dark at -20 °C. The low concentration of Amplex® UltraRed was 
used as it is known to exert a degree of toxicity (Makrecka-Kuka et al., 2015). 
Table 2.5. Compounds used for fluorometric measurements of mitochondrial 
H2O2 production.  
Compound 
Stock 
concentration 
Titration 
volume (µL) 
Dilution 
Final 
concentration 
Source and 
product code 
Amplex® 
UltraRed 
10 mM 2 1:1000 10 µM 
A36006, 
Invitrogen 
Horseradish 
peroxidase 
500 U/mL 4 1:500 1 U/mL 
P8375, 
Sigma-Aldrich  
Superoxide 
dismutase 
5 KU/mL 2 1:1000 5 U/mL 
S9697, 
Sigma-Aldrich 
Hydrogen 
peroxide 
40 µM 5 1:400 100 nM 
H1009, 
Sigma-Aldrich 
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2.8.5 Protocol optimisation 
Prior to starting experiments on human samples, preliminary experiments were 
performed to optimise the protocol and settings of the fluorometric sensors. 
These experiments involved optimising the timing and number of H2O2 
calibrations as well as determining how the fluorometric sensors responded to 
reoxygenations and individual exogenous titrations included in the SUIT protocol 
in the absence of biological material. Additionally, the gain and polarization 
voltage of the fluorometric sensors were optimised to ensure that the recorded 
raw voltage signals were within the range of 1-9 V, which is the capacity of 
detection by the photodiode (Fasching et al., 2014b). This optimisation resulted 
in a gain of 100 and a polarization voltage of 100 mV being used for each 
experiment.  
 
2.8.6 SUIT protocol with simultaneous H2O2 production  
Saponin-permeabilized skeletal muscle fibres for high-resolution respirometry 
with simultaneous H2O2 production were prepared as outlined above. Following 
the addition of Amplex® UltraRed, HRP, and SOD, the machine was calibrated 
in the absence of biological material (Krumschnabel et al., 2014). After adding 
samples to the chambers of the respirometer, a modified version of the SUIT 
protocol previously outlined was followed. There were four major modifications 
to this SUIT protocol. Firstly, all experiments were carried out in the dark by 
switching off the internal chamber lights and using black cover-slips placed on 
top of black stoppers to prevent any external light from penetrating into the 
chamber through the injection ports and potentially interfering with the optical 
fluorometric measurements. The fluorometric sensors attached to the chamber 
windows also prevented any external light from entering. Secondly, all H2O2 
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production experiments were performed under normoxic conditions (O2 
concentrations of ~200 nmol·mL⁻1) by maintaining the O2 concentration within the 
chambers between 150-250 nmol·mL⁻1 as H2O2 production is significantly 
increased under hyperoxic conditions (Boveris & Chance, 1973). Thirdly, 
cytochrome c was not included in any of the experiments as this strongly redox 
compound is known to interfere with the measurements and is therefore 
incompatible with the method (Krumschnabel et al., 2015b). Therefore intactness 
of the outer mitochondrial membrane had to be assumed during these 
experiments. Finally, three additional H2O2 calibrations were included as outlined 
above. After the recorded fluorescent signal had been corrected to account for 
changes in sensitivity, the H2O2 production rate was normalized to pmol·s⁻1·mg⁻1 
Ww by correcting to sample wet weight. There is a known “background” H2O2 
production rate measured after the addition of the sample but prior to titrating in 
substrates, which was subtracted from all subsequent measurements as a 
correcting factor (Krumschnabel et al., 2015a). pmol·s⁻1·mg⁻1 
 
2.9 Muscle isoform composition, cross-sectional area and 
capillarity indices 
2.9.1 Immunohistochemistry 
Isopentane-frozen samples were removed from the -80 °C freezer and allowed 
to warm up to -20 °C for 30 minutes before cutting sections. Serial cross-sections 
(10 µm thick) of muscle biopsy samples were cut using a sharp blade (Leica 819 
Low Profile microtome blades, Leica Biosystems, Nussloch, Germany) on a 
cryostat maintained at -20 °C (Leica CM1860 UV cryostat, Leica Biosystems, 
Nussloch, Germany). Samples were attached to the specimen disc of the 
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cryostat, which is perpendicular to the blade and therefore provided transverse 
cross-sections. Cross-sections were mounted on to Polysine®-coated adhesion 
slides (Thermo Fisher Scientific, Waltham, MA) and stored at -20 °C until 
staining.  
 
All immunohistochemistry methods outlined below were modified based on a 
recently published optimised protocol on rat extensor digitorum longus muscle 
(Kissane et al., 2018). Briefly, slides were warmed to room temperature and 
allowed to air dry for 1 hour before histochemical analysis. Thereafter all 
subsequent procedures were performed at room temperature on the same day. 
Each section to be stained was encircled using a wax pen (Pink PAP Pen, 
Sigma-Aldrich, St Louis, MO) to create a well. Sections were initially fixed for 2 
minutes in a 2% paraformaldehyde solution, washed in phosphate-buffered 
saline (PBS; P4417, Sigma-Aldrich, St Louis, MO), and then blocked for 10 
minutes in a 1% BSA (A6003, Sigma-Aldrich, St Louis, MO) solution to prevent 
any non-specific binding (~150 µL/well). Two monoclonal antibodies specific to 
different MHC isoforms were used to differentiate muscle fibre types: a mouse 
BA-D5 (IgG2B, 1:1000) antibody specific to type I (MHC-I) slow oxidative fibres 
and a mouse SC-71 (IgG1, 1:500) antibody specific to fast oxidative, glycolytic 
type IIA (MHC-IIa) fibres (Developmental Studies Hybridoma Bank, University of 
Iowa, IA). The remaining unstained fibres were assumed to be type IIx (fast 
glycolytic) fibres (Elliott et al., 2016). Laminin, an extracellular matrix glycoprotein 
within the basement membrane, was stained with a rabbit anti-laminin antibody 
(1:200; L9393, Sigma-Aldrich, St Louis, MO) to identify muscle fibre boundaries. 
This dilution was determined after establishing the required concentration 
needed for the software to detect the fibre boundaries (Figure 2.10). All primary 
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antibodies were dissolved in PBS and incubated for 1 hour at room temperature. 
Samples were then washed in PBS and incubated for another hour at room 
temperature with appropriate polyclonal secondary antibodies also dissolved in 
PBS: Alexa Fluor® 555-conjugated goat anti-mouse IgG (1:1000; A-21422, 
Thermo Fisher Scientific, Waltham, MA); Alexa Fluor® 488-conjugated rabbit 
anti-mouse IgG (1:1000; A11059, Thermo Fisher Scientific, Waltham, MA); and 
CF™ 405M-conjugated goat anti-rabbit IgG (1:500; SAB4600461, Sigma-
Aldrich, ST Louis, MO). Capillaries were simultaneously stained with the 
carbohydrate binding protein (lectin) biotinylated ulex europaeus agglutinin I 
(1:200; B1065, Vector Labs, Peterborough, UK), which is a specific and 
established marker for human endothelial cells (Kirkeby et al., 1993; Parsons et 
al., 1993) that preferentially binds to glycoproteins and glycolipids containing α-
linked fucose residues. Cover-slips (VWR International, Radnor, PA) were 
applied to samples using mounting medium (Fluoromount-G®, SouthernBiotech, 
Birmingham, AL). Slides were then imaged using the Nikon Eclipse E600 (Nikon, 
Tokyo, Japan) optical microscope attached to a digital camera (QIMAGING, 
MicroPublisher™ 5.0 RTV, Surrey, BC, Canada) and analysed using digital 
image software (AcQuis, Syncroscopy, Cambridge, UK). All slides were imaged 
at ×10 magnification, which produced images that were 866.33 × 649.75 µm 
(2560 x 1920 pixels) in size.  
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Figure 2.10. Laminin staining optimisation. Serial dilutions of laminin were tested 
to determine the appropriate concentration to use for the Dtect software to 
identify the fibre boundary. 1:1000 dilution was undetected by the software. 
1:200 gave an appreciable improvement compared to 1:500 and was therefore 
used throughout all subsequent staining. Scale bar represents 200 µm. 
 
2.9.2 Dtect Analysis 
An unbiased sampling method was used to create a quadrat counting frame 
containing a region of interest (Figure 2.11B) from which quantitative measures 
of tissue morphometric indices were obtained, as recommended (Egginton, 
1990a). Fibre segmentation and isoform identification was performed using a 
novel semi-automated software, Dtect, which is coded in MATLAB. This software 
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firstly identifies the blue stained lamina to delineate fibre boundaries with a 
magenta outline (Figure 2.12A). Secondly, the software uses the different MHC 
isoform stains to classify all fibres into the three primary human phenotypes 
(types I, IIa, and IIx) (Figure 2.12B). At each of these stages, the user can make 
manual adjustments to remove artefacts, improve the demarcation of the fibre 
boundary and tailor the fibre typing allocation. The third step to this method 
involves manually identifying individual capillaries on the fibre boundaries (Figure 
2.12C), which are then used to generate fibre type-specific morphometric indices 
of capillarisation. 
 
Figure 2.11. Quantifying capillary domain areas using unbiased sampling. 
Representative image of histological staining with lectin (ulex europaeus 
agglutinin I) (A). A quadrat counting frame was used to overlay histological 
images to create a region of interest using unbiased sampling (B). Fibres and 
capillaries overlaying the dotted line were included whilst those overlaying the 
solid lines were excluded. These histological images may be digitised to compute 
the number of capillaries within the region of interest (C). MATLAB software was 
used to create capillary domain areas as tessellating voronoi polygons by 
bisecting the intercapillary distances between each capillary and adjacent 
capillaries to produce boundaries (blue borders) that are equidistant from 
neighbouring capillaries. Scale bar represents 200 µm. 
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Figure 2.12. Screenshots showing how Dtect software generates fibre-type 
specific indices of cross-sectional area and capillarity. Firstly, the software 
identifies the blue laminin staining to create fibre boundaries in magenta (A). 
Individual fibres are numbered and included in the output file detailing fibre-
specific characteristics. Secondly, the software detects the individual fibre types 
based on the MHC staining (B). Within each box, the only fibres are visible are 
those corresponding to that fibre type (I, IIa, or IIx). Remaining fibres are filled in 
colours to show what fibre type they correspond to (type I in red; type IIa in green; 
type IIx in yellow). Finally, capillaries (in small yellow circles) are identified 
manually by the user (C). The numbers within each fibre correspond to the 
number of contiguous capillaries with that specific fibre.  
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2.9.3 Morphometric analyses 
Global average numerical indices of the capillary-to-fibre (C:F, NN(c,f)) ratio and 
capillary density (CD, in mm-2; NA(c,f)) were quantified using standard equations:  
NN(c,f) = N(c)/N(f) 
NA(c,f) = N(c)/n·a̅(f) 
Both C:F and CD are scale-dependent and are therefore heavily influenced by 
changes in fibre cross-sectional area (FCSA) (Egginton, 1990b), which can often 
accompany pathophysiological conditions, such as CHF and DM. Therefore it is 
more appropriate to provide localised scale-independent measures of capillarity, 
which are less sensitive to changes in FCSA and can detect very subtle changes 
in capillary distribution. Moreover, when capillary and MHC isoform markers are 
used simultaneously, it is possible to quantify fibre type-specific interactions with 
individual capillaries, which can be used to identify changes in capillary 
distribution, and thus O2 supply, within a particular fibre type. To calculate scale-
independent measures of capillary distribution, the capillary domain area (in 
µm2), which is defined as the 2-dimensional area of a muscle cross-section 
closest to an individual capillary, was determined using as previously described 
method (Al-Shammari et al., 2014). By bisecting the intercapillary distances 
between each capillary and adjacent capillaries, this method produces 
tessellating voronoi polygons with boundaries that are equidistant from 
neighbouring capillaries (Al-Shammari et al., 2014). Capillary domain areas were 
calculated as follows: 
𝑉𝑖 = {𝑥|𝑥 ∈ 𝛺; ||𝑥 −  𝑥𝑖||  ≤  ||𝑥 −  𝑥𝑘||, 𝐾 ≠ 𝑖}, 
Where Ω represents the global domain and Vi and xi denote the voronoi polygon 
(capillary domain area) and position of the centroid of the ith capillary, 
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respectively (Al-Shammari et al., 2014). These capillary domains provide an 
estimate of the area of tissue supported by a particular capillary in terms of O2 
delivery. By overlapping these capillary domain areas with individual muscle 
fibres, it is possible to derive the fractional areas of each fibre supplied by a 
particular capillary. This provides a measure of the local capillary-to-fibre ratio 
(LCFR; Figure 2.13) for each fibre, which was derived from the automated Dtect 
computational analysis by calculating the sum of these fractional domain areas 
overlapping each individual fibre using the following equation: 
𝐿𝐶𝐹𝑅𝑗
𝑉𝑃 =  ∑
𝐴(𝛺𝑗  ∩  𝑉𝑖)
𝐴(𝑉𝑖)
𝑖
 
Where Ωj and A represent the region and area of the jth fibre, and 𝐿𝐶𝐹𝑅𝑗
𝑉𝑃 
denotes the sum of the fractions of each voronoi polygon (VP) overlapping the 
jth fibre (Al-Shammari et al., 2014). This LCFR method is more sensitive for 
detecting the heterogeneity of capillary supply and can therefore be more 
informative with regards to dysfunctional changes that may occur in certain 
conditions (Egginton, 1990b). The local capillary density (LCD, in µm-2), a 
normalised measure of CD to account for allometric scaling, was quantified for 
each fibre in Dtect by dividing the LCFR by the FCSA, accordingly:  
𝐿𝐶𝐷𝑗
𝑉𝑃 =  
1
𝐴(𝛺𝑗)
∑
𝐴(𝛺𝑗  ∩  𝑉𝑖)
𝐴(𝑉𝑖)
𝑖
 
These individual measures of LCFR and LCD were then used to provide mean 
averages for each fibre type according to the MHC staining.  
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Figure 2.13. Quantifying local capillary-to-fibre ratio. Transverse cross-sectional 
areas are first simultaneously stained to identify fibre boundaries, capillaries and 
MHC isoform (A). Fibre boundaries (B) and capillary locations (C) are then 
identified within specialised software. The tessellating capillary domains (voronoi 
polygons) overlay the magenta outline of the individual muscle fibres (D). Scale 
bar represents 50 µm. *Identifies the same corresponding fibre in each image. 
 
The Dtect software also quantified the FCSA (in µm2) for each fibre which was 
then used to calculate the mean FCSA for each fibre type. The number of fibres 
as well as the average FCSA for each respective fibre type were then used to 
compute the corresponding mean fibre numerical and areal densities (both in %) 
according to previously published equations (Egginton, 1990a). These equations 
compute total muscle cross-sectional area (A) and number of fibres (N) as 
follows: 
A = (ni·?̅?i) + (nj·?̅?j) + (nk·?̅?k) 
N = (ni + nj + nk) 
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Where n and ?̅? represent the number and mean cross-sectional area of fibre 
types i, j, and k, respectively. From these values, the total and fibre-type specific 
mean cross-sectional areas were calculated as follows:  
?̅? =  
(𝑛𝑖 · 𝑎𝑖)  +  (𝑛𝑗 · 𝑎𝑗)  +  (𝑛𝑘 · 𝑎𝑘)
𝑁
 
Accordingly, the fibre numerical density of fibre type i could be quantified as: 
𝑛𝑖
(𝑛𝑖  +  𝑛𝑗  +  𝑛𝑘)
 
Similarly, the fibre areal density of fibre type i could be quantified as: 
𝑎𝑖
(𝑎𝑖  +  𝑎𝑗  + 𝑎𝑘)
 
 
2.10 Gene expression analysis 
2.10.1 RNA extraction 
RNA molecules longer than 200 nucleotides were extracted and purified from 
~30-40mg muscle tissue using the RNeasy® Fibrous Tissue Mini Kit (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instructions. All procedures, 
including centrifugation steps, were carried out at room temperature and 
performed as quickly as possible. Firstly, samples were homogenized and lysed 
in 2 mL microcentrifuge tubes containing 300 µL buffer RLT (with 10 µL·mL⁻1 β-
mercaptoethanol) and 5 mm stainless steel beads (QIAGEN, Hilden, Germany) 
using the TissueLyser II (QIAGEN, Hilden, Germany) operated for 2 minutes at 
20 Hz. Lysates were then transferred to new 1.5 mL microcentrifuge tubes and 
mixed with 590 µL RNase-free water and 10 µL Proteinase K, which digests 
proteins. After incubating for 10 minutes at 55 °C in a heating block 
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(AccuBlock™, Labnet International Inc., Edison, NJ), samples were centrifuged 
for 3 minutes at 10,000 × g to pellet tissue debris. The supernatant was then 
mixed with 0.5 volumes (~450 µL) 100% ethanol and transferred to RNeasy mini 
spin columns, placed in 2 mL collection tubes, and centrifuged for 15 seconds at 
10,000 × g. Column membranes were washed by centrifuging a further two times 
for 15 seconds at 10,000 × g, firstly with 350 µL buffer RW1 and then 500 µL 
buffer RPE (diluted 1:5 with 100% ethanol). Columns were centrifuged again for 
2 minutes at 10,000 × g. Flow-through was discarded after each centrifugation 
step. Columns were centrifuged at maximum speed to dry the membrane. To 
elute the purified RNA bound to the silica membrane, 30 µL RNase-free water 
was added to the column and centrifuged for 1 minute at 10,000 × g. RNA eluent 
concentrations (ng·µL⁻1) and purities were quantified at 260 nm using a 
spectrophotometer (NanoDrop™ 2000, Thermo Fisher Scientific, Waltham, MA).  
 
2.10.2 cDNA synthesis 
RNA extractions were reverse transcribed to cDNA using the RT2 First Strand 
Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. 
Briefly, normalized RNA extractions (to account for differences in RNA 
concentration) were mixed with 2 µL Buffer GE and RNase-free water in PCR 
tubes to give a final volume of 10 µL. Tubes were incubated for 5 minutes at 42 
°C in a thermal cycler (3Prime, Techne, Cambridge, UK) to eliminate genomic 
DNA. After adding a 10 µL reverse transcription mix (containing 4 µL buffer BC3, 
1 µL control P2, 2 µL RE3 reverse transcriptase mix, and 3 µL RNase-free water), 
tubes were incubated again in the thermal cycler for 15 minutes at 42 °C followed 
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by 5 minutes at 95 °C to generate cDNA. All cDNA samples were stored at -20 
°C until further analysis.  
 
2.10.3 Real-Time quantitative Reverse Transcription Polymerase 
Chain Reaction (qRT-PCR) analysis 
Triplicate samples of cDNA (20 ng) and a master mix (containing 10 µL RT2 
SYBR® Green ROX™ qPCR Mastermix (QIAGEN, Hilden, Germany), 0.6 µL 
primer, and RNase-free water) were loaded on to a 96-well plate (MicroAmp™ 
Optical 96-Well Reaction Plates, Applied Biosystems, Foster City, CA) to give a 
final volume of 20 µL/well. The qPCR mastermix contains real-time PCR buffer, 
a DNA Taq polymerase, nucleotides, SYBR Green dye, and ROX dye. Plates 
were sealed with adhesive film (MicroAmp™ Clear, Applied Biosystems, Foster 
City, CA), centrifuged and loaded on to a standard real-time qRT-PCR system 
(Applied Biosystems Prism 7900HT, Foster City, CA). The qRT-PCR protocol 
consisted of 40 thermal cycles of denaturation (95 °C), annealing (60 °C) and 
amplification (95 °C). All human primers for qRT-PCR were purchased from 
QIAGEN and are summarized in Table 2.6 below. The difference in threshold 
cycles (ΔCT) relative to a control was quantified for each sample and then 
normalized to an endogenous control, beta-actin (ACTB), to quantify gene 
expression using the Δ-Δ-CT method (Schmittgen & Livak, 2008). mRNA 
expression was then quantified relative to the control cohort. 
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Table 2.6. Summary of human primers used in real-time qRT-PCR, including 
their QIAGEN catalogue code and function. 
 Primer Catalogue code Function 
ACTB (Beta-actin) PPH00073G 
Part of actin protein family. Housekeeping 
gene 
PPARGC1A (PGC-1α) PPH00461F 
Transcriptional coactivator regulating muscle 
metabolism and mitochondrial biogenesis 
SOD2 PPH01716B 
Encodes for the SOD2 antioxidant enzyme in 
the mitochondrial matrix 
NDUFS1 PPH19871A 
Largest subunit of complex I forming the iron-
sulphur component of the enzyme 
NDUFS3 PPH05975A 
Core subunit of complex I forming the iron-
sulphur component of the enzyme 
FIS1 PPH19947A 
Regulates mitochondrial morphology by 
promoting mitochondrial fission 
OPA1 PPH12084A 
Regulates mitochondrial morphology by 
promoting mitochondrial fusion 
 
2.11 Statistical analyses  
All data were analysed using the IBM Statistical Package for the Social Sciences 
for Windows (SPSS for Windows Version 25.0; IBM Corporation, Armonk, NY). 
Outliers were first identified and removed using the robust regression and outlier 
removal (ROUT) method (Motulsky & Brown, 2006) before proceeding with 
further analyses. The assumption of homogeneity of variance was confirmed 
using Levene’s test (Levene, 1961). Shapiro-Wilk and Kolmogorov–Smirnov 
normality tests were employed to confirm the parametric assumption of normal 
(Gaussian) distribution of continuous data variables from each cohort. In cases 
where the parametric assumptions of homogeneity and normality were violated, 
appropriate nonparametric tests were performed instead. For normally 
distributed data, continuous variables were compared between cohorts using 
separate one-way (one-factor) 1 × 4 analysis of variance (ANOVA). Where 
significant differences were detected by the ANOVA, post hoc analyses were 
performed using Tukey’s multiple comparisons test to identify significant 
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differences between the multiple pairwise comparisons. In instances where only 
two cohorts were compared against one another, unpaired Student’s t-tests were 
employed. Pearson correlations were included where appropriate to examine the 
relationships between different variables. Categorical variables, such as treatment 
and clinical factors, were compared using the two-sided Pearson’s χ2 test. Where 
appropriate, the P-value from Fisher’s exact test was used i.e. if ≥ 20% of cells had 
expected counts < 5. Categorical variables are presented as a percentage (%) of 
the cohort and the number (n). Continuous variables are expressed as mean ± 
standard error of the mean (SEM) unless otherwise stated. Statistical 
significance was accepted as P < 0.05. Each results chapter details specific 
statistical tests where appropriate.  
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Chapter 3 Results I 
Chronic heart failure patients have underestimated exercise 
capacity using standard cardiopulmonary exercise testing 
2.1 Introduction 
Chronic heart failure (CHF) patients are characterised by symptoms of exercise 
intolerance, which are exacerbated in the presence of concomitant type 2 
diabetes (diabetic heart failure; D-HF) (Guazzi et al., 2002; Tibb et al., 2005; 
Ingle et al., 2006). This exercise intolerance can be evaluated noninvasively 
using a symptom-limited treadmill or cycle-ergometer exercise test with 
continuous measurement of cardiopulmonary responses from rest to peak 
pulmonary oxygen uptake (V̇O2peak) at the limit of tolerance (Piepoli et al., 2006). 
V̇O2peak is prognostically predictive of all-cause (Keteyian et al., 2016) and 
cardiac-related mortality and hospitalisations in CHF patients (Arena et al., 
2004). Furthermore, V̇O2peak is used to guide clinical interventions, such as 
cardiac transplantation in those patients with a V̇O2peak ≤ 14 mL·kg⁻1·min⁻1 
(Mancini et al., 1991; Mehra et al., 2016). Therefore, accurate and reliable 
measurements of this physiological parameter are essential in CHF and D-HF 
patients.  
 
Cardiopulmonary exercise tests to volitional exhaustion are invariably terminated 
prematurely in CHF patients due to symptoms of breathlessness and fatigue 
(Piepoli et al., 2006). This precludes the confirmation of maximal pulmonary 
oxygen uptake (V̇O2max), defined as a plateau in the V̇O2 response to increasing 
89 
 
work rate (Hill & Lupton, 1923). With insufficient objective data to discriminate 
between a submaximal V̇O2peak and V̇O2max, corroborating secondary criteria, 
such as blood lactate, peak heart rate (HR), and the peak respiratory exchange 
ratio (RERpeak), are often employed to confirm V̇O2max (Howley et al., 1995). 
However, the validity of these secondary criteria have been questioned, 
particularly in elderly and exercise testing naïve patient populations (Poole & 
Jones, 2017).  
 
Verification phases at the end of a peak exercise test have been advocated to 
overcome this limitation and circumvent the need to employ secondary criteria 
(Day et al., 2003). One such alternative protocol is the RISE-95 protocol, which 
involves a ramp-incremental (RI) phase followed by a short recovery period and 
a constant-load step-exercise (SE) phase at 95% of the peak work rate achieved 
during RI (Rossiter et al., 2006). A non-significant difference in V̇O2peak between 
RI and SE can confirm V̇O2max attainment by satisfying the traditional criterion 
plateau (Rossiter et al., 2006). This protocol recently demonstrated that V̇O2max 
is often underestimated in ~20% of CHF patients by ~1.3 mL·kg⁻1·min⁻1 (Bowen 
et al., 2012a). However, it remains to be elucidated how D-HF patients, whom 
represent a significant CHF subpopulation characterised by a worse prognosis 
(Cubbon et al., 2013), respond to this novel protocol.  
 
Therefore, the purpose of this study was to determine if the RISE-95 protocol is 
1) well tolerated in a large, non-selective sample of CHF and D-HF patients; and 
2) sufficiently sensitive for identifying clinically significant differences within both 
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CHF and D-HF patients in terms of prognosis, treatment, symptomatic status and 
outcomes. 
 
3.1 Methods 
3.1.1 Patients 
211 unselected and consecutive patients with symptomatic stable CHF, 
secondary to left ventricular systolic dysfunction, provided written informed 
consent to participate in the current study. Of these, 195 were able to 
successfully complete the RISE-95 protocol. Patients were only considered and 
approached about the study if they were capable and willing to perform the 
protocol but also had clear evidence of exercise intolerance, as demonstrated by 
a previous V̇O2peak < 20 mL·kg⁻1·min⁻1. This threshold was used as patients with 
a V̇O2peak < 20 mL·kg⁻1·min⁻1 present with symptoms of exercise intolerance and 
have a poor prognosis (Myers et al., 2002). All patients were referred to 
undertake the protocol under the supervision of clinical exercise physiologists at 
Leeds General Infirmary. The investigation followed the guidelines set out in the 
Declaration of Helsinki (Appendix B) and was approved by the Leeds West Local 
Research Ethics Committee.  
 
3.1.2 Equipment and measurements  
Exercise tests were performed on a computer-controlled electromagnetically-
braked cycle ergometer with continuous recording of cadence and power output 
(Excalibur Sport, Lode BV, Groningen, NL). Patients were monitored throughout 
each test using a 12-lead electrocardiogram and HR was determined beat-by-
beat from the R-R interval. Arterial O2 saturation (SpO2) was measured from the 
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finger using pulse oximetry (Biox 3745, Ohmeda, Louisville, KY). Breath-by-
breath measurements of pulmonary gas exchange (V̇O2, V̇CO2, RER) and 
ventilatory variables (V̇E, VT, and Bf) were recorded throughout the protocol 
(MedGraphics Ultima™ CardiO2®, Medical Graphics UK Limited, Gloucester, 
UK). This measurement system was recalibrated prior to each experiment using 
manufacturer-recommended volume and gas calibration methods.  
 
3.1.3 Exercise protocols 
All patients completed a symptom-limited RISE-95 cycle ergometry test to the 
limit of tolerance (Rossiter et al., 2006; Bowen et al., 2012a) during a single visit. 
A schematic in the General Methods chapter outlines the different components 
of the RISE-95 protocol (Figure 2.2). Following a 5 minute baseline warm-up 
period at a work rate of 5 W, patients completed the RI phase of the test at a 
mean ramp rate of 13.4 ± 0.2 W·min⁻1 and a range of 10-20 W·min⁻1. After RI, 
patients exercised at 10 W for 5 minutes before completing the SE component 
of the test at 95% of the peak work rate achieved during RI. Both the RI and SE 
phases of the test were terminated when pedal cadence could not be maintained 
> 50 rpm despite strong verbal encouragement. The test was then preceded by 
a cool-down period at 10 W. Patients were encouraged to attend the test in a 
postprandial (2-3 hr) state, having refrained from strenuous activity (24 hr), 
caffeine (3 hr) and alcohol consumption (48 hr) prior to testing.  
 
3.1.4 Data analyses 
The breath-by-breath data were edited in the V̇O2 domain, to exclude occasional 
breaths that lay outside four standard deviations of the local mean, which may 
92 
 
have resulted from sighs, coughs, swallows etc. (Lamarra et al., 1987). The final 
12 consecutive breaths prior to exercise termination were averaged to allow for 
a sufficient comparison between the peak pulmonary and ventilatory variables 
obtained during RI and SE with a measurement sensitivity of 50 mL·min⁻1 in the 
V̇O2 domain. It has been previously demonstrated that a sample size of 12 
breaths is sufficient to identify a 50 mL·min⁻1 difference in V̇O2 even in individuals 
with the widest breath-by-breath fluctuations (Bowen et al., 2012a). This number 
of breaths may also be collected over a sufficiently short duration to allow an 
appropriate comparison to be made. Therefore V̇O2peak, V̇CO2peak, RERpeak, 
V̇Epeak, Bf, and VTpeak were determined from the average of the same 12 breaths 
using automated software. Peak HR, SpO2, and oxygen pulse were averaged 
over approximately the last 20 s of exercise. The lactate threshold (LT) was 
estimated non-invasively using the V-slope method (Beaver et al., 1986) and 
subsequently corroborated by an independent researcher. The V̇E/V̇CO2 nadir 
was determined as the lowest ratio of V̇E:V̇CO2.  
 
3.1.5 Statistical analyses 
All statistical analyses were completed using the Statistical Package for the 
Social Sciences (SPSS for Windows Version 25.0; IBM Corporation, Armonk, 
NY) after confirming the assumptions met for parametric testing outlined in 2.11 
of the General Methods chapter. The V̇O2peak measures obtained from RI and 
SE were assessed within each patient using unpaired Student’s t-tests to 
compare the 12-breath measures obtained at V̇O2peak. Even though this 
comparison was made within each patient, unpaired tests were used because 
the order of appearance in V̇O2 values is not paired. V̇O2max was confirmed when 
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the RI and SE V̇O2peak values did not differ significantly (P > 0.05). Where 
differences occurred (P < 0.05), the greater of the two V̇O2peak values was 
reported with its 95% confidence interval (CI95). This analysis resulted in the 
identification of two patient groups; one that confirmed V̇O2max and the other that 
did not confirm V̇O2max. A two-way repeated measures ANOVA with group and 
phase (RI and SE) treated as the independent variables was used to examine 
differences in the peak pulmonary variables between the two patient cohorts 
across RI and SE, respectively. For variables that were only obtained on one 
phase of the test, unpaired Student’s t-tests were used to evaluate differences 
between the two cohorts. Significance was accepted at P < 0.05 and all data are 
reported as mean ± SEM unless otherwise stated.  
 
3.2 Results 
3.2.1 Demographic, clinical and treatment variables 
Table 3.1 illustrates the demographic, clinical and treatment variables for all 195 
patients that completed the protocol. Of the 16 that were not included in the final 
analysis, 2 patients exhibited hyperventilation and the remaining 14 were only 
able to complete the RI phase of the test. Twelve of these patients felt unable to 
continue due to a combination of fatigue, dyspnoea, and chest pain whereas 2 
patients were stopped due to safety concerns. Therefore 7% of the patients were 
unable to complete the RISE-95 protocol giving a 93% completion rate for the 
test.  
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Table 3.1. Demographic, physical, clinical and treatment characteristics of 
patients that completed the RISE-95 protocol. Data are expressed as mean ± 
SEM unless otherwise stated.  
 n = 195 
Male sex [% (n)] 85 (166) 
Age (years) 65.2  ± 1.0 
Weight (kg) 85.9  ± 1.2 
Clinical factors    
NYHA functional class [% (n)]    
  I 34 (66) 
  II 54 (106) 
  III 12 (23) 
DM [% (n)] 23 (45) 
Ischaemic aetiology [% (n)] 41 (80) 
Mortality [% (n)] 20 (39) 
Hospitalisations [% (n)]  41 (79) 
LVEF (%) 29  ± 1 
LVIDd (mm) 58 ± 1 
Haemoglobin (g·L⁻1) 141.4  ± 1.1 
Sodium (mmol·L⁻1) 139.7  ± 0.2 
Potassium (mmol·L⁻1) 4.44 ± 0.03 
Creatinine (µmol·mL⁻1) 97.1 ± 2.2 
eGFR (mL·min⁻1·1.73m-2) 69.8 ± 1.3 
Treatment factors    
ACEi/ARB use [% (n)] 76 (149) 
Ramipril equivalent dose (mg) 6.1 ± 0.8 
Beta-blocker use [% (n)] 82 (159) 
Bisoprolol equivalent dose (mg) 5.3 ± 0.3 
Loop diuretic use [% (n)] 58 (113) 
Furosemide equivalent dose (mg) 57.4 ± 4.4 
ICD [% (n)] 7 (14) 
CRT [% (n)] 12 (24) 
NYHA, New York Heart Association; DM, type 2 diabetes mellitus; LVEF, left 
ventricular ejection fraction; LVIDd, left ventricular internal diameter at diastole; 
eGFR, estimated glomerular filtration rate; ACEi/ARB, angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers; ICD, implantable cardioverter 
defibrillator; CRT, cardiac resynchronisation therapy. 
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The cardiopulmonary responses (n = 195) to the RI and SE phases of the RISE-
95 protocol are outlined in Table 3.2. The SE phase was performed at a lower 
peak work rate and over a shorter duration (both P < 0.0001; Table 3.2). 
Importantly, however, mean group V̇O2peak was significantly increased by 0.5 
mL·kg⁻1·min⁻1 (3%) in the SE phase compared to RI (P < 0.0001; Table 3.2). 
Furthermore the highest V̇O2peak recorded over both phases of the test was 5.3% 
and 2.0% higher than RI and SE, respectively (both P < 0.0001; Table 3.2). 
Despite these findings, there were concomitant reductions in V̇CO2peak and 
RERpeak in the SE phase by 6% and 9%, respectively (both P < 0.0001; Table 
3.2). There was a small but significant 5% increase in breathing frequency in the 
SE phase (P < 0.0001), which was offset by a marginal 2% decrease in VTpeak (P 
= 0.001), both of which collectively yielded a trend for an increase in V̇Epeak by 
3% (P = 0.09; Table 3.2). Although SpO2 (%) was decreased by 1% (P = 0.006), 
oxygen pulse increased by 0.7 mL·beat⁻1 (6 %) in the SE phase (P < 0.0001; 
Table 3.2). 
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Table 3.2. Cardiopulmonary responses to the RI and SE phases of the RISE-95 
test in all 195 patients that completed the protocol. Data are expressed as mean 
± SEM.  
 RI SE 
Ramp rate (W·min⁻1) 13.4  ± 0.2    
Peak work rate (W) 97 ± 3 92  ± 3* 
Duration (mins) 6.7 ± 0.2 2.0  ± 0.1* 
V̇O2peak (L·min⁻1) 1.23 ± 0.03 1.26 ± 0.04* 
V̇O2peak (mL·kg⁻1·min⁻1) 14.3  ± 0.3 14.8 ± 0.4* 
Highest V̇O2peak, mL·kg⁻1·min⁻1 (CI95) 15.1 ± 0.3 (0.91 ± 0.06)* 
V̇CO2peak (L·min⁻1) 1.40  ± 0.04 1.31 ± 0.04* 
RERpeak  1.13 ± 0.01 1.03 ± 0.01* 
V̇Epeak (L·min⁻1) 49.3 ± 1.2 50.7 ± 1.4 
Bf (breaths·min⁻1) 29.7 ± 0.5 31.1 ± 0.5* 
VTpeak (L) 1.68 ± 0.04 1.64 ± 0.04* 
LT (L·min⁻1) 0.78  ± 0.02    
LT (mL·kg⁻1·min⁻1) 9.1 ± 0.2    
LT (% V̇O2peak) 65 ± 1    
V̇E/V̇CO2 nadir 34.3 ± 0.5    
Peak HR (beats·min⁻1) 118  ± 2 118  ± 2 
SpO2 (%) 96 ± 1 95 ± 1* 
Oxygen pulse (mL·beat⁻1) 11.4 ± 0.6 12.1 ± 0.7* 
V̇O2peak, peak pulmonary oxygen uptake; CI95, 95% confidence interval; 
V̇CO2peak, peak pulmonary carbon dioxide output; RERpeak, peak respiratory 
exchange ratio; V̇Epeak, peak ventilation; Bf, breathing frequency; VTpeak, peak 
tidal volume; LT, lactate threshold; V̇E/V̇CO2, ratio of ventilation to carbon dioxide 
output; HR, heart rate; SpO2, arterial oxygen saturation. *P < 0.01 vs. RI phase 
within subjects. 
  
3.2.2 Confirming V̇O2max using the RISE-95 protocol 
The cardiopulmonary responses (n = 195) to the RISE-95 protocol are presented 
in Table 3.3. Using a within-subject comparison to assess the 12 highest breaths 
recorded in the RI and SE phases, the RISE-95 protocol was able to statistically 
identify 74 patients (39%) that confirmed V̇O2max without the need for secondary 
criteria (Table 3.3 and Figure 3.1). The RISE-95 protocol demonstrated that the 
remaining 121 patients (61%) failed to confirm V̇O2max. Collectively these 121 
patients increased V̇O2peak by a mean 0.7 mL·kg⁻1·min⁻1 (5%) between the RI 
97 
 
and SE phases (Table 3.3 and Figure 3.1); however, amongst these 121 
patients, a small proportion (n = 32) actually had a decrease in V̇O2peak between 
these phases. Nevertheless, these 121 patients that failed to confirm V̇O2peak had 
a 1.7 mL·kg⁻1·min⁻1 (11%) higher V̇O2peak on the SE phase of the test compared 
to patients that confirmed V̇O2max. This was confirmed by a significant 
phase*group interaction in the two-way repeated measures ANOVA showing that 
the two cohorts had divergent V̇O2peak responses between RI and SE  (P = 0.006; 
Table 3.3). Furthermore, the unconfirmed cohort had a 2.0 mL·kg⁻1·min⁻1 (14%) 
higher V̇O2peak when comparing the highest V̇O2peak achieved across both phases 
(P = 0.005; Table 3.3). Representative traces of the breath-by-breath pulmonary 
oxygen uptake (V̇O2) dynamics from a confirmed cohort patient and an 
unconfirmed cohort patient are displayed in Figure 3.2 to highlight the differences 
in V̇O2peak responses between the RI and SE phases.  
 
The two-way repeated measures ANOVAs confirmed that the two cohorts 
exhibited some divergent responses in several of the pulmonary and cardiac 
variables obtained from the two phases of the test. Firstly, there was a significant 
phase*group interaction (P = 0.009) for V̇CO2peak, which decreased by 0.14 
L·min⁻1 (10%) in the confirmed cohort but only by 0.06 L·min⁻1 (4%) in the 
unconfirmed cohort (Table 3.3). There was also a significant phase*group 
interaction (P = 0.001) for peak ventilation, which decreased by 1.2 L·min⁻1 (2%) 
between RI and SE in the confirmed cohort but increased by 2.9 L·min⁻1 (6%) 
across the two phases in the unconfirmed cohort (Table 3.3). This discrepancy 
in peak ventilation may be attributed to a significant phase*group interaction (P 
= 0.033) for peak breathing frequency, which increased by 1.9 breaths·min⁻1 
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(6%) in the unconfirmed cohort between RI and SE but only increased by 0.6 
breaths·min⁻1 (2%) in the confirmed cohort (Table 3.3). Finally, there was also a 
significant phase*group interaction (P = 0.007) for peak HR, which decreased by 
2 beats·min⁻1 (2%) between the two phases in the confirmed cohort but 
increased by 2 beats·min⁻1 (2%) in the unconfirmed cohort (Table 3.3). An 
additional difference to note was that the unconfirmed cohort reached lactate 
threshold at a V̇O2 that was 1.1 mL·kg⁻1·min⁻1 (13%) higher than the confirmed 
cohort during the RI phase (P = 0.005; Table 3.3), suggesting that they had a 
delayed onset of anaerobic metabolism. In terms of clinical variables, the only 
differences between the two cohorts were a higher presence of ischaemia within 
the confirmed cohort (50% vs. 36%; P = 0.031) whilst the unconfirmed cohort 
were younger by an average of 4.4 years (P = 0.018). 
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Table 3.3. Cardiopulmonary responses to the RI and SE phases of the RISE-95 test in patients who either confirmed or failed to confirm 
V̇O2max. Data are expressed as mean ± SEM unless otherwise stated.  
 V̇O2max 
 Confirmed 
U 
Unconfirmed 
 RI 
SE 
RI 
SE RI SE 
n (%) 74 (37.9) 121 (62.1) 
Peak work rate (W) 91 ± 4 87 ± 4 100 ± 4 95 ± 3 
Duration (mins) 6.6 ± 0.3 1.8 ± 0.1 6.8 ± 0.2 2.1 ± 0.1 
V̇O2peak (L·min⁻1)* 1.18 ± 0.05 1.19 ± 0.05 1.26 ± 0.04 1.32  ± 0.05 
V̇O2peak (mL·kg⁻1·min⁻1)* 13.7  ± 0.5 
 
13.7 ± 0.5 14.7 ± 0.4 15.4 
 
± 0.5 
Highest V̇O2peak, mL·kg⁻1·min⁻1 (CI95) 13.9 ± 0.5 (1.29 ± 0.11) 15.9 ± 0.5 (0.68 ± 0.05)† 
V̇CO2peak (L·min⁻1)* 1.34 ± 0.06 1.20 ± 0.05 1.44 ± 0.05 1.38  ± 0.05 
RERpeak 1.13 ± 0.01 1.02 ± 0.01 1.13 ± 0.01 1.04  ± 0.01 
V̇Epeak (L·min⁻1)* 48.9  ± 1.8 47.7 ± 1.9 49.6 ± 1.6 52.5  ± 1.9 
Bf (breaths·min⁻1)* 30.0 ± 0.8 30.6 ± 0.8 29.5 ± 0.6 31.4  ± 0.7 
VTpeak (L) 1.66 ± 0.05 1.58 ± 0.05 1.70 ± 0.05 1.68  ± 0.05 
LT (L·min⁻1) 0.72 ± 0.03    0.82 ± 0.03†    
LT (mL·kg⁻1·min⁻1) 8.4  ± 0.2    9.5 ± 0.3†    
LT (% V̇O2peak) 63 ± 2    66 ± 1    
V̇E/V̇CO2 nadir 35.6 ± 0.9    33.4 ± 0.6    
Peak HR (beats·min⁻1)* 114 ± 3 112 ± 3 120 ± 3 122 ± 3 
SpO2 (%) 95 ± 1 95 ± 2 96 ± 1 96 ± 1 
Oxygen pulse (mL·beat⁻1) 11.1 ± 0.8 11.8 ± 1.1 11.6 ± 0.8 12.3 ± 0.9 
V̇O2peak, peak pulmonary oxygen uptake; CI95, 95% confidence interval; V̇CO2peak, peak pulmonary carbon dioxide output; RERpeak, peak 
respiratory exchange ratio; V̇Epeak, peak ventilation; Bf, breathing frequency; VTpeak, peak tidal volume; LT, lactate threshold; V̇E/V̇CO2, 
ratio of ventilation to carbon dioxide output; HR, heart rate; SpO2, arterial oxygen saturation. *P < 0.05 using a mixed two-way repeated 
measures ANOVA with group and phase (RI and SE) as the independent variables. †P < 0.05 between groups.
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Figure 3.1. V̇O2peak measures from the RISE-95 protocol. Relationship (A) and 
Bland-Altman plot (±SD) of the mean difference (Δ) (B) between the V̇O2peak 
achieved during the RI and SE phases of the RISE-95 protocol in patients who 
either confirmed (n = 74; ●) or failed to confirm (n = 121; ○) V̇O2max. 
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Figure 3.2. Representative traces of breath-by-breath V̇O2 dynamics from two 
patients that completed both phases of the RISE-95 protocol. In the top panel 
(A), the patient confirmed V̇O2max. The bottom panel (B) shows a patient that 
failed to achieve V̇O2max as demonstrated by a significant increase in the V̇O2peak 
recorded in the SE phase compared to the RI phase. Dotted lines correspond to 
the V̇O2peak measures recorded in the RI and SE phases. *P < 0.05 between RI 
and SE. 
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3.2.3 Identifying patients that increased V̇O2peak in the step-exercise 
phase of the protocol 
Table 3.5 illustrates the cardiopulmonary responses to the RI and SE phases of 
the test between “responders” and “non-responders”. Of the 121 patients that 
failed to confirm V̇O2max, 89 (46% of total cohort; Figures 3.1B and 3.3A) were 
defined as “responders” as they significantly increased their V̇O2peak by a mean 
of 1.6 mL·kg⁻1·min⁻1 (range 0.3-4.7 mL·kg⁻1·min⁻1) between the RI and SE 
phases (Figure 3.3B and Table 3.5). This corresponded to an 11.0% (range 1.5-
33.5%) increase in V̇O2peak (Figure 3.3C). Notably, out of these 89 patients, 38 
increased their V̇O2peak by > 10% in SE compared to RI. The remaining 106 
(54%) patients, deemed as “non-responders”, exhibited a mean difference (Δ) in 
V̇O2peak of -0.5 mL·kg⁻1·min⁻1 (range -6.2-1.5 mL·kg⁻1·min⁻1; Figure 3.3B and 
Table 3.5) between the RI and SE phases, which corresponded to a percentage 
difference (Δ) of -3.9% (range -37.5-9.7%; Figure 3.3C). These divergent 
responses were confirmed by a significant phase*group interaction in the two-
way repeated measures ANOVA (P < 0.0001; Table 3.5). Similarly, “responders” 
had a 2.5 mL·kg⁻1·min⁻1 (18%) higher V̇O2peak compared to “non-responders” 
when assessing the highest V̇O2peak achieved across both phases (P < 0.0001; 
Table 3.5).  
 
The two cohorts also exhibited many divergent responses between the RI and 
SE phases as evidenced from several significant phase*group interactions in the 
two-way ANOVAs. Firstly, there was a trend for the two cohorts to differ in their 
exercise durations across the two protocols (P = 0.0104) with the “responders” 
exercising for 0.8 minutes (50%; P < 0.0001; Table 3.5) longer in the SE phase 
compared to “non-responders”. There was a significant phase*group interaction 
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(P < 0.0001) for V̇CO2peak, which decreased by 0.19 L·min⁻1 (14%) in “non-
responders” but increased by 0.04 L·min⁻1 (3%) in “responders” (Table 3.5). 
Similarly, V̇Epeak decreased by 3.1 L·min⁻1 (6%) between RI and SE in “non-
responders” but increased by 6.6 L·min⁻1 (13%) in “responders” (P < 0.0001; 
Table 3.5). This response was matched by similar divergent responses in VTpeak, 
which decreased by 0.11 L (7%) in “non-responders” but increased by 0.04 L 
(2%) in “responders” (P = 0.0301; Table 3.5). Additionally, breathing frequency 
increased by 3.3 breaths·min⁻1 (11%) in “responders” whilst the “non-
responders” had a decrease in breathing frequency of 0.1 breaths·min⁻1 (0.3%)  
(P > 0.0001; Table 3.5). These changes in pulmonary variables likely contributed 
to a significant phase*group interaction (P < 0.0001) for RERpeak, which 
decreased by 0.12 (11%) in the “non-responders” but only decreased by 0.08 
(7%) in the “responders” (Table 3.5). These divergent pulmonary responses 
were matched by comparable cardiac responses such that the “non-responders” 
had a decrease in peak HR of 4 beats·min⁻1 (4%) between the two phases whilst 
“responders” increased their peak HR by 4 beats·min⁻1 (3%; P < 0.0001; Table 
3.5). There were also significant between group differences during the RI phase 
alone, with “responders” achieving LT at a V̇O2 that was 1.0 mL·kg⁻1·min⁻1 (12%) 
higher than “non-responders” (P = 0.013; Table 3.5). “Responders” also had a 
significantly lower V̇E/V̇CO2 nadir (P = 0.047; Table 3.5).  
 
Table 3.4 presents the demographic, clinical and treatment variables for the 
patients identified as either “responders” or “non-responders”. Of note, 
“responders” were younger by an average of 4.9 years (P = 0.005), were more 
likely to be NYHA class I (44% vs. 26%; P = 0.023), and were less likely to be 
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ischaemic (34% vs. 47%; P = 0.05). Interestingly, however, this cohort had more 
hospitalisations in the follow-up period (48% vs. 34%; P = 0.042).  
 
 
 
Figure 3.3. Comparing “responders” to “non-responders” from the RISE-95 test. 
Percentage of the total cohort that were defined as either "non-responders" (n = 
106) or "responders" (n = 89) as determined by the difference (Δ) in V̇O2peak 
between the RI and SE phases of the RISE-95 protocol (A). Group mean (± SEM) 
of the difference (Δ) in V̇O2peak between the RI and SE phases of the protocol in 
"non-responders" vs. "responders" expressed as an absolute V̇O2peak difference 
(Δ) (B) and a relative percentage difference (C). 
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Table 3.4. Demographic, physical, clinical and treatment characteristics of 
“responders” and “non-responders” as determined by the difference (Δ) in 
V̇O2peak between the RI and SE phases of the RISE-95 protocol. Data are 
expressed as mean ± SEM unless otherwise stated. Significant differences (P < 
0.05) are shown in bold. 
 Non-responders Responders 
n (%) 106 (54) 89 (46) 
Male sex [% (n)] 86 (91) 84.3 (75) 
Age (years) 67.4 ± 1.3 62.5 ± 1.4† 
Weight (kg) 85.1 ± 1.6 86.9 ± 1.8 
Clinical factors       
NYHA functional class [% (n)]       
  I 26 (27) 44 (39)* 
  II 62 (66) 45 (40) 
  III 12 (13) 11 (10) 
DM [% (n)] 21 (22) 26 (23) 
Ischaemic aetiology [% (n)] 47 (50) 34 (30)* 
Mortality [% (n)] 20 (21) 20 (18) 
Hospitalisations [% (n)] 34 (36) 48 (43)* 
LVEF (%) 30 ± 1 28 ± 1 
LVIDd (mm) 56 ± 1 59 ± 1 
Haemoglobin (g·L⁻1) 140.1 ± 0.2 143.0 ± 0.2 
Sodium (mmol·L⁻1) 139.5 ± 0.3 139.9 ± 0.3 
Potassium (mmol·L⁻1) 4.42 ± 0.05 4.47 ± 0.04 
Creatinine (µmol·mL⁻1) 96.7 ± 2.7 97.6 ± 3.7 
eGFR (mL·min⁻1·1.73m-2) 69.4 ± 1.7 70.3 ± 2.0 
Treatment factors       
ACEi/ARB use [% (n)] 75 (79) 79 (70) 
Ramipril equivalent dose (mg) 5.9 ± 0.4 6.4 ± 0.4 
Beta-blocker use [% (n)] 79 (84) 85 (76) 
Bisoprolol equivalent dose (mg) 4.9 ± 0.3 5.7 ± 0.4 
Loop diuretic use [% (n)] 58 (61) 58 (52) 
Furosemide equivalent dose (mg) 55.3 ± 5.0 60.0 ± 7.9 
ICD [% (n)] 5 (5) 10 (9) 
CRT [% (n)] 12 (13) 12 (11) 
NYHA, New York Heart Association; DM, type 2 diabetes mellitus; LVEF, left 
ventricular ejection fraction; LVIDd, left ventricular internal diameter at diastole; 
eGFR, estimated glomerular filtration rate; ACEi/ARB, angiotensin converting 
enzyme inhibitors/angiotensin receptor blockers; ICD, implantable cardioverter 
defibrillator; CRT, cardiac resynchronisation therapy. *P < 0.05 vs. non-
responders; †P < 0.01 vs. non-responders.   
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Table 3.5. Cardiopulmonary responses to the RI and SE phases of the RISE-95 test in “responders” and “non-responders” as determined 
by the difference (Δ) in V̇O2peak between the RI and SE phases of the protocol. Data are expressed as mean ± SEM unless otherwise 
stated. 
 Non-Responders 
U 
Responders 
 RI 
SE 
RI 
SE RI SE 
n (%) 106 (54.4) 89 (45.6) 
Peak work rate (W)* 92 ± 4 87 ± 4 103 ± 4† 97 ± 4 
Duration (mins) 6.6 ± 0.2 1.6 ± 0.1 6.8 ± 0.2 2.4 ± 0.1 
V̇O2peak (L·min⁻1)* 1.19 ± 0.05 1.15 ± 0.05 1.28 ± 0.05 1.42 ± 0.05 
V̇O2peak (mL·kg⁻1·min⁻1)* 13.8 ± 0.4 13.3 ± 0.4 14.9 ± 0.5 16.5 ± 0.5 
Highest V̇O2peak, mL·kg⁻1·min⁻1 (CI95) 14.0 ± 0.4 (1.11 ± 0.09) 16.5 ± 0.5 (0.67 ± 0.05)† 
V̇CO2peak (L·min⁻1)* 1.34 ± 0.05 1.15 ± 0.05 1.47 ± 0.06 1.51 ± 0.06 
RERpeak* 1.13 ± 0.01 1.01 ± 0.01 1.14 ± 0.01 1.06 ± 0.01 
V̇Epeak (L·min⁻1)* 48.4 ± 1.6 45.3 ± 1.6 50.5 ± 1.8 57.1 ± 2.2 
Bf (breaths·min⁻1)* 29.9 ± 0.6 29.8 ± 0.6 29.4 ± 0.7 32.7 ± 0.8 
VTpeak (L)* 1.64 ± 0.05 1.53 ± 0.05 1.73 ± 0.05 1.77 ± 0.05 
LT (L·min⁻1) 0.74 ± 0.02    0.83 ± 0.03†    
LT (mL·kg⁻1·min⁻1) 8.6 ± 0.2    9.6 ± 0.3†    
LT (% V̇O2peak) 64.2 ± 1.3    65.8 ± 1.3    
V̇E/V̇CO2 nadir 35.3 ± 0.7    33.1 ± 0.6†    
Peak HR (beats·min⁻1)* 114 ± 3 110 ± 3 123 ± 3† 127 ± 3 
SpO2 (%) 94 ± 1 95 ± 1 98 ± 1 96 ± 1 
Oxygen pulse (mL·beat⁻1) 11.9 ± 1.0 12.3 ± 1.2 10.9 ± 0.3 11.8 ± 0.6 
V̇O2peak, peak pulmonary oxygen uptake; CI95, 95% confidence interval; V̇CO2peak, peak pulmonary carbon dioxide output; RERpeak, peak 
respiratory exchange ratio; V̇Epeak, peak ventilation; Bf, breathing frequency; VTpeak, peak tidal volume; LT, lactate threshold; V̇E/V̇CO2, 
ratio of ventilation to carbon dioxide output; HR, heart rate; SpO2, arterial oxygen saturation. *P < 0.05 using a mixed two-way repeated 
measures ANOVA with group and phase (RI and SE) as the independent variables. †P < 0.05 between groups.
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3.2.4 Responses to the RISE-95 protocol in D-HF patients 
Of the 195 CHF patients, 45 (23%) had concomitant type 2 diabetes (D-HF). 
Compared to the 150 non-DM CHF patients, these 45 D-HF patients had higher 
mortality in follow-up (33% vs. 16%; P = 0.011), were less likely to be NYHA 
class I (18% vs. 39%; P = 0.034), were more ischaemic (56% vs. 38%; P = 
0.036), were more likely to be receiving a loop diuretic (82% vs. 55%; P = 0.001) 
and were more likely to have an ICD (16% vs. 5%; P = 0.016) or CRT device 
(22% vs. 10%; P = 0.027). Additionally, D-HF patients were on average 9.3 kg 
(11%) heavier (93.0 ± 3.1 vs. 83.7 ± 1.3 kg; P = 0.006), and were receiving higher 
dosages of beta-blockers (6.3 ± 0.5 mg vs. 4.9 ± 0.3 mg; P = 0.023) and loop 
diuretics (75mg ± 11 mg vs. 49 ± 4 mg; P = 0.038).  
 
Compared to CHF patients, D-HF patients had a 20% lower V̇O2peak in both the 
RI and SE phases of the RISE-95 protocol (both P < 0.0001; Figure 3.4). 
Furthermore the highest V̇O2peak measured across both phases was also 3.13 
mL·kg⁻1·min⁻1 (20%) lower in D-HF (P < 0.0001). The functional consequence 
of this exercise intolerance is demonstrated by comparably lower peak work 
rates in D-HF compared to CHF for both the RI (84 ± 5 W vs 100 ± 3 W; P = 
0.017) and SE phases (80 ± 4 W vs 95 ± 3 W; P = 0.017). Compared to CHF, D-
HF patients also exhibited a trend for a lower exercise duration over the RI phase 
only (6.0 ± 0.3 minutes vs. 6.9 ± 0.2 minutes; P = 0.071).  
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Figure 3.4. V̇O2peak responses measured in the RI and SE phases of the RISE-
95 protocol between CHF and D-HF patients. *P < 0.0001 between groups. 
 
Within the D-HF cohort of 45 patients, 16 (36%) confirmed V̇O2max and 29 (64%) 
failed to confirm V̇O2max. Additionally, 23 (51%) were defined as “responders” 
and 22 (49%) as “non-responders” (Figure 3.5A). Amongst the 150 CHF patients, 
66 (44%) were “responders” and 84 (56%) were “non-responders” (Figure 3.5A). 
There were no significant differences in terms of the percentages of “non-
responders” and “responders” between the CHF and D-HF cohorts (P > 0.05; 
Figure 3.5A). However, within the “responders” cohort, the absolute increase in 
V̇O2peak was found to be 0.49 mL·kg⁻1·min⁻1 (29%) lower in D-HF compared to 
CHF (P = 0.028; Figure 3.5B), suggesting that CHF patients may be able to 
access a greater absolute “aerobic reserve” compared to D-HF. Nevertheless, 
both the CHF and D-HF “responders” increased by a similar amount when 
expressed as a relative percentage difference (Δ) in V̇O2peak between the two 
phases (P > 0.05; Figure 3.5C).  
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Figure 3.5. V̇O2peak responses of “responders” and “non-responders” within CHF 
and D-HF patients . Percentage of the patients that were defined as either "non-
responders" or "responders" within the CHF and D-HF patient cohorts (A). Group 
mean (± SEM) of the difference (Δ) in V̇O2peak between the RI and SE phases of 
the protocol in "non-responders" vs. "responders" within the CHF and D-HF 
patient cohorts expressed as an absolute V̇O2peak difference (Δ) (B) and a relative 
percentage difference (C). 
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Although D-HF “responders” were able to increase peak ventilation and 
breathing frequency between the RI and SE phases (both P < 0.05), there were 
no differences in V̇CO2peak, VTpeak, and peak HR (all P > 0.05), thus suggesting 
that peripheral factors may play a more significant role in improving V̇O2peak in 
these patients. Indeed, oxygen pulse significantly increased from 10.9 ± 0.7 
mL·beat⁻1 to 13.2 ± 2.0 mL·beat⁻1 (P < 0.0001) between RI and SE in the D-HF 
“responders”. Although CHF “responders” also increased oxygen pulse between 
the two phases (10.9 ± 0.4 mL·beat⁻1 vs. 11.4 ± 0.4 mL·beat⁻1; P = 0.019), the 
magnitude of difference was comparably attenuated. This was supported by a 
trend for a greater increase in oxygen pulse in the D-HF “responders” compared 
to CHF “responders” between the RI and SE phases (2.3 ± 1.6 mL·beat⁻1 vs. 0.5 
± 0.2 mL·beat⁻1; P = 0.067). Therefore these D-HF “responders” appear to be 
characterised by greater peripheral limitations which are only overcome with 
prior exercise.  
 
In terms of clinical and treatment variables, D-HF “responders” were less likely 
to be ischaemic (39% v 73%; P = 0.023) yet recorded more hospitalisations in 
the follow-up period compared to D-HF “non-responders” (61% v 27%; P = 
0.023). This is consistent with the collective CHF cohort. Additionally, D-HF 
“responders” were also on a higher dosage of bisoprolol compared to the D-HF 
“non-responders” (7.7 ± 0.6 vs. 5.0 ± 0.7 mg; P = 0.010). Interestingly, however, 
these differences between “non-responders” and “responders” in terms of 
ischaemia and hospitalisations were not evident when assessing the CHF cohort 
without DM alone (both P > 0.05 between “non-responders” vs. “responders”). 
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This suggests that the RISE-95 protocol is more sensitive for detecting these 
important clinical factors in D-HF patients. Nevertheless, this comparison did 
demonstrate that the RISE-95 protocol was more sensitive for determining NYHA 
classification in the CHF without DM cohort as 35 (53%) of the 66 “responders” 
were NYHA class I whereas only 23 (27%) of the 84 “non-responders” fell into 
this classification (P = 0.002). Thus, the RISE-95 protocol may be of clinical utility 
in terms of identifying and directing treatment in both CHF and D-HF patients.  
 
3.3 Discussion 
The primary novel findings from this current study were that 1) the RISE-95 
protocol was well tolerated by a large cohort of CHF patients in a clinical setting 
with a 93% completion rate; 2) the test was sufficiently sensitive to confirm 
V̇O2max using patient-specific criterion without resorting to secondary criteria; 3) 
V̇O2max was only confirmed in 39% of CHF patients; 4) this test identified a large 
subpopulation of 89 patients (46% of the total cohort) termed “responders” that 
significantly increased their V̇O2peak by an average of 1.6 mL·kg⁻1·min⁻1 and also 
displayed distinct clinical characteristics; and 5) D-HF patients have a reduced 
exercise capacity and limited “aerobic reserve” (i.e. a blunted response to the SE 
phase of the test), which may explain the poorer prognosis seen within this 
subpopulation.  
 
3.3.1 Application of the RISE-95 protocol in patients 
One of the primary findings from this current chapter was that a large unselected 
cohort of CHF patients successfully tolerated this novel protocol without any 
adverse events. Indeed, nearly 200 patients completed the protocol safely with 
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only 14 (7%) unable to complete both phases of the test giving a completion rate 
of 93%. This is significant given that others have previously suggested that a 
verification phase following a RI test is unethical and unrealistic in clinical 
populations (van Breda et al., 2017). The current study demonstrates that this 
was not the case in our cohort of CHF patients and therefore supports previous 
studies showing the safety and efficacy of such tests in different patient 
populations (de Groote et al., 2004; Saynor et al., 2013; Astorino et al., 2018).  
 
3.3.2 Confirming V̇O2max in patients using the RISE-95 protocol 
V̇O2max is considered the gold standard measure of the maximal integrated 
functioning of the pulmonary, cardiovascular, and neuromuscular systems to 
uptake, transport, and utilize O2. V̇O2max is traditionally confirmed by a criterion 
plateau in V̇O2 despite an increase in work rate (Hill & Lupton, 1923). However, 
this plateau is rarely evident in CHF patients during continuous RI protocols 
(Piepoli et al., 2006), which has led to the recommendation that a constant-load 
SE verification phase be completed following RI to satisfy this criterion (Rossiter 
et al., 2006). Using patient-specific criterion to compare V̇O2peak measured during 
RI and SE, the current RISE-95 protocol was sufficiently sensitive to confirm 
V̇O2max in just 39% of all CHF patients without requiring secondary criteria. This 
contrasts with previous studies that have questionably rejected the necessity of 
verification phases based on the finding that the group mean “V̇O2max” is not 
statistically different between the two phases and therefore the V̇O2peak from RI 
alone is sufficient to assume a plateau (Hawkins et al., 2007; Murias et al., 2018). 
However, as previously noted (Noakes, 2008), this logic is flawed as it dismisses 
any potential within-subject differences between the two phases. Indeed, by 
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statistically comparing the highest mean V̇O2 achieved across 12 consecutive 
breaths in RI and SE, the current study demonstrates that large within-subject 
differences can exist, at least within CHF patients (Figures 3.1 and 3.2). Thus, 
future studies and current guidelines should consider the inclusion of a 
verification phase, such as that used in the RISE-95 protocol, to unequivocally 
confirm V̇O2max in the absence of a plateau.  
 
Traditionally several corroborating secondary criteria measurements have been 
used to confirm V̇O2max in the absence of the criterion plateau (Howley et al., 
1995). Of these secondary criteria, RERpeak is the most commonly used and 
recommended in CHF patients (Piepoli et al., 2006), with several thresholds (e.g. 
1.00 (Gibbons et al., 1997); > 1.05 (Mehra et al., 2016); ≥ 1.10 (Mezzani et al., 
2009)) being applied to “confirm” V̇O2max. However, the current study questions 
the validity of RERpeak for confirming (or refuting) V̇O2max attainment as we found 
that RERpeak can significantly decrease even with a significant increase in V̇O2peak 
(Table 3.2). This seemingly paradoxical finding is explained by a simultaneous 
decrease in V̇CO2peak, which was likely due to the 5 minute recovery phase 
allowing sufficient time for the lungs to fully expire CO2 accumulated from the 
metabolic acidosis induced by the RI phase. Nevertheless, this finding 
compliments previous studies querying the validity of RERpeak, which is 
significantly influenced by the ramp rate in both healthy (Buchfuhrer et al., 1983) 
and CHF (Bowen et al., 2012a) populations. Thus RERpeak should not be used 
to confirm V̇O2max in CHF patients.  
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3.3.3 Identifying “responders” to the RISE-95 protocol 
Another interesting finding of the present study was that 89 (46%) patients 
statistically increased their V̇O2peak in the SE phase of the test. This 
subpopulation of “responders” achieved a V̇O2peak in the SE phase that was, on 
average, 1.6 mL·kg⁻1·min⁻1 higher than RI, which corresponds to a remarkable 
11% increase. Furthermore there was significant inter-individual variability even 
within these 89 patients with a range of differences from 0.3-4.7 mL·kg⁻1·min⁻1 
(1.5-33.5%). Notably, 38 of these 89 patients, which represents nearly 20% of 
the entire cohort, were able to increase their V̇O2peak by > 10% in SE compared 
to RI. Importantly, these large individual differences may have been overlooked 
if only the group means were examined, as these only showed a modest increase 
of 0.5 mL·kg⁻1·min⁻1 (3%) in V̇O2peak between the RI and SE phases in all 195 
patients (Table 3.2). Therefore, the significant advantage of performing the 
RISE-95 protocol, and employing patient-specific criterion that directly compare 
the 12-breath averages between the RI and SE phases, is the ability to identify 
those CHF patients who, for some yet unknown reason, are capable of 
increasing their V̇O2peak further in the SE phase.  
 
This increase of 1.6 mL·kg⁻1·min⁻1 in V̇O2peak in these “responders” is of 
substantial clinical significance given that every reduction of just 1 mL·kg⁻1·min⁻1 
increases all-cause mortality risk by ~16% in CHF patients (Keteyian et al., 
2016). The corresponding 11% increase in V̇O2peak is also clinically significant 
given that a 6% increase in V̇O2peak can reduce all-cause mortality by 7% in CHF 
patients (Swank et al., 2012). Additionally, this acute increase in V̇O2peak is also 
impressive when compared to studies that intentionally aimed to increase 
V̇O2peak in CHF patients with long-term exercise interventions. For instance, this 
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increase of 1.6 mL·kg⁻1·min⁻1 in V̇O2peak is greater than the 1.3 mL·kg⁻1·min⁻1 
increase achieved after a 12-week high-intensity interval training program in CHF 
patients (Benda et al., 2015). Furthermore, given that 10 years of regular 
exercise training in CHF patients has been shown to increase V̇O2peak by just 3.6 
mL·kg⁻1·min⁻1 (Belardinelli et al., 2012), the acute increase of 1.6 mL·kg⁻1·min⁻1 
seen with the RISE-95 protocol is rather remarkable.  
 
Such improvements in V̇O2peak are rarely seen in healthy subjects performing 
similar protocols (Day et al., 2003; Rossiter et al., 2006). This suggests that CHF 
patients may have an “aerobic reserve”, which is alleviated by RI, allowing a 
higher V̇O2peak in SE. The functional consequence of this increase in V̇O2peak in 
terms of exercise tolerance was demonstrated by “responders” exercising at a 
12% higher peak work rate and for 50% longer during the SE phase of the 
protocol compared to “non-responders” (Table 3.5).  
 
To further elucidate the mechanisms which may be allowing this increase in 
aerobic capacity, we statistically compared the “non-responders” and 
“responders” in terms of exercise responses. This discrimination identified some 
divergent responses between the RI and SE phases of the protocol within these 
two cohorts. Firstly, V̇CO2peak decreased in “non-responders” but increased in 
“responders”, with this contributing towards a higher RERpeak in the “responders” 
during the SE phase (Table 3.5). This difference was also reflected in a lower 
V̇E/V̇CO2 nadir and a higher lactate threshold in the “responders”. Another 
significant divergent response was that V̇Epeak decreased in “non-responders” but 
increased in “responders” as a result of comparable responses in VTpeak and 
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breathing frequency (Table 3.5). This difference was matched by similar cardiac 
responses as “non-responders” exhibited a decrease in peak HR whilst 
“responders” increased their peak HR between the two phases (Table 3.5). 
Oxygen pulse significantly increased by 0.9 mL·beat⁻1 in the SE phase in only 
the “responders” (Table 3.5). This suggests that, even in the presence of an 
increased peak heart rate, O2 consumption is still increased, possibly as a result 
of increased extraction and utilization within the skeletal muscle mitochondria. 
Interestingly, even in all 195 patients oxygen pulse significantly increased by an 
average of 0.7 mL·beat⁻1, despite no change in peak HR, and therefore may 
have contributed to the modest yet significant 0.5 mL·kg⁻1·min⁻1 increase in 
V̇O2peak in the SE phase (Table 3.2). Thus, these data suggest that CHF patients, 
particularly those that may be discriminated as “responders” using the RISE-95 
protocol, may have an intramuscular limitation in O2 extraction, possibly due to 
mitochondrial utilisation, which is overcome with prior exercise, as previously 
noted (Bowen et al., 2012b).  
 
In terms of clinical characteristics, it was observed that these “responders” were 
younger, more likely to be NYHA class I and less likely to be ischaemic. 
Interestingly, however, this cohort had more hospitalisations in the follow-up 
period (48% vs. 34%). Therefore use of the RISE-95 protocol should be 
considered in CHF patients to identify these “responders” and subsequently 
guide the appropriate clinical and therapeutic intervention(s). A better 
understanding of the mechanisms underpinning this “aerobic reserve”, and an 
improved understanding of the characteristics defining these “responders”, may 
prove fruitful for developing targeted therapeutic interventions that 
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pharmacologically increase V̇O2peak in CHF patients and thus improve 
symptoms, prognosis and outcomes in this exercise intolerant population.  
 
3.3.4 Application of the RISE-95 protocol in D-HF patients 
Another aim of the present study was to determine if the RISE-95 protocol was 
sensitive to clinically significant differences in subpopulations by comparing D-
HF patients with CHF patients. Consistent with previous studies (Cubbon et al., 
2013), we found that the D-HF cohort exhibited poorer symptoms and a worse 
prognosis characterised by an increased risk of all-cause mortality. Furthermore, 
D-HF patients also had a 20% lower V̇O2peak across both phases of the protocol 
with comparable reductions in peak work rate, which is consistent with previous 
findings (Tibb et al., 2005; Ingle et al., 2006). However, it remains unclear what 
mechanisms contribute towards these differences in D-HF patients compared to 
the CHF population without DM.  
 
By using the RISE-95 protocol, we were able to compare the “responder” patients 
within both the D-HF and CHF cohorts. This comparison highlighted that the 
absolute increase in V̇O2peak is 29% lower in D-HF compared to CHF (Figure 
3.5B), suggesting that D-HF patients have greater limitations within their “aerobic 
reserve”. Indeed, this was supported by the fact that, unlike CHF “responders”, 
D-HF “responders” were unable to significantly increase V̇CO2peak, VTpeak, and 
peak HR between the RI and SE phases. Therefore peripheral factors may play 
a more significant role in increasing V̇O2peak in these patients. This postulation 
was supported by a trend for a greater increase in oxygen pulse in the D-HF 
“responders” compared to CHF “responders” between the RI and SE phases, 
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suggesting that these patients are able to improve skeletal muscle O2 extraction 
to a greater extent with prior exercise. Thus, CHF “responders” appear to be able 
to increase V̇O2peak predominantly through increases in peak HR and respiration 
whereas D-HF “responders” rely substantially more on increasing O2 extraction 
within the skeletal muscles. This discrepancy also likely explains why D-HF 
“responders” have a lower “aerobic reserve” compared to CHF “responders”. 
Future work is therefore required to uncover the mechanisms that contribute to 
the reduced V̇O2peak and “aerobic reserve” in D-HF patients, with a particular 
emphasis on what factors may be limiting skeletal muscle O2 extraction. A better 
understanding of the mechanism(s) which allow these limitations to be overcome 
(i.e. prior exercise in D-HF “responders”) may help identify potential therapeutic 
targets by which V̇O2peak can be pharmacologically increased in D-HF patients.  
 
Further scrutiny of the clinical characteristics between CHF and D-HF patients 
defined as either “non-responders” and “responders” also yielded some 
interesting findings. D-HF “responders” were less likely to be ischaemic (39% v 
73%) yet recorded more hospitalisations (61% v 27%) compared to D-HF “non-
responders”. Interestingly, these differences were not apparent when assessing 
the CHF cohort without DM alone. Thus D-HF, rather than CHF, patients appear 
to contribute substantially more to the higher incidence of hospitalisations seen 
in the “responders”. However, the RISE-95 protocol was more sensitive for 
determining NYHA classification in the CHF without DM cohort. Therefore the 
RISE-95 protocol is capable of identifying significant clinical characteristics in 
both CHF and D-HF patients and may be used to direct treatment(s) and/or 
intervention(s).  
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3.3.5 Clinical implications 
The current study proposes that RERpeak should no longer be used as a 
corroborating secondary criteria for confirming V̇O2max and that the RISE-95 test 
should be used to confirm V̇O2max attainment in CHF patients. The RISE-95 
protocol could easily be incorporated within large clinical settings, and the 
method proposed in the current study of confirming V̇O2peak by statistically 
comparing the final 12 breaths of exercise in the RI and SE phases, could also 
be installed within commercial software to provide a quick and accurate 
confirmation of V̇O2max attainment. This study demonstrates that a SE phase at 
95% peak work rate, rather than a supramaximal effort at 105% as has been 
proposed (Poole & Jones, 2017), is safe and sufficient to confirm V̇O2max and 
may be more desirable in patient populations to encourage tolerability and avoid 
potentially adverse events.  
 
3.3.6 Limitations 
One of the potential limitations of this chapter is that the clinical application of 
cardiopulmonary exercise tests may not be as rigorous as ramp-incremental 
tests undertaken in a supervised laboratory environment, where patients are 
perhaps more likely encouraged to exercise to volitional exhaustion. However, 
as one of the primary outcomes of this study was to determine the clinical utility 
of the RISE-95 protocol in a large patient population, this drawback was known 
and accepted beforehand.  
 
These assertions have significant implications for current clinical practice and 
how future CPX tests are conducted in clinical populations, such as CHF 
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patients. It is essential that accurate and reliable V̇O2max measurements are 
obtained in such clinical populations so clinicians can be confident in the 
accuracy of such measures to discriminate clinically meaningful differences 
resulting from disease progression and/or therapeutic/rehabilitation 
intervention(s) (Williams et al., 2017). Such knowledge can inform on the 
prognosis/symptomatic status of the patient and thus guide future therapeutic 
treatment(s) and/or clinical intervention(s). Indeed, it is conceivably plausible that 
incorrect measurements of V̇O2max may result in misguided clinical evaluations 
and, consequentially, misdirected therapeutic treatments and interventions.  
 
3.4 Conclusions 
The present study demonstrates that the RISE-95 exercise protocol is well 
tolerated by a large cohort of CHF patients and is sufficiently sensitive to confirm 
V̇O2max using patient-specific criterion without requiring secondary criteria. 
Therefore this protocol should be incorporated within standard clinical practice. 
Additionally, this protocol identified a large subpopulation of CHF patients 
capable of significantly increasing their V̇O2peak between the RI and SE phases 
of the test. This cohort have a distinct clinical phenotype characterised by an 
increased risk of hospitalisation despite being younger and less symptomatic. 
Finally, this study identified that the reduced V̇O2peak and “aerobic reserve” 
observed in D-HF patients may be due to impaired skeletal muscle O2 extraction. 
Therefore future research is required to better understand the mechanism(s) 
contributing towards this limitation to help identify potential therapeutic targets 
by which V̇O2peak may be pharmacologically increased. 
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Chapter 4 Results II  
Skeletal muscle mitochondrial dysfunction from upper body 
biopsies in chronic heart failure and type 2 diabetes 
4.1 Introduction 
Chronic heart failure (CHF) is characterised by exercise intolerance in the 
presence of cardiac dysfunction. However CHF patients with type 2 diabetes 
mellitus (DM) as a co-morbidity (diabetic heart failure; D-HF) have even greater 
impairments of exercise tolerance by ~20 % in terms of peak pulmonary O2 
uptake (V̇O2peak) (Results I) (Guazzi et al., 2003; Tibb et al., 2005) and 6-minute 
walk test (6-MWT) distance (Ingle et al., 2006). This reduced exercise capacity 
is associated with greater mortality (Myers et al., 2002) and a worse prognosis 
(de Groote et al., 2004; From et al., 2006; MacDonald et al., 2008a) even with 
current optimal therapies (Cubbon et al., 2013). However the mechanisms 
underpinning the poorer exercise tolerance in D-HF compared to CHF remain 
poorly resolved. One key mechanism may be related to exacerbated cardiac 
dysfunction in D-HF, yet studies have shown that D-HF patients have similar 
measures of cardiac function compared with CHF patients (MacDonald et al., 
2008b; Cubbon et al., 2013). Whether global measures of left ventricular 
performance provide the most appropriate assessment of cardiac function 
between cohorts remains to be established. However, at least for now, evidence 
suggests exercise intolerance in D-HF is at least partially exacerbated by 
peripheral mechanisms.  
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The most common assessment of exercise intolerance in CHF patients is 
V̇O2peak, which is dictated by the products of the Fick equation (Q̇ and O2 
extraction). As such, reduced skeletal muscle O2 extraction, possibly due to 
mitochondrial impairments, could be a key determinant underlying the reduced 
V̇O2peak in D-HF patients. Indeed, patients with CHF demonstrate skeletal muscle 
impairments that closely correlate to symptoms and exercise tolerance 
independent of cardiac function (Wilson et al., 1985; Massie et al., 1987a; Lipkin 
et al., 1988; Mancini et al., 1989; Mancini et al., 1992; Schaufelberger et al., 
1996; Okita et al., 1998). In particular, mitochondrial impairments have been 
reported in patients with CHF (Drexler et al., 1992; Massie et al., 1996; Guzman 
Mentesana et al., 2014), both in terms of content and function, which would limit 
the ability of muscle to utilize O2 to support energetic demands. However, 
whether D-HF exacerbates mitochondrial impairments beyond that observed in 
patients with CHF, or even DM, remains to be determined. As CHF and DM are 
associated with many factors that have been suggested to induce skeletal 
muscle abnormalities, such as fibre-type shifts, mitochondrial dysfunction, 
elevated inflammatory cytokines, increased ROS, accumulation of intracellular 
lipids, and detraining, it is likely that D-HF patients may suffer even greater 
deficits to mitochondria. 
 
At present, there are limited data available regarding mitochondrial alterations in 
D-HF patients. Despite the absence of a control group, one study observed that 
D-HF patients have low mitochondrial protein expression as well as low 
mitochondrial cristae abundance and volume density in leg muscle biopsies in 
10 people on optimal therapy (Taub et al., 2012). Interestingly, studies in CHF 
patients have largely shown that mitochondrial function, determined as the 
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activity of the individual enzyme complexes, remains normal whereas content is 
lower compared to controls (Drexler et al., 1992; Mettauer et al., 2001; Toth et 
al., 2012). This indicates that quantitative rather than qualitative mitochondrial 
impairments might form the most important factor for exercise intolerance in CHF 
patients. This has also been reported in DM patients (i.e., mitochondrial 
respiration is normal after accounting for mitochondrial content) (Kelley et al., 
2002; Morino et al., 2005; Ritov et al., 2005; Boushel et al., 2007). In subjects 
matched for physical activity, previous studies have found very few differences 
in mitochondrial measures (Mettauer et al., 2001; Williams et al., 2004; Toth et 
al., 2012; Middlekauff et al., 2013). However, these findings may have been 
confounded by detraining of the lower limbs. Indeed, while the lower limbs can 
be impacted significantly in disease due to associated detraining, the upper limbs 
may provide a more appropriate sampling site as they are more often recruited 
during daily activities (Rabøl et al., 2010).  
 
The present study, therefore, took advantage of routine pacemaker implantation 
surgery performed in the upper limbs of age-matched control, DM, CHF, and D-
HF patients, to sample the pectoralis major in order to examine whether D-HF 
induces significant impairments to mitochondrial function and content in isolation 
from the changes induced by detraining. We hypothesized that patients with D-
HF would demonstrate greater decrements in mitochondrial respiration 
compared to DM and CHF patients with these functional differences being 
negated once normalized to mitochondrial content.   
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4.2 Methods 
4.2.1 Patients 
Eligible and consecutive patients (n = 130) undergoing routine pacemaker 
therapy at Leeds General Infirmary volunteered to participate in the present 
study. All patients provided written informed consent prior to the study (Appendix 
D) after reading the participant information sheet (Appendix C). The study was 
approved by the Leeds West Research Ethics Committee (11/YH/0291) and the 
Leeds Teaching Hospitals R+D committee (CD11/10015) and all procedures 
were conducted in accordance with the Declaration of Helsinki (Appendices A 
and B). Patients were grouped into four cohorts based on the criteria for CHF 
and DM outlined in 2.1 in the General Methods chapter.   
 
4.2.2 Muscle sampling and high-resolution respiroemtry 
Skeletal muscle biopsies from pectoralis major were obtained from all patients 
during pacemaker surgery as outlined in 2.5.1 in the General Methods chapter. 
Samples (~50mg) were immediately placed in 1 mL of ice-cold BIOPS (Table 
2.1) (Fontana-Ayoub et al., 2014) and transported on ice back to the laboratory. 
Samples then underwent the appropriate mechanical and chemical 
permeabilization steps as outlined in 2.6.2 of the General Methods chapter.  
 
Samples were then dried, weighed (wet weight, WW) to ~2-6 mg (Kuznetsov et 
al., 2008) and placed within the two sealed chambers of the Oxygraph-2K 
(Oroboros Instruments, Innsbruck, Austria), each of which contained 2 mL Mir05 
(Figure 2.6B) and 5 μM blebbistatin (13186, Cayman Chemical, Ann Arbor, MI). 
Thereafter a standard SUIT protocol (outlined in 2.6.4 of the General Methods 
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chapter) was followed on the high-resolution respirometer. All solutions used in 
respirometry, including stock and final concentrations, injection volume and 
dilution, plus manufacturer’s names and product codes are detailed in Table 2.3. 
Following the SUIT protocol, the complex IV assay described in 2.6.5 was 
included to normalise the data to a marker of mitochondrial content. To confirm 
the validity of this method (Figure 2.8), mitochondrial content was quantified in a 
selection of samples (n = 27) using the citrate synthase assay given in 2.7. The 
RCR and FCRs were calculated according to the formulae outlined in 2.6.6.  
 
In 7 samples there was a complete failure to respond to any of the titrations. 
These samples were not included in the final analysis, which resulted in a total 
of 15 excluded samples (n = 8 mitochondrial membrane damage and n = 7 non-
responders). Overall, therefore, 115 patients were included in the final analysis.  
 
4.2.3 Statistical analyses 
All statistical analyses were completed using the Statistical Package for the 
Social Sciences (SPSS for Windows Version 25.0; IBM Corporation, Armonk, 
NY) after confirming the assumptions met for parametric testing and removing 
outliers as detailed in 2.11 of the General Methods chapter. Continuous variables 
were compared between groups using unpaired Student’s t-tests and separate 
one-way (one-factor) 1 × 4 ANOVA tests with post hoc analyses using Tukey’s 
multiple comparisons test. Categorical variables were compared using the two-
sided Pearson’s χ2 test. Categorical variables are presented as a percentage (%) 
of the cohort and the number (n). Continuous variables are expressed as mean 
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± SEM unless otherwise stated. Statistical significance was accepted as P < 
0.05.  
 
4.3 Results 
4.3.1 Demographic and clinical variables 
The demographic and physical characteristics of the 115 patients included in the 
final analysis are presented in Table 4.1. There were between group differences 
in body weight and renal function.  
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Table 4.1. Demographic, physical, and clinical characteristics of patients included in the final analysis grouped by their respective patient cohorts. Data are expressed 
as mean ± SEM unless otherwise stated. Significant differences (P < 0.05) are shown in bold.
 CON 
 
( 
DM CHF D-HF 
n (%) 25 (22) 10 (9) 52 (45) 28 (24) 
Male sex [% (n)] 64.0 (16) 90.0 (9) 82.7 (43) 85.7 (24) 
Age (years) 72.2 ± 2.0 74.5 ± 1.9 71.6 ± 1.6 71.4 ± 1.9 
Weight (kg) 81.0 ± 3.4 105.6 ± 8.9** 81.0 ± 2.6†† 88.6 ± 3.3† 
V̇O2peak (mL·kg⁻1·min⁻1)       15.3 ± 0.9 13.0 ± 0.6 
Clinical Factors             
NYHA functional class [% (n)] 
   I       7.7 (4) 3.6 (1) 
   II       55.8 (29) 50.0 (14) 
   III       36.5 (19) 46.4 (13) 
Ischaemic aetiology [% (n)] 
 
  
  61.5 (32) 64.3 (18) 
DCM aetiology [% (n)] 
 
 
      25.0 (13) 25.0 (7) 
AF [% (n)] 48.0 (12) 30.0 (3) 17.3 (9) 28.6 (8) 
CABG [% (n)] 28.0 (7) 10.0 (1) 21.2 (11) 25.0 (7) 
Hypertension [% (n)] 36.0 (9) 60.0 (6) 32.7 (17) 57.1 (16) 
LVEF (%)  24.8 ± 1.9 30.2 ± 2.2 
LVIDd (mm)       58.5 ± 1.4 58.4 ± 1.9 
Haemoglobin (g·L⁻1) 134.1 ± 3.7 140.8 ± 4.8 138.8 ± 2.2 128.1 ± 4.6 
Sodium (mmol·L⁻1) 138.9 ± 0.8 136.3 ± 1.4 139.4 ± 0.7 132.8 ± 5.5 
Potassium (mmol·L⁻1) 4.7 ± 0.1 4.6 ± 0.1 4.5 ± 0.1 4.6 ± 0.1 
Creatinine (µmol·mL⁻1) 86.9 ± 4.0 106.7 ± 9.3 101.1 ± 5.9 106.3 ± 9.4 
eGFR (mL·min⁻1·1.73 m-2) 69.4 ± 3.2 51.8 ± 5.5** 60.8 ± 2.6* 55.4 ± 3.6** 
Plasma Glucose (mmol·L⁻1)    9.3 ± 1.9    8.1 ± 0.6 
HbA1c (mmol·mol⁻1)    50.5 ± 6.9    62.3 ± 3.3 
V̇O2peak, peak pulmonary oxygen uptake; NYHA, New York Heart Association; DCM, dilated cardiomyopathy; AF, atrial fibrillation; CABG, coronary artery bypass 
graft; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter at diastole; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin. *P < 0.05 vs. CON; **P < 0.01 vs. CON; †P < 0.05 vs. DM; ††P < 0.01 vs. DM.  
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4.3.2 Drug and device therapy 
The use of pharmacological treatments and device therapies by each group are 
shown in Table 4.2 alongside equivalent daily dosages (mg) where appropriate. 
Patients in the two CHF cohorts were more frequently taking beta-blockers and 
at a higher dosage compared to the two non-CHF cohorts, with the D-HF cohort 
receiving a higher dose than CHF (P = 0.031). Loop diuretic use was highest in 
the two CHF cohorts with D-HF patients more likely to be taking a loop diuretic 
and also at higher equivalent dose compared with CHF alone. This is in 
agreement with the impaired renal function and worse symptoms seen in these 
patients. There was a trend for aldosterone antagonist use to be higher in the D-
HF cohort compared to CHF. Aspirin use was higher in the two CHF cohorts.  
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Table 4.2. Pharmacological treatments and device therapy. Data are expressed as mean ± SEM unless otherwise stated. Significant differences (P 
< 0.05) are shown in bold. 
 CON 
 
( 
DM CHF D-HF 
Pharmacological treatments     
ACEi use [% (n)] 36.0 (9) 50.0 (5) 61.5 (32) 53.6 (15) 
Ramipril equivalent dose (mg) 4.3 ± 1.1 8.3 ± 1.7 6.8 ± 0.9 7.0 ± 0.8 
Beta-blocker use [% (n)] 32.0 (8) 60.0 (6) 86.5 (45)**† 85.7 (24)**† 
Bisoprolol equivalent dose 
(mg) 
3.0 ± 0.6 2.9 ± 0.6 5.2 ± 0.5*† 7.6 ± 0.7**†† 
Loop diuretic use [% (n)] 16.0 (4) 30.0 (3) 48.1 (25)* 64.3 (18)**† 
Furosemide equivalent dose 
(mg) (mg) 
55 ± 15 33 ± 7 45 ± 4 100 ± 20*†‡ 
ARB use [% (n)]   21.2 (11) 32.1 (9) 
Candesartan equivalent dose 
(mg) 
 (mg) 
      15.3 ± 4.2 16.6 ± 3.1 
Aldosterone antagonist use [% 
(n)] 
  44.2 (23) 57.1 (16) 
Aldosterone antagonist dose 
(mg) 
      26.1 ± 1.1 29.7 ± 5.1 
Statin use [% (n)] 48.0 (12) 90.0 (9) 63.5 (33) 67.9 (19) 
Statin dose (mg) 35.0 ± 6.9 38.8 ± 7.2 46.4 ± 4.1 44.2 ± 6.2 
Aspirin use [% (n)] 20.0 (5) 10.0 (1) 46.2 (24)*† 46.4 (13)*† 
Metformin use [% (n)]  50.0 (5)  46.4 (13) 
Insulin use [% (n)]  20.0 (2)  10.7 (3) 
Device therapy             
PPM [% (n)] 96.0 (24) 90.0 (9)       
ICD [% (n)] 4.0 (1) 10.0 (1) 26.9 (14) 3.6 (1) 
CRT [% (n)]       73.1 (38) 96.4 (27) 
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PPM, permanent pacemaker; ICD, implantable cardioverter defibrillator; CRT, 
cardiac resynchronisation therapy. *P < 0.05 vs. CON; **P < 0.01 vs. CON; †P < 0.05 vs. DM; ††P < 0.01 vs. DM; ‡P < 0.5 vs. CHF. 
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4.3.3 High-resolution respirometry representative traces 
Figure 4.1 shows four representative O2 flux traces obtained from standard high-
resolution respirometry experiments using the SUIT protocol outlined above. 
Specific titrations of certain substrates, uncouplers and inhibitors are highlighted 
on the figure. Of note the control patient has a higher response to ADP than the 
other three patients, which was blunted most significantly in D-HF patients. 
 
Figure 4.1. Representative O2 flux traces for patients from each cohort time-
aligned to match titrations. Arrows indicate where individual titrations were made 
throughout the protocol.  
 
4.3.4 Mitochondrial oxygen flux 
Mean group O2 flux results from each of the respiratory states are presented in 
Figure 4.2. There were significant between group differences for each respiratory 
state measured. Follow-up multiple comparisons identified a lower complex I 
Leak respiration in D-HF compared to both CON (P < 0.0001; Figure 4.2) and 
CHF (P = 0.011; Figure 4.2). CHF was also lower compared to CON for complex 
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I Leak (P = 0.042; Figure 4.2). DM, CHF, and D-HF had lower measures than 
CON for complex I OXPHOS, by 33% (P = 0.002), 26% (P < 0.0001) and 62% 
(P < 0.0001), respectively (Figure 4.2). Additionally, complex I OXPHOS, in D-
HF was 43% (P = 0.008; Figure 4.2) and 49% (P < 0.0001; Figure 4.2) lower than 
DM and CHF, respectively. For complex I+II OXPHOS, the only differences were 
seen in D-HF (P < 0.0001 vs. CON; P = 0.007 vs. DM; P = 0.001 vs. CHF; Figure 
4.2). This same trend was seen for uncoupled complex I+II respiration with D-
HF being lower than each respective cohort (P = 0.003 vs. CON; P = 0.016 vs. 
DM; P = 0.004 vs. CHF; Figure 4.2). For complex II-supported ETS capacity, D-
HF was lower than both CON (P = 0.003; Figure 4.2) and DM (P = 0.011; Figure 
4.2).  
 
Figure 4.2. D-HF patients have lower mitochondrial respiration in all respiratory 
states compared to CON. The data displayed above are given as mean ± SEM. 
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using Tukey’s multiple 
comparisons post-hoc tests following significant one-way ANOVAs. 
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4.3.5 Respiratory control ratio 
The RCR, a ratio of PI to LI respiration, for each group is presented in Figure 4.3. 
A main effect (P = 0.024) was detected between groups, with post-hoc tests 
revealing a 28% reduction in D-HF compared to CHF (Figure 4.3) with similar 
trends when compared to CON (P = 0.070) and DM (P = 0.175).  
 
Figure 4.3. D-HF patients have a lower respiratory control ratio (RCR) compared 
to CHF. The RCR is the ratio between O2 flux measured with complex I substrates 
in the Leak and OXPHOS respiratory states. The data displayed above are given 
as mean ± SEM. *P < 0.05 compared to CHF using Tukey’s multiple comparisons 
post-hoc test following a significant one-way ANOVA.  
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4.3.6 Flux control ratios 
Figure 4.4 shows the group mean flux control ratios for each respiratory state. 
For complex I OXPHOS, DM, CHF, and D-HF were lower by 36% (P = 0.002), 
22% (P = 0.005), and 40% (P < 0.0001) compared to CON, respectively (Figure 
4.4). D-HF was also 23% lower than CHF (P = 0.0208; Figure 4.4). For complex 
I+II OXPHOS, only CHF was lower than CON (P = 0.0483; Figure 4.4), while D-
HF were higher than CHF for complex II-supported ETS capacity (P = 0.020; 
Figure 4.4).  
 
Figure 4.4. D-HF patients have a lower complex I flux control ratio. The data 
displayed above are given as mean ± SEM. *P < 0.05; **P < 0.01; ****P < 0.0001 
using Tukey’s multiple comparisons post-hoc tests following significant one-way 
ANOVAs. 
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4.3.7 Complex IV assay for mitochondrial content 
The O2 flux measured with the artificial complex IV electron donors TMPD and 
ascorbate is presented in Figure 4.5. A main effect (P = 0.003) was detected, 
with post hoc tests revealing that O2 flux was 33% lower in D-HF than in CON (P 
= 0.001; Figure 4.5). These findings were supported by measures of citrate 
synthase activity, which was 46% lower in D-HF compared to CON (P = 0.010; 
data not shown). The validity of the complex IV protocol was demonstrated by a 
significant correlation between these measures and citrate synthase activity in 
the 27 samples (Figure 2.8).  
 
Figure 4.5. Mitochondrial content is lower in D-HF patients. Complex IV O2 flux, 
as a marker of mitochondrial content, is significantly lower in D-HF compared to 
CON. The data displayed above are given as mean ± SEM. **P < 0.01 compared 
to CON using Tukey’s multiple comparisons test following a significant (P < 0.05) 
one-way ANOVA.  
 
 
 
C O N D M C H F D -H F
0
2 0
4 0
6 0
8 0
C
o
m
p
le
x
 I
V
 O
2
F
lu
x
(p
m
o
l 
O
2
·s
-1
·m
g
-1
W
w
)
* *
135 
 
4.3.8 Corrected mitochondrial respiration 
To account for differences in mitochondrial content, the raw O2 flux measures for 
each respiratory state were normalized to the O2 flux recorded from the complex 
IV activity assay (Figure 4.6). After adjusting the data to this measure of 
mitochondrial content, complex I OXPHOS was the only respiratory state that 
remained significantly different between the 4 cohorts (P < 0.0001; Figure 4.6). 
For this measure, D-HF was 43% and 36% lower than CON and CHF, 
respectively (both P < 0.0001; Figure 4.6).  
 
Figure 4.6. Impaired complex I function in D-HF patients. After correcting for 
mitochondrial content, only complex I OXPHOS remained significantly different 
between groups. The data displayed above are given as mean ± SEM. ****P < 
0.0001 using Tukey’s multiple comparisons test following a significant (P < 0.05) 
one-way ANOVA.  
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4.3.9 Correlation between mitochondrial function and V̇O2peak  
Exploratory analysis revealed that only O2 flux with complex I OXPHOS 
substrates correlated with V̇O2peak (Figure 4.7).  
 
Figure 4.7. Complex I O2 flux correlates with V̇O2peak. Oxygen flux with substrates 
for complex I OXPHOS significantly correlated with V̇O2peak across all patients.  
 
4.4 Discussion 
The present study aimed to explore whether D-HF patients demonstrate greater 
deficits to mitochondrial function and content than CHF, which would help 
provide a novel mechanism for why this patient cohort present with exacerbated 
exercise intolerance despite similar cardiac function. The major finding from this 
study is that D-HF patients demonstrate more severe reductions in skeletal 
muscle mitochondrial respiration compared to either CHF or DM patients, with 
the greatest impact residing at complex I. Mitochondrial complex I dysfunction 
induced by D-HF was present even after normalizing for mitochondrial content, 
suggesting D-HF induces both qualitative as well as quantitative impairments – 
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a finding that was not observed in CHF and DM patients. Furthermore 
mitochondrial coupling, as assessed by the RCR, was further impaired in D-HF 
compared to CHF and DM, which implicates a limitation linking respiration and 
phosphorylation. Functional complex I impairments were closely correlated to 
V̇O2peak, which provides strong support of a new mechanism that mediates 
exercise intolerance in patients with D-HF. Collectively, therefore, this study 
indicates that patients with D-HF are characterised by severe skeletal muscle 
mitochondrial dysfunction, which resides at complex I, and is closely correlated 
to exercise intolerance.  
 
4.4.1 Effects of CHF and DM on mitochondrial function 
Traditionally, CHF has been associated with skeletal muscle mitochondrial 
dysfunction, which is closely associated with exercise intolerance (Drexler et al., 
1992; Massie et al., 1996). However, most of these seminal early studies were 
in patients not on modern optimized medical therapies, such as beta-blockers, 
while mitochondrial alterations were inferred from standard measures such as 
assaying mitochondrial content (e.g. citrate synthase and succinate 
dehydrogenase enzyme activity levels) or isolating mitochondria for respiration. 
Both of these approaches, therefore, have limited our ability to draw inferences 
on the true effect of mitochondrial dysfunction in contemporary patients. Perhaps 
not surprisingly therefore, more recent studies on CHF patients with optimized 
drug therapy have found no significant differences in terms of in situ 
mitochondrial respiration when compared to controls matched for physical 
activity levels (Mettauer et al., 2001; Williams et al., 2004; Toth et al., 2012; 
Middlekauff et al., 2013). Similarly, many other mitochondrial measures in CHF 
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patients, with exception to a reduction in citrate synthase activity, have shown no 
differences for oxidative capacity and key mitochondrial enzymes, including 
complex I, of the vastus lateralis muscle between CHF patients and sedentary 
controls (Garnier et al., 2005).  
 
The current study used high resolution respirometry as assessed in 
permeabilized fibres and in a large cohort, to provide more rigorous insights into 
mitochondrial respiration across various complexes in CHF. The current study 
found that mitochondrial O2 flux is lower in D-HF patients and to a certain extent 
in CHF and DM patients independently. However, we also observed that 
mitochondrial content was lower in D-HF patients. Once all the data were 
corrected for mitochondrial content the majority of differences were negated 
suggesting that quantitative mitochondrial differences play a key role. However, 
a novel finding was that D-HF patients still had lower complex I OXPHOS 
respiration compared to both control and CHF patients that persisted even after 
correcting for mitochondrial content. Any differences between previous studies 
and this current study may be explained by controls being matched for physical 
activity levels as the biopsy was from the vastus lateralis. In the current study we 
sampled from the pectoralis major muscle. This represents an alternative 
approach to investigating skeletal muscle in CHF, but may be beneficial since 
the upper limbs do not undergo such extensive non-specific detraining that 
frequently occurs in the locomotor muscles of the lower limbs as a result of a 
sedentary lifestyle.  
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In contrast to human studies in CHF patients, in which subjects have many 
confounding factors, several well-control animal studies have described specific 
skeletal muscle mitochondrial alterations as a result of CHF (De Sousa et al., 
2000; Garnier et al., 2003; Zoll et al., 2006). The hind limb skeletal muscles of 
rats with heart failure induced by aortic banding show that CHF induces a 
reduction in mitochondrial respiration and oxidative enzyme activity of ~40% (De 
Sousa et al., 2000). Using a similar animal model, it was demonstrated that CHF 
decreased oxidative capacity and mitochondrial enzyme activities with 
concomitant reductions in the mRNA expression of mitochondrial proteins and 
transcription factors (Garnier et al., 2003). Similarly, O2 flux was reduced by 
~30% in saponin-permeabilized fibres of the gastrocnemius muscle in rats 4 
months after inducing a myocardial infarction via ligation of the left coronary 
artery (Zoll et al., 2006). Specifically, they noted that these reductions were 
apparent with substrates for complex I. However, even though they observed 
comparable reductions in mitochondrial content measures, the authors failed to 
correct the O2 flux measures to these and therefore failed to observe any 
potential qualitative impairments within complex I. Nevertheless there were no 
differences in the respiratory control ratio which may suggest that complex I was 
not specifically effected by this model. The discrepancies between these animal 
studies and the human studies may be explained by the large variability inherent 
with human studies coupled with the relatively small sample sizes studied.  
  
Similar to CHF, studies in DM patients have shown skeletal muscle mitochondrial 
impairments when compared to age-matched healthy controls, including lower 
complex I respiration and citrate synthase activity (Kelley et al., 2002; Boushel 
et al., 2007; Mogensen et al., 2007). However, these authors failed to normalise 
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complex I activity to mitochondrial content. Some studies have shown that 
complex I respiration is decreased in the skeletal muscle of DM patients although 
in this case, the authors concluded that DM patients have normal mitochondrial 
function since no differences between patients and control subjects remained 
after normalising the data to both citrate synthase activity and mitochondrial 
DNA, which are both markers for mitochondrial content (Boushel et al., 2007). 
Nevertheless, others have highlighted evidence of skeletal muscle mitochondrial 
dysfunction in terms of function per mitochondrial mass. Specifically, one study 
demonstrated that O2 flux in isolated mitochondria from the vastus lateralis 
muscle was lower in 10 obese DM patients compared to an age- and BMI-
matched group of 8 non-DM controls (Mogensen et al., 2007). Interestingly, 
though, this study showed that respiration was decreased in the presence of the 
complex I substrates malate and pyruvate, even after normalizing to citrate 
synthase activity as a marker of mitochondrial content. Collectively, these studies 
as well as the current study all describe mitochondrial impairments specific to 
complex I. However, discrepancies exist between the studies as to whether there 
are qualitative impairments within complex I after correcting for mitochondrial 
content. The current study shows that normalising to mitochondrial content 
negated the differences in complex I O2 flux between the control and DM groups. 
This result suggests that quantitative differences probably play a bigger role than 
qualitative changes with regards to DM. Therefore, whilst DM alone appears to 
exert a small effect on mitochondrial function, the majority of evidence (and 
including ours here) illustrates that DM exerts its greatest impact on 
mitochondrial content. 
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4.4.2 Maladaptations of mitochondria in D-HF patients 
While many studies have investigated mitochondrial function in either CHF or 
DM patients, the combined impact of D-HF remains largely unknown. This may 
have important implications, as D-HF patients have poorer outcomes compared 
to either CHF or DM alone, in terms of exercise intolerance, quality of life, and 
mortality (Guazzi et al., 2002; Tibb et al., 2005; Ingle et al., 2006; MacDonald et 
al., 2008a; Cubbon et al., 2013). The few studies investigating D-HF have 
generally shown that patients present with several different mitochondrial 
perturbations, including lower mitochondrial protein expression, fewer 
mitochondrial cristae (Taub et al., 2012), and lower mitochondrial antioxidant 
defences (Ramirez-Sanchez et al., 2013). However these studies have lacked 
control, DM, and CHF groups to make observational comparisons.  
 
In the present study one major key finding was that D-HF patients demonstrated 
the most severe impairments in mitochondrial respiration when compared to both 
the CHF and DM patient cohorts, which was specific to complex I. This suggests 
that D-HF patients have a reduced mitochondrial capacity per unit muscle mass, 
which would be predicted to contribute to a reduced V̇O2peak. Importantly, this 
effect would become even greater if D-HF patients demonstrate muscle atrophy, 
meaning V̇O2peak would be lowered by both the loss of mass and the 
mitochondrial content in the remaining mass. This reduction in mitochondrial 
respiration per unit muscle mass is probably explained in part by a lower 
mitochondrial content, which was lowest in D-HF. The current method of 
measuring complex IV activity has the advantage of being easily incorporated in 
to respirometry studies and has been previously validated against the 
aforementioned established methods of assessing mitochondrial content 
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(Larsen et al., 2012a) and our close correlation between these measures 
supports its utility. This lower mitochondrial content in D-HF is mirrored by that 
seen in previous studies of CHF and DM, which have both demonstrated lower 
mitochondrial content (Drexler et al., 1992; Kelley et al., 2002; Morino et al., 
2005; Boushel et al., 2007; Toth et al., 2012; Guzman Mentesana et al., 2014) 
compared to matched controls, as assessed by electron microscopy, 
mitochondrial DNA content, and citrate synthase activity.  
 
A major finding of the current data is that even after normalizing for mitochondrial 
content, D-HF patients still demonstrated substantial impairments to complex I 
function – a trend that was not observed in either the CHF or DM cohorts when 
compared to controls. This has important implications for our understanding of 
mitochondrial dysfunction in D-HF, as it suggests that while quantitative 
reductions underpin the lower respiration in CHF or DM, it seems that qualitative 
impairments are also playing a key role in D-HF. In particular, our data indicate 
a complex I impairment that is specific to only D-HF patients, which may offer a 
novel therapeutic target in this patient cohort. In addition, the qualitative measure 
of RCR also showed an impairment in D-HF patients that was not present in 
either CHF or DM alone. The RCR, which quantifies the capacity for complex I-
supported OXPHOS, suggests that D-HF impairs the ability of the mitochondria 
to increase respiration at complex I following the addition of ADP. This finding is 
supported by comparable results in the FCR data, which showed that the 
complex I FCR was lower in all 3 patient groups compared to the control cohort. 
Furthermore, D-HF was significantly lower than CHF, thereby suggesting that 
DM and CHF may independently impact upon the coupling efficiency of complex 
I, which is therefore exacerbated in D-HF patients.  
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4.4.3 Complex I and exercise intolerance 
Another observation of the present study was that complex I O2 flux strongly 
correlated with exercise capacity, measured as V̇O2peak. Therefore complex I 
dysfunction may provide a mechanism by which mitochondrial O2 uptake is 
impaired, which would then subsequently limit V̇O2peak as defined by the muscle 
O2 extraction component of the Fick equation. Thus, complex I may be 
considered a potential therapeutic target by which the exacerbated exercise 
intolerance seen in D-HF patients may be ameliorated. This study clearly 
indicates that D-HF induces specific impairment to mitochondrial function that 
likely underlies, in part, the severe reduction in exercise intolerance. While this 
current study did not explore the mechanisms that may induce mitochondrial 
dysfunction in D-HF patients, it may be related to a combination of mechanisms 
suggested to play a role in CHF and/or DM, such as fibre-type shifts, insulin 
resistance, chronic hyperglycaemia, elevated inflammatory cytokines, increased 
ROS, substrate overload, and accumulation of intracellular lipids. 
 
4.4.4 Limitations 
One of the drawbacks of high-resolution respirometry is that mitochondrial O2 
consumption is measured in an artificial hyperoxygenated environment that is 
not reflective of the in vivo tissue O2 concentration, which is dictated by several 
factors, including tissue capillarity and the diffusion gradient of oxygen across 
the cell membrane. Nevertheless, given that all experiments were conducted 
under the same conditions, the finding that O2 flux is reduced with complex I 
substrates is still novel and of clinical relevance. Another disadvantage is that 
this method relies on using fresh human skeletal muscle samples, as frozen 
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samples result in a reduction in mitochondrial oxygen consumption likely as a 
result of the mitochondrial membranes being damaged in the freeze-thawing 
process. Consequently, this limited the number of samples that could have 
potentially been taken and analysed, particularly from DM patients.  
 
Aside from these methodological limitations, the current SUIT protocol employed 
in this study did not directly assess the enzymatic activities of complexes III, IV 
and V, which is possible in homogenised muscle tissue. However, as O2 accepts 
electrons at complex IV, the O2 flux measured in these SUIT protocols do provide 
an indirect ex vivo measure of the capacity of complexes III and IV as well as the 
electron carriers, ubiquinone and cytochrome c, to support electron flow to 
complex IV. It may even be argued that these ex vivo measures are more 
functionally relevant than isolated measures of individual complexes. Indeed, the 
observation that O2 flux was only reduced in the presence of complex I 
substrates rather than with the complex II substrate succinate implies that D-HF 
patients have an impairment specifically within complex I and not complexes II, 
III or IV, respectively. An additional limitation is that this study did not directly 
measure ATP production or complex V activity, which would give a more 
accurate functional measurement of mitochondrial ATP resynthesis. 
Nevertheless, the reduction in O2 flux with complex I substrates observed in the 
current study suggests that electron flow to complex IV is limited, which would 
decrease proton pumping across the inner mitochondrial membrane, thus 
reducing the mitochondrial membrane potential and the capacity for ATP 
resynthesis at complex V.  
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Additionally, the correlations between mitochondrial function and exercise 
capacity were determined from V̇O2peak measurements taken from standard 
clinical cardiopulmonary ramp-incremental exercise tests, which, according to 
Results I, likely underestimated V̇O2peak. An intriguing hypothesis may be that the 
“responders” identified in Results I may be those individuals with a complex I 
impairment, which is overcome with the initial ramp-incremental component of 
the RISE-95 test thereby allowing them to achieve a higher V̇O2peak during the 
step-exercise phase. Therefore future studies may wish to sample muscle 
biopsies from CHF and D-HF patients that also completed the RISE-95 protocol.  
 
4.5 Conclusions 
This study has shown for the first time that D-HF patients are characterized by 
skeletal muscle mitochondrial dysfunction and this is more severe when 
compared to CHF or DM patients. This dysfunction is the result of both qualitative 
and quantitative alterations at mitochondrial complex I, which was well correlated 
to exercise intolerance. As such, mitochondrial complex I specific dysfunction 
may represent a novel therapeutic target for treating exercise intolerance in 
patients with D-HF. 
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Chapter 5 Results III 
Systemic skeletal muscle mitochondrial dysfunction in diabetic 
heart failure patients  
5.1 Introduction 
Patients with diabetic heart failure (D-HF) demonstrate more severe reductions 
in exercise intolerance compared to CHF without DM (Guazzi et al., 2002; Tibb 
et al., 2005; Ingle et al., 2006), which cannot be simply explained by central 
factors such as lower left ventricular ejection fraction (MacDonald et al., 2008a; 
Cubbon et al., 2013). Peripheral skeletal muscle alterations are known to 
exacerbate symptoms of exercise intolerance in CHF and DM patients, due to 
mitochondrial abnormalities (Drexler et al., 1992; Hambrecht et al., 1995; Kelley 
et al., 2002), an oxidative to glycolytic fibre type switch (Schaufelberger et al., 
1995; Mogensen et al., 2007), and impaired microvasculature (Williams et al., 
2004; Groen et al., 2014). As such, further understanding of the pathophysiology 
underlying these changes in D-HF patients may be particularly useful for 
developing potential therapeutic targets to reduce the symptoms of exercise 
intolerance.  
 
Previous studies in CHF or DM patients have generally used thigh biopsies 
extracted from the vastus lateralis to investigate skeletal muscle (mitochondrial) 
alterations (Drexler et al., 1992; Mettauer et al., 2001; Kelley et al., 2002; 
Williams et al., 2004; Garnier et al., 2005; Morino et al., 2005; Ritov et al., 2005; 
Boushel et al., 2007; Mogensen et al., 2007; Toth et al., 2012). While it is 
generally agreed mitochondrial content is lower in both CHF and DM patients 
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when measured in the vastus lateralis (Drexler et al., 1992; Mettauer et al., 2001; 
Kelley et al., 2002; Williams et al., 2004; Garnier et al., 2005; Morino et al., 2005; 
Ritov et al., 2005; Boushel et al., 2007; Mogensen et al., 2007), there is more 
controversy with regards to functional measures (normalized per muscle mass 
or mitochondria) with some (Ritov et al., 2005; Mogensen et al., 2007) but not all 
reporting impairments (Mettauer et al., 2001; Garnier et al., 2005; Boushel et al., 
2007). One explanation may be that the leg muscle is known to be considerably 
susceptible to detraining in disease (Olsen et al., 2005; Reynolds et al., 2007; 
Rehn et al., 2012). In contrast to the lower limbs, however, the upper limbs may 
represent an alternative sampling site less impacted by detraining (i.e. due to 
constant recruitment during activities of daily living). Despite this, Results II 
confirmed that the pectoralis major demonstrates greater reductions in 
mitochondrial function in patients with D-HF when compared to CHF or DM, 
which was due to both quantitative and qualitative impairments residing at 
complex I. Nevertheless, the pectoralis major has not been historically studied 
and our findings are difficult to generalize to the current literature and require 
further validation. We argued that if the proportion of mitochondrial dysfunction 
induced by D-HF is similar between the upper and lower limb extremities, then it 
would: 1) validate the pectoralis major as an alternative research site for 
investigating muscle alterations; and 2) suggest a systemic whole-body 
pathology is acting to limit mitochondrial energetics.  
 
This study, therefore, aimed to determine the impact of D-HF on mitochondrial 
function in the vastus lateralis muscle, and subsequently compare the degree of 
mitochondrial dysfunction demonstrated between upper (chest) and lower (leg) 
limb muscle groups. We hypothesized that mitochondrial alterations in the vastus 
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lateralis would be apparent, and of a similar proportion to that of the pectoralis 
major, which would indicate a systemic myopathy is present in D-HF, thus 
validating the pectoralis major as a viable alternative sampling site for assessing 
muscle alterations in disease.  
 
5.2 Methods 
5.2.1 Patients 
Fifty eligible and consecutive patients undergoing routine pacemaker therapy at 
Leeds General Infirmary volunteered to participate in the present study. All 
patients provided written informed consent prior to the study (Appendix D) after 
reading through the relevant participant information sheet (Appendix C), which 
included a detailed outline regarding the addition of the vastus lateralis biopsy. 
The study was approved by the Leeds West Research Ethics Committee 
(11/YH/0291) and the Leeds Teaching Hospitals R+D committee (CD11/10015) 
and all procedures were conducted in accordance with the Declaration of 
Helsinki (Appendices A and B). Patients were grouped into four cohorts based 
on the criteria for CHF and DM outlined in 2.1 in the General Methods chapter.  
All patients consenting to the thigh biopsy were advised to stop taking any anti-
coagulation medicine for 3 days prior to the procedure. Patients with known 
bleeding disorders were excluded from the study. One CHF patient was excluded 
from the study after consenting and performing an incremental cycle ergometer 
exercise test prior to the procedure that failed to show the presence of exercise 
intolerance (V̇O2peak = 25.87 mL·kg⁻1·min⁻1). As only a V̇O2peak < 20 
mL·kg⁻1·min⁻1 is associated with a poor prognosis in CHF (Mancini et al., 1991; 
Myers et al., 2002), this patient was considered to be unrepresentative of the 
exercise intolerant CHF population that this study was primarily interested in.  
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5.2.2 Muscle sampling and high-resolution respirometry 
Immediately prior to the pacemaker procedure, percutaneous skeletal muscle 
biopsies from the vastus lateralis muscle were obtained from patients according 
to the experimental methods outlined in 2.5.2. Following the thigh muscle biopsy 
procedure, skeletal muscle biopsies from pectoralis major were obtained from all 
patients during their pacemaker operation as described in 2.5.1. Both samples 
(~20mg) were immediately placed in to separate labelled Eppendorf tubes each 
containing 1 mL of ice-cold BIOPS (Table 2.1) (Fontana-Ayoub et al., 2014) and 
transported back to the laboratory on ice to be used for high-resolution 
respirometry analysis on the same day. The remaining muscle tissue from both 
samples was processed for histochemistry (~30 mg) or frozen in liquid nitrogen 
(~50 mg) and stored at -80 °C for later analyses. Following the procedure, 
patients received detailed verbal and written advice on how to look after the thigh 
biopsy site and were contacted several days later to ensure they had not 
experienced any adverse effects as a result of the procedure. The majority of 
patients reported that they had no discomfort with only 3 patients reporting minor 
discomfort the following day. Only one patient had an adverse response, which 
was remedied by stitching the incision site the following day to stop bleeding.  
 
High-resolution respirometry was performed on 46 of the 49 patients that 
provided vastus lateralis samples. Three samples were omitted from the analysis 
as these muscle biopsy specimens did not contain sufficient mitochondria to 
perform respirometry analysis. Of these samples, one appeared to be 
predominantly subcutaneous adipose tissue and another was mostly blood with 
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little visible skeletal muscle tissue. These were only detected after inspecting the 
samples under a light microscope and could not have been noticed when 
performing the biopsy procedure. The third sample had become necrotic 
between taking the sample and transporting back to the laboratory and did not 
respond to any of the subsequent substrate titrations included in the protocol so 
the experiment was terminated.  
 
All samples were transported back to the laboratory, typically within a few hours 
of sampling, and simultaneously underwent the mechanical and chemical 
permeabilization steps detailed in 2.6.2. Vastus lateralis and pectoralis major 
samples from the same patient were then measured in duplicate simultaneously 
on two separate Oxygraph-2K (Oroboros Instruments, Innsbruck, Austria) 
machines. Both samples were then subjected to the SUIT protocol detailed in 
2.6.4 as well as the complex IV activity assay given in 2.6.5. In all 46 samples, 
the recorded measures from each duplicate simultaneous experiment were 
averaged after correcting for ROX and the RCR and FCRs were calculated 
according to the formulae detailed in 2.6.6. The raw O2 flux results for each 
respiratory state were also corrected to complex IV activity, as a marker of 
mitochondrial content.  
 
5.2.3 Statistical analyses 
Data were analysed using the Statistical Package for the Social Sciences (SPSS 
for Windows Version 25.0; IBM Corporation, Armonk, NY) after confirming the 
assumptions met for parametric testing and removing outliers as detailed in 2.11 
of the General Methods chapter. Separate one-way (one-factor) 1 × 4 ANOVA 
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tests with appropriate post hoc tests were used to compare demographical 
variables, blood measurements, pharmacotherapy dosages and respirometry 
measurements between the four patient cohorts. Unpaired Student’s t-tests were 
also employed when comparing just two cohorts. Categorical variables were 
compared using the two-sided Pearson’s χ2 test. Pearson correlations were 
included to examine the relationships between the O2 flux measurements from 
the two muscle samples and to also explore the association between these 
measures and V̇O2peak. Categorical variables are presented as a percentage (%) 
of the cohort and the number (n). Continuous variables are expressed as mean 
± SEM unless otherwise stated. Statistical significance was accepted as P < 
0.05.  
 
5.3 Results 
5.3.1 Demographic and clinical variables  
Table 5.1 illustrates the demographic, physical and clinical characteristics for the 
46 patients on whom respirometry was performed. The four cohorts were well 
matched for age, weight and sex.  
 
 
1
5
2
 
Table 5.1. Demographic, physical and clinical characteristics of patients that provided vastus lateralis muscle biopsies grouped by their respective cohorts. Data are 
expressed as mean ± SEM unless otherwise stated. Significant differences (P < 0.05) are shown in bold. 
 CON 
 
( 
DM CHF D-HF 
n (%) 11 (24) 5 (11) 18 (39) 12 (26) 
Male sex [% (n)] 90.9 (10) 80.0 (4) 88.9 (16) 100 (12) 
Age (years) 74.0 ± 1.4 77.0 ± 3.9 68.8 ± 3.3 67.6 ± 2.9 
Weight (kg) 84.4 ± 3.3 94.1 ± 15.0 85.0 ± 5.1 88.7 ± 4.0 
V̇O2peak (mL·kg⁻1·min⁻1)       16.1 ± 1.3 13.6 ± 0.9 
Clinical Factors             
NYHA functional class [% (n)] 
   I       16.7 (3) 0 (0) 
   II       61.1 (11) 58.3 (7) 
   III       22.2 (4) 41.7 (5) 
Ischaemic aetiology [% (n)] 
 
  
  55.6 (10) 66.7(8) 
DCM aetiology [% (n)] 
 
 
      27.8 (5) 33.3 (4) 
AF [% (n)] 27.3 (3) 0 (0) 33.3 (6) 41.7 (5) 
CABG [% (n)] 0 (0) 0 (0) 22.2 (4) 16.7 (2) 
Hypertension [% (n)] 27.3 (3) 80.0 (4) 38.9 (7) 41.7 (5) 
LVEF (%) > 50 23.4 ± 1.9 27.7 ± 2.2 
LVIDd (mm)       62.2 ± 1.5 59.1 ± 2.3 
Haemoglobin (g·L⁻1) 144.1 ± 3.8 135.0 ± 5.2 141.7 ± 3.7 134.0 ± 5.5 
Sodium (mmol·L⁻1) 140.7 ± 0.8 139.0 ± 1.6 140.1 ± 0.8 137.5 ± 1.0 
Potassium (mmol·L⁻1) 4.4 ± 0.2 4.7 ± 0.2 4.5 ± 0.1 4.7 ± 0.1 
Creatinine (µmol·mL⁻1) 82.7 ± 5.8 82.6 ± 6.9 97.4 ± 11.4 116.5 ± 10.7 
eGFR (mL·min⁻1·1.73 m-2) 77.4 ± 4.4 75.4 ± 4.9 67.4 ± 4.8 58.4 ± 5.5 
Plasma Glucose (mmol·L⁻1)    7.4 ± 1.1    10.2 ± 2.0 
HbA1c (mmol·mol⁻1)    53.4 ± 7.5    63.8 ± 4.2 
V̇O2peak, peak pulmonary oxygen uptake; NYHA, New York Heart Association; DCM, dilated cardiomyopathy; AF, atrial fibrillation; CABG, coronary artery bypass 
graft; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter at diastole; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin. 
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5.3.2 Drug and device therapy 
The use of pharmacological treatments and device therapy by the 46 patients 
from each of the four cohorts are shown in Table 5.2. Equivalent daily dosages 
(mg) are given where appropriate. The two CHF cohorts received a higher 
frequency of angiotensin-converting enzyme inhibitors, beta-blockers, and loop 
diuretics treatment, while furosemide dose was highest in D-HF patients. Aspirin 
use was higher in the three patient cohorts compared to CON, while only D-HF 
patients received metformin and insulin treatment. 
 
 
1
5
4
 
Table 5.2. Pharmacological treatments and device therapy. Data are expressed as mean ± SEM unless otherwise stated. Significant 
differences (P < 0.05) are shown in bold. 
 CON 
 
( 
DM CHF D-HF 
Pharmacological treatments     
ACEi use [% (n)] 9.1 (1) 60.0 (3) 77.8 (14)**† 75.0 (9)**† 
Ramipril equivalent dose (mg) 10.0 7.5 ± 2.5 7.1 ± 1.2 8.9 ± 0.7 
Beta-blocker use [% (n)] 0 (0) 40.0 (2) 100.0 (18)**† 100.0 (12)**† 
Bisoprolol equivalent dose 
(mg) 
   2.8 ± 0.3 5.8 ± 0.9 7.6 ± 1.0 
Loop diuretic use [% (n)] 0 (0) 20.0 (1) 66.7 (12)**† 75.0 (9)**†† 
Furosemide equivalent dose 
(mg) (mg) 
   20 47 ± 5† 113 ± 54†† 
ARB use [% (n)]    16.7 (2) 
Candesartan equivalent dose 
(mg) 
 (mg) 
         12.0 ± 4.0 
Aldosterone antagonist use [% 
(n)] 
  55.6 (10) 83.3 (10) 
Aldosterone antagonist dose 
(mg) 
      23.8 ± 1.3 23.8 ± 4.0 
Statin use [% (n)] 72.7 (8) 100.0 (5) 55.6 (10) 75.0 (9) 
Statin dose (mg) 35.0 ± 8.0 44.0 ± 9.9 52.7 ± 7.1 52.2 ± 9.4 
Aspirin use [% (n)] 9.1 (1) 40.0 (2)* 44.4 (8)* 33.3 (4)* 
Metformin use [% (n)]    75.0 (9) 
Insulin use [% (n)]    16.7 (2) 
Device therapy             
PPM [% (n)] 100.0 (11) 100.0 (5) 5.6 (1) 
 
0 (0) 
ICD [% (n)] 0 (0) 0 (0) 33.3 (6) 16.7 (2) 
CRT [% (n)]   61.1 (11) 96.4 (10) 
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PPM, permanent pacemaker; ICD, implantable 
cardioverter defibrillator; CRT, cardiac resynchronisation therapy. *P < 0.05 vs. CON; **P < 0.01 vs. CON; †P < 0.05 vs. DM; ††P < 0.01 
vs. DM.  
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5.3.3 High-resolution respirometry representative traces from leg 
and chest samples 
 
Figure 5.1. Representative O2 flux traces of vastus lateralis (VL) and pectoralis 
major (PM) samples. Arrows indicate where individual titrations were made 
throughout the protocol.  
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5.3.4 Effects of D-HF on mitochondrial oxygen flux in leg muscle  
Figure 5.2 illustrates the group mean O2 flux results for the vastus lateralis 
samples. Complex I Leak respiration (LI) was 54% lower in the D-HF cohort 
compared to CON (P = 0.003) and tended to be 43% lower compared to CHF (P 
= 0.053; Figure 5.2). Complex I OXPHOS was 52% (P < 0.001) and 40% (P = 
0.010) lower in D-HF compared to CON and CHF, respectively, with a similar 
trend also observed when compared to DM (P = 0.054; Figure 5.2). Complex I+II 
OXPHOS was 39% lower in D-HF compared to CON (P = 0.016; Figure 5.2). 
Compared to CON, complex IV activity (as an index of mitochondrial content) 
was 30% and 36% lower in CHF (P = 0.040), and D-HF (P = 0.020) patients, 
respectively (Figure 5.2). There was also a trend for DM patients to be 33% lower 
than CON for complex IV activity (P = 0.139). 
  
Figure 5.2. D-HF patients have lower mitochondrial respiration in vastus lateralis 
muscle samples. The data displayed above are given as mean ± SEM.*P < 0.05; 
**P < 0.01; ***P < 0.001 using Tukey’s multiple comparisons post-hoc tests 
following significant one-way ANOVAs. 
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Figure 5.3 displays the O2 flux data after normalizing to complex IV activity as a 
marker of mitochondrial content. Although there was a main effect for complex I 
Leak (P = 0.045), pair-wise comparisons revealed no between group differences. 
Complex I OXPHOS was different between groups (P = 0.005), with D-HF being 
35% and 30% lower compared to DM (P = 0.009) and CHF (P = 0.025), 
respectively (Figure 5.3).  
 
Figure 5.3. Impaired complex I function in leg muscle of D-HF patients. After 
correcting for mitochondrial content, only complex I OXPHOS remained 
significantly different between groups. The data displayed above are given as 
mean ± SEM. *P < 0.05 using Tukey’s multiple comparisons test following a 
significant (P < 0.05) one-way ANOVA.  
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The RCR (a measure of respiratory coupling capacity) was not different between 
groups (P = 0.837; Figure 5.4A). Similarly, the flux control ratios did not differ 
between groups across all respiratory states (all P > 0.05; Figure 5.4B). 
 
 
Figure 5.4. Respiratory control ratios and flux control ratios for leg muscle 
samples. Respiratory control ratios for vastus lateralis samples did not differ 
significantly between cohorts (A). The flux control ratios did not significantly differ 
between cohorts for all respiratory states (B). The data displayed above are given 
as mean ± SEM. 
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5.3.5 Correlation between mitochondrial function and exercise 
intolerance 
To investigate the relationship between exercise intolerance and mitochondrial 
function, V̇O2peak measures from an incremental cycle ergometer exercise test 
were compared with O2 flux measures from the two muscle biopsy sites (Figure 
5.5). There were correlations between V̇O2peak with both complex I OXPHOS and 
complex IV (as a marker of mitochondrial content) O2 fluxes in both the vastus 
lateralis and pectoralis major muscle biopsies (all P < 0.05; R2: 0.29-0.61; Figure 
5.5).  
 
Figure 5.5. Muscle mitochondrial function correlates with V̇O2peak. Complex I and 
complex IV O2 flux measurements were both significantly correlated with V̇O2peak 
in both the vastus lateralis (A & B) and pectoralis major muscle samples (C & D).  
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5.3.6 Comparison of mitochondrial oxygen flux between leg and 
chest muscles 
Figure 5.6 displays the O2 flux data, both in absolute and relative terms, as well 
as the respiratory control ratio and flux control ratios for the pectoralis major 
samples taken from the 46 patients that were included in the vastus lateralis 
analysis above. These data showed comparable results to the pectoralis major 
data obtained from the larger cohort of participants that were included in Results 
II. There were between group differences for the O2 flux measurements (Figure 
5.6A). Firstly, complex I OXPHOS was 26% and 54% lower in CHF (P = 0.030) 
and D-HF (P < 0.0001) compared to CON, respectively (Figure 5.6A). 
Furthermore D-HF was also 47% and 38% lower compared to both DM (P = 
0.008) and CHF (P = 0.013) for complex I OXPHOS (Figure 5.6A). Similarly, both 
CHF and D-HF were 25% (P = 0.049) and 47% (P = 0.0002) lower than CON for 
complex I+II OXPHOS (Figure 5.6A). D-HF were also 40% (P = 0.030) lower 
than DM for this measure with a similar trend seen when compared to CHF (P = 
0.080; Figure 5.6A). D-HF were also 37% (P = 0.030) lower than CON for 
complex II-supported ETS capacity (Figure 5.6A). The RCR tended to be ~35% 
lower in D-HF compared to the 3 other groups (P = 0.203; Figure 5.6B). After 
normalizing the data to complex IV O2 flux, as a marker of mitochondrial content, 
only D-HF remained significantly lower than the other cohorts (Figure 5.6C). 
Specifically, for complex I OXPHOS, D-HF were 29% (P = 0.008), 36% (P = 
0.003), and 28% (P = 0.004) lower than CON, DM, and CHF, respectively (Figure 
5.6C). Additionally, for complex I+II OXPHOS, D-HF were 19% (P = 0.046) and 
27% (P = 0.007) lower than CON and DM, with a similar trend observed when 
compared to CHF (P = 0.068; Figure 5.6C). There were similar findings when the 
data were expressed as flux control ratios (Figure 5.6D). For complex I 
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OXPHOS, D-HF were 34% (P = 0.0003), 31% (P = 0.012), and 30% (P = 0.001) 
lower than CON, DM, and CHF, respectively (Figure 5.6D). Additionally, D-HF 
were 24% (P = 0.001) lower than CON for complex I+II OXPHOS (Figure 5.6D).  
 
Figure 5.6. D-HF patients that provided vastus lateralis samples also exhibit 
impaired mitochondrial function in pectoralis major thereby confirming the 
systemic effect of this condition. D-HF patients have lower skeletal muscle 
mitochondrial respiration in pectoralis major (A). There was a trend for the 
respiratory control ratio to be lower in D-HF compared to the other cohorts in 
pectoralis major samples (B). After correcting for mitochondrial content, complex 
I OXPHOS and complex I+II OXPHOS remained significantly lower in D-HF 
patients in pectoralis major (C). The flux control ratios for both complex I 
OXPHOS and complex I+II OXPHOS were also lower in pectoralis major 
samples from D-HF patients (D). The data displayed above are given as mean ± 
SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 using Tukey’s multiple 
comparisons post-hoc tests following significant one-way ANOVAs. 
 
To investigate the mitochondrial responses between leg and chest muscle, data 
collected from these two sampling sites were compared across the different 
respiratory states (Figure 5.7). Absolute values of mitochondrial O2 flux were well 
correlated between vastus lateralis and pectoralis major for all respiratory states 
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as well as complex IV activity (all P < 0.01; R2: 0.17-0.49; Figure 5.7). 
Interestingly, once normalized to complex IV activity, only complex I Leak and 
OXPHOS correlated across the two muscles (both P < 0.05; R2: 0.10-0.17; 
Figures 5.8A and 5.8B). Similarly, when data were expressed as flux control 
ratios, only complex I Leak and OXPHOS correlated between the two muscles 
(both P < 0.05; R2: 0.15-0.23; Figures 5.8C and 5.8D). There was also a trend 
(P = 0.056) for a correlation between the two muscles when expressed as the 
RCR (Data not shown).  
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Figure 5.7. Mitochondrial oxygen flux is well correlated between leg and chest 
samples for complex I Leak (A), complex I OXPHOS (B), complex I+II OXPHOS 
(C), complex I+II ETS (D), complex II ETS (E), and complex IV activity (F). The 
Pearson R2 value and P value obtained for each measure are displayed on the 
relevant panel. Filled circles are CON (n = 11), open circles are DM (n = 5), filled 
triangles are CHF (n = 15), and open triangles are D-HF (n = 10).    
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Figure 5.8. Complex I function is well correlated between leg and chest samples. 
After correcting for complex IV O2 flux, as a marker of mitochondrial content, 
complex I Leak (A) and complex I OXPHOS (B) remained significantly correlated 
between the two muscle samples. Similarly, when expressed as a flux control 
ratio, complex I Leak (C) and complex I OXPHOS (D) remained significantly 
correlated. The Pearson R2 value and P value obtained for each measure are 
displayed on the relevant panel. Filled circles are CON (n = 11), open circles are 
DM (n = 5), filled triangles are CHF (n = 15), and open triangles are D-HF (n = 
10). 
 
5.3.7 Mitochondrial function between leg and chest muscle  
To further characterise the relationship between vastus lateralis and pectoralis 
major O2 flux, we pooled data from all participants for each muscle group in order 
to provide global comparisons across respiratory states independent of disease 
state (Figure 5.9). In general, vastus lateralis tissue had higher absolute O2 flux 
compared to the pectoralis major samples across all respiratory states ranging 
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from 16% for complex I OXPHOS to 36% for complex IV activity (Figure 5.9A). 
However, after normalizing the data to complex IV O2 flux as a marker of 
mitochondrial content, the chest samples were higher than the leg muscle: 24% 
for complex I Leak (P = 0.006), 15% for complex I OXPHOS (P = 0.003), and 
13% for complex II ETS (P = 0.024; Figure 5.9B). The RCR did not differ between 
the two muscle samples (Figure 5.9C; P = 0.138), while complex I Leak for FCR 
was 17 % higher in pectoralis major compared to vastus lateralis (P = 0.006; 
Figure 5.9D). Therefore, this suggests that while mitochondrial capacity is higher 
per muscle mass in the leg, mitochondrial O2 flux normalised per mitochondrial 
content is higher in the chest muscle.  
 
Figure 5.9. Comparison of mitochondrial function between chest and leg 
samples. Oxygen flux per milligram of muscle tissue is consistently higher in 
vastus lateralis samples compared to pectoralis major (A). This trend is reversed 
after normalizing the data to complex IV activity (B). The respiratory control ratio 
did not differ significantly between the two tissue samples (C). Only complex I 
Leak respiration was significantly higher in the pectoralis major muscle when 
expressed as a flux control ratio (D).  
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5.4 Discussion 
The novel finding of the present study is that patients with D-HF demonstrate 
impairments to absolute mitochondrial respiration per unit muscle mass in the 
leg when compared to CHF, DM, and control patients. In particular, mitochondrial 
deficits at complex I remained in the vastus lateralis even after being normalized 
to mitochondrial content, which supports both qualitative and quantitative 
limitations to mitochondrial function. As mitochondrial impairments observed in 
D-HF were of a similar degree and well correlated to those reported from the 
chest muscle (Results II), a systemic mechanism may be acting to induce a 
mitochondrial myopathy to limit whole-body exercise tolerance. Overall, these 
data provide strong validation that the pectoralis major may be used as an 
alternative sampling site for investigating mitochondrial dysfunction in patients.  
 
5.4.1 Effects of D-HF on mitochondrial function in leg muscle 
Previous studies have examined biopsies from the vastus lateralis muscle in 
patients with both CHF (Drexler et al., 1992; Mettauer et al., 2001; Williams et 
al., 2004; Garnier et al., 2005; Brassard et al., 2006; Toth et al., 2012; 
Middlekauff et al., 2013) and DM (Kelley et al., 2002; Ritov et al., 2005; Boushel 
et al., 2007; Mogensen et al., 2007; Phielix et al., 2008; Rabøl et al., 2010; Ritov 
et al., 2010; Larsen et al., 2011). However, no previous studies have 
characterized in situ mitochondrial function in leg muscle from D-HF patients as 
compared to age-matched CHF or DM controls. While previous studies have 
taken thigh muscle biopsies from D-HF patients (Taub et al., 2012; Ramirez-
Sanchez et al., 2013), these pilot studies assessed only 5 patients and lacked 
relevant control groups of DM or CHF patients. Furthermore they did not 
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measure mitochondrial function in situ using high-resolution respirometry so 
were unable to specifically identify dysfunction within the individual complexes.  
 
Previous studies have failed to detect significant differences between CHF 
patients and sedentary age-matched controls when using respirometry methods 
to measure in situ mitochondrial O2 flux of saponin-permeabilized muscle fibres 
from the vastus lateralis (Mettauer et al., 2001; Garnier et al., 2005). These 
findings are corroborated by studies demonstrating no significant differences in 
mitochondrial ATP production rate and oxidative enzyme activity in leg muscle 
from CHF patients (Williams et al., 2004; Toth et al., 2012; Middlekauff et al., 
2013). Whilst these findings are in agreement with the present investigation, we 
did observe a trend for mitochondrial O2 flux to be 17-30% lower in in all of the 
respiratory states measured between CHF patients and controls (Figure 5.2). 
Potential explanations for any discrepancies may reside in the different methods 
employed (different substrate protocols employed) or the age of the CHF patients 
(i.e., mean age of CHF patients in the current study was 69 years while previous 
studies the age averaged 55 years (Mettauer et al., 2001; Garnier et al., 2005; 
Middlekauff et al., 2013)). Thus, any reductions in mitochondrial function 
observed in CHF may take place over a prolonged period of time with 
concomitant effects of the ageing process on mitochondrial function (Johnson et 
al., 2013). Interestingly, after normalizing for mitochondrial content such 
differences were no longer apparent, which would support other studies that 
have shown CHF lowers mitochondrial content by ~50 % even when compared 
to sedentary activity-matched controls (Mettauer et al., 2001) or by seminal 
studies showing a 20% reduction in the surface and volume density of 
mitochondrial cristae (Drexler et al., 1992). Overall, therefore, the present data 
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together with previous studies strongly suggest that a reduction in leg 
mitochondrial content is likely playing a leading role to impair mitochondrial 
bioenergetics, and thus exercise intolerance, in CHF patients.  
 
Oxygen flux was not significantly lower in DM patients compared to controls 
across the respiratory states. Several previous studies have reported 
mitochondrial respiration per unit muscle mass in vastus lateralis biopsies from 
DM patients using the same or very similar methods to those used in the present 
study. Collectively, these studies have identified reductions in O2 flux or enzyme 
activity in complex I, complex I+II, and uncoupled respiration (ETS) (Kelley et al., 
2002; Ritov et al., 2005; Boushel et al., 2007; Mogensen et al., 2007; Phielix et 
al., 2008; Rabøl et al., 2009; Ritov et al., 2010; Larsen et al., 2011). Interestingly, 
however, in some (Boushel et al., 2007; Rabøl et al., 2009; Larsen et al., 2011), 
but not all (Ritov et al., 2005; Mogensen et al., 2007; Phielix et al., 2008; Ritov et 
al., 2010), of these studies these differences were eradicated after adjusting the 
data to a marker of mitochondrial content, such as citrate synthase activity. Using 
the same substrate combinations as the current study, previous studies have 
reported a 24% and 17% reduction in complex I and complex I+II OXPHOS, 
respectively (Rabøl et al., 2009). Similarly, others have reported differences of 
18% and 27% for complex I Leak and complex I OXPHOS (Boushel et al., 2007). 
These findings are not too dissimilar to the 16%, 15% and 18% differences 
observed in the present study between DM and control for complex I Leak, 
complex I OXPHOS and complex I+II OXPHOS, respectively. Similarly, these 
two studies also found that these differences were negated after normalising the 
data to citrate synthase activity (Boushel et al., 2007; Rabøl et al., 2009), which 
is also in agreement with the current study, thereby suggesting that lower 
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mitochondrial content is the primary driver for mitochondrial deficits in DM 
patients.  
 
In relation to D-HF patients, the present study noted a significant 36% reduction 
in mitochondrial content compared to controls, as evidenced by lower complex 
IV activity, which was also lower in both the CHF and DM patients. Consistent 
with previous studies in CHF or DM, it seems D-HF induces a deficit in 
mitochondrial content. Importantly, however, the current study still found 
respiratory impairments were present in D-HF patients after normalizing the data 
to mitochondrial content. This was not apparent in either the CHF or DM patients 
alone. This would support the hypothesis that the D-HF phenotype per se 
induces qualitative as well as quantitative mitochondrial impairments, which 
seem to primarily reside at complex I. Collectively, therefore, these findings build 
upon the hypothesis we drew from the pectoralis major muscle in that CHF and 
DM independently lower mitochondrial content, but also that D-HF leads to a 
specific complex I dysfunction. Whether this complex I impairment provides a 
potential mechanism for the lower exercise capacity in D-HF remains unclear, 
but our correlative data support this hypothesis.  
 
5.4.2 Mitochondrial function is comparable across upper and lower 
limbs  
An additional aim of the current study was to examine if mitochondrial function 
yielded comparable results between vastus lateralis and pectoralis major 
muscles, in order to validate our novel chest sampling method. We found O2 flux 
measurements across respiratory states were well correlated between both leg 
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and chest muscle samples (Figure 5.7), which provides initial evidence that 
pectoralis major sampling may be considered an alternative surrogate for 
investigating mitochondrial dysfunction in both health and disease.  
 
This is the first study to demonstrate parallel upper and lower limb mitochondrial 
function in both CHF and DM populations. Previous studies have compared leg 
with shoulder biopsies in DM patients and age-matched obese and lean controls 
(Larsen et al., 2009; Rabøl et al., 2010). Similar to the current study, these two 
studies found that O2 flux per milligram muscle tissue are consistently higher in 
the vastus lateralis muscle (Larsen et al., 2009; Rabøl et al., 2010), yet they 
differed after normalising data to citrate synthase activity. For example, one 
study found respiration per mitochondria content in the musculus deltoideus was 
higher than vastus lateralis (Rabøl et al., 2010), which is similar to our data here 
where pectoralis major had higher respiratory function normalized for 
mitochondrial content. This finding suggests that intrinsic qualitative function for 
this muscle is higher than that seen in vastus lateralis, which, in contrast, is 
characterised by an increased mitochondrial content. Although studies have 
shown arm and leg muscle have divergent adaptive responses to exercise 
training (Turner et al., 1997; Nordsborg et al., 2015), the exact mechanisms 
behind this higher intrinsic function in pectoralis major remain to be fully 
elucidated. It is likely that the higher O2 fluxes and mitochondrial content seen in 
vastus lateralis muscle are localised effects driven by the higher metabolic 
requirements placed upon this muscle in daily life, which would promote a shift 
in muscle phenotype to predominantly type I oxidative fibres and a higher 
mitochondrial content (Holloszy & Booth, 1976). While mitochondrial O2 flux has 
yet to be investigated in two separate muscle tissues from CHF patients, 
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previous studies have shown that CHF patients present with comparable 
abnormalities across both upper and lower limbs, including a higher activity of 
the metaboreflex system during exercise (Scott et al., 2002) and earlier 
decreases in muscle PCr and pH during submaximal exercise (Nagai et al., 
2004).  
 
One major finding of the current study is that D-HF causes mitochondrial complex 
I dysfunction when normalized to either muscle mass or mitochondrial content in 
both leg and chest muscle – a finding that neither we nor others have reported 
in CHF or DM patients previously (Mettauer et al., 2001; Garnier et al., 2005; 
Boushel et al., 2007). Given these effects were seen in both the lower and upper 
limbs in D-HF only, it is intriguing to speculate that a systemic mechanism(s) may 
be driving a potential mitochondrial myopathy. Interestingly, RCR values were 
comparable across all groups when assessed in leg muscle, which is in contrast 
to that observed in the chest muscle where D-HF patients showed greater 
deficits. While previous studies have reported no significant differences in the 
RCR in the vastus lateralis muscle between controls and DM (Boushel et al., 
2007; Larsen et al., 2011) or CHF patients (Mettauer et al., 2001), our findings 
suggest mitochondria in D-HF show greater impairments to respond to an influx 
of ADP in the upper compared to the lower limbs. While the underlying 
mechanisms causing this potential systemic mitochondrial myopathy in D-HF are 
yet to be determined, likely factors include chronic hyperglycaemia, insulin 
resistance, circulating inflammatory cytokines, and ROS. Importantly, as similar 
impairments were largely seen in D-HF between chest and leg mitochondrial 
function, it would imply a detraining effect is playing a limited role as this would 
be expected to impact the leg muscles to a greater extent.  
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5.4.3 Limitations 
The current study did not investigate any differences in fibre type composition 
between pectoralis major and vastus lateralis. Therefore it is unknown whether 
the observed differences between these two muscles in terms of mitochondrial 
function may be attributed to differences in muscle fibre types e.g. a higher 
proportion of type I fibres may explain the higher mitochondrial O2 flux observed 
in vastus lateralis. Moreover, it is also unknown how each of the clinical 
populations included in this study may differ in terms of fibre type composition 
within each of these muscles. Therefore future studies may wish to further 
explore fibre type composition within two different muscles.   
 
5.5 Conclusions 
This study demonstrated that skeletal muscle mitochondrial dysfunction in D-HF 
patients is not isolated to the pectoralis major by showing comparable defects in 
the vastus lateralis. This dysfunction appears to be, at least in part, due to a 
reduction in mitochondrial content, which has been extensively reported in CHF 
and DM populations alone. However, and similar to the pectoralis major, a 
qualitative defect to mitochondrial complex I function specific to D-HF patients 
was apparent even after adjusting for mitochondrial content. This study further 
demonstrated O2 flux measurements measured from chest and leg muscle are 
well correlated, which provides validation for using the pectoralis major as an 
appropriate sampling site for investigating mitochondrial dysfunction in patients 
with chronic disease when more viable than invasive leg biopsies (e.g., during 
routine pacemaker surgery
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Chapter 6 Results IV 
Identification of the mechanisms contributing to skeletal 
muscle mitochondrial dysfunction in diabetic heart failure 
6.1 Introduction 
Diabetic heart failure (D-HF) patients are characterised by a systemic skeletal 
muscle mitochondrial dysfunction, with both quantitative and qualitative 
impairments being revealed in the last few chapters. Mitochondrial dysfunction 
may contribute, at least in part, to the poorer exercise tolerance seen in D-HF 
patients, as it would be expected to decrease the capacity of the muscle to 
extract and utilise O2. Together with O2 delivery, the latter is a major component 
of the Fick equation and thus a key determinant of peak pulmonary oxygen 
uptake (V̇O2peak). As such, a better understanding of the mechanisms 
contributing to mitochondrial dysfunction in D-HF patients may uncover novel 
therapeutic targets to treat symptoms of exercise intolerance, and thus improve 
prognosis. 
 
Imbalance in cellular gene expression is implicated in many pathological 
conditions. In this regard, seminal studies have identified a lower expression in 
the genes encoding for mitochondrial OXPHOS proteins, including PPARγ 
coactivator-1α (PGC-1α) in DM and insulin-resistant skeletal muscle (Sreekumar 
et al., 2002; Yang et al., 2002; Mootha et al., 2003; Patti et al., 2003). 
Interestingly, similar results have been observed in animal models of CHF 
(Garnier et al., 2003; Zoll et al., 2006; Seiler et al., 2016); however patient data 
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remains inconclusive (Garnier et al., 2003; Toth et al., 2012; Forman et al., 2014). 
Additionally, studies in DM patients have shown that several genes encoding for 
the core subunits of complex I, such as NDUFS1, are downregulated in skeletal 
muscle (Wu et al., 2017). One key mechanism modulating mitochondrial gene 
and protein expression is increased mitochondrial ROS production (Kowaltowski 
et al., 2009). Animal models (Coirault et al., 2007; Bowen et al., 2015a; Martinez 
et al., 2015; Mangner et al., 2016) and patient studies (Linke et al., 2005; 
Guzman Mentesana et al., 2014) with CHF have shown enhanced skeletal 
muscle ROS production and oxidative stress. However, whether D-HF muscle 
generates elevated mitochondrial ROS remains unknown. 
 
In addition, reductions in muscle mitochondrial function in D-HF may be linked to 
fiber atrophy and isoform shifts (Schiaffino & Reggiani, 2011), with several 
studies demonstrating these effects in CHF and DM patients. Specifically, these 
studies demonstrate that both CHF and DM induce a similar fibre type shift from 
type I oxidative to type II glycolytic fibres (Sullivan et al., 1990; Schaufelberger 
et al., 1995; Massie et al., 1996; Schaufelberger et al., 1997; Sullivan et al., 1997; 
Oberbach et al., 2006; Mogensen et al., 2007). This fibre type shift is associated 
with atrophy, which is more apparent in type II fibres in CHF and DM (Li et al., 
2007; Yu et al., 2008; Kemp et al., 2009). Furthermore, impairment in O2 delivery 
may also predispose to mitochondrial alterations and exercise intolerance. 
Several studies have shown that CHF and DM are both characterised by 
impairments in skeletal muscle capillarisation (Marin et al., 1994; Schaufelberger 
et al., 1995; Schaufelberger et al., 1997; Duscha et al., 1999; Nusz et al., 2003; 
Williams et al., 2004; Groen et al., 2014); however the impact in D-HF patients 
remains unknown.  
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The current chapter, therefore, aimed to characterise in detail the molecular, 
cellular, and structural alterations that occur in D-HF skeletal muscle, in order to 
identify mechanisms that may be potentially underlying the severe mitochondrial 
dysfunction in these patients. We were particularly interested in determining 
whether differences existed between D-HF relative to both the DM and CHF 
patients in relation to measures of muscle gene expression, mitochondrial ROS 
production, fibre properties, and capillarity.  
 
6.2 Methods 
6.2.1 Patients 
Seventy-seven eligible and consecutive patients undergoing routine pacemaker 
therapy at Leeds General Infirmary volunteered to participate in the present 
study. All patients provided written informed consent (Appendix D) prior to the 
study after reading through the relevant participant information sheet (Appendix 
C). The study was approved by the Leeds West Research Ethics Committee 
(11/YH/0291) and the Leeds Teaching Hospitals R+D committee (CD11/10015) 
and all procedures were conducted in accordance with the Declaration of 
Helsinki (Appendices A and B). Patients were grouped into four cohorts based 
on the criteria for CHF and DM outlined in 2.1 in the General Methods chapter.   
 
6.2.2 Pectoralis major muscle sampling and tissue processing 
Skeletal muscle biopsies from pectoralis major were obtained from all patients 
during their pacemaker operation as described in 2.5.1 of the General Methods 
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chapter. Immediately following the biopsy, one sample was immediately snap-
frozen in liquid nitrogen and stored at -80 °C for gene expression analyses as 
detailed in 2.10. A second sample (~20mg) was placed in to a labelled 1.5 mL 
Eppendorf tube containing 1 mL of ice-cold BIOPS (Table 2.1) (Fontana-Ayoub 
et al., 2014) to be used for simultaneous high-resolution respirometry with H2O2 
production measurements as described in 2.8. A third sample was mounted on a 
pinned cork disc in optimum cutting temperature (Thermo Fisher Scientific, 
Waltham, MA) embedding medium (Figure 2.5). This sample was snap frozen in 
isopentane (2-Methylbutane; Sigma-Aldrich, St Louis, MO) cooled in liquid 
nitrogen and stored at -80 °C until later immunohistochemical analyses, which 
are outlined in 2.9.  
 
6.2.3 Statistical analyses 
Data were analysed using the Statistical Package for the Social Sciences (SPSS 
for Windows Version 25.0; IBM Corporation, Armonk, NY) after confirming the 
assumptions met for parametric testing and removing outliers as detailed in 2.11 
of the General Methods chapter. Independent samples Student t-tests and 
separate one-way (one-factor) 1 × 4 ANOVA tests with Tukey’s post hoc test were 
used to compare differences in continuous variables between the four patient 
cohorts. Categorical variables were compared using the two-sided Pearson’s χ2 test. 
Categorical variables are presented as a percentage (%) of the cohort and the 
number (n). Continuous variables are expressed as mean ± SEM unless 
otherwise stated. Statistical significance was accepted as P < 0.05.  
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6.3 Results 
6.3.1 Demographic and clinical variables 
Table 6.1 illustrates the demographic, physical and clinical characteristics for the 
77 patients included in these analyses. The four cohorts were well matched for 
weight and sex with a trend for the D-HF cohort to be younger. In agreement with 
previous studies, D-HF had a lower V̇O2peak compared to CHF. Despite this, D-
HF had better cardiac function, as evidenced by a higher LVEF compared to 
CHF. In agreement with the previous chapters, DM and D-HF also had greater 
renal impairments, as indicated by a lower eGFR.  
 
6.3.2 Drug and device therapy 
The use of pharmacological treatments and device therapy by the 77 patients 
are shown in Table 6.2. Equivalent daily dosages (mg) are given where 
appropriate. The two CHF cohorts received a higher frequency of angiotensin-
converting enzyme inhibitors, beta-blockers, and loop diuretics, with dosages for 
these tending to be higher in the D-HF patients. 
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Table 6.1. Demographic, physical, and clinical characteristics of patients grouped by their respective patient cohorts. Data are expressed as mean ± SEM unless 
otherwise stated. Significant differences (P < 0.05) are shown in bold. 
 CON 
 
( 
DM CHF D-HF 
n (%) 20 (26.0) 17 (22.0) 20 (26.0) 20 (26.0) 
Male sex [% (n)] 75.0 (15) 88.2 (15) 90.0 (18) 90.0 (18) 
Age (years) 74.2 ± 1.6 77.6 ± 1.6 72.4 ± 2.5 69.1 ± 2.3 
Weight (kg) 85.5 ± 3.7 94.8 ± 6.4 82.0 ± 3.4 82.4 ± 3.4 
V̇O2peak (mL·kg⁻1·min⁻1)       15.3 ± 1.4 12.1 ± 0.5‡ 
Clinical Factors             
NYHA functional class [% (n)] 
   I       10.0 (2) 5.0 (1) 
   II       65.0 (13) 50.0 (10) 
   III       25.0 (5) 45.0 (9) 
Ischaemic aetiology [% (n)] 
 
  
  60.0 (12) 65.0 (13) 
DCM aetiology [% (n)] 
 
 
      30.0 (6) 35.0 (7) 
AF [% (n)] 40.0 (8) 17.6 (3) 30.0 (6) 40.0 (8) 
CABG [% (n)] 20.0 (4) 11.8 (2) 30.0 (6) 40.0 (8) 
Hypertension [% (n)] 35.0 (7) 47.1 (8) 40.0 (8) 55.0 (11) 
LVEF (%) >50 22.6 ± 2.6 30.0 ± 2.2‡ 
LVIDd (mm)  
 
± 
59.8 ± 1.7 59.3 ± 1.8 
Haemoglobin (g·L⁻1) 136.4 ± 4.6 132.9 ± 4.3 141.2 ± 3.0 135.4 ± 4.4 
Sodium (mmol·L⁻1) 139.3 ± 0.9 137.0 ± 1.2 139.9 ± 0.8 132.7 ± 6.7 
Potassium (mmol·L⁻1) 4.4 ± 0.1 4.7 ± 0.1 4.6 ± 0.1 4.6 ± 0.1 
Creatinine (µmol·mL⁻1) 87.9 ± 4.1 104.3 ± 7.2 107.8 ± 10.4 114.4 ± 10.5 
eGFR (mL·min⁻1·1.73 m-2) 69.6 ± 3.6 57.2 ± 4.2* 61.8 ± 4.0 52.5 ± 4.1* 
Plasma Glucose (mmol·L⁻1)    9.1 ± 1.3    8.8 ± 0.8 
HbA1c (mmol·mol⁻1)    47.6 ± 4.8    62.6 ± 4.2 
V̇O2peak, peak pulmonary oxygen uptake; NYHA, New York Heart Association; DCM, dilated cardiomyopathy; AF, atrial fibrillation; CABG, coronary artery bypass 
graft; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal diameter at diastole; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin. *P < 0.05 vs. CON; ‡P < 0.05 vs. CHF. 
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Table 6.2. Pharmacological treatments and device therapy. Data are expressed as mean ± SEM unless otherwise stated. Significant 
differences (P < 0.05) are shown in bold. 
 CON 
 
( 
DM CHF D-HF 
Pharmacological treatments     
ACEi use [% (n)] 30.0 (6) 35.3 (6) 75.0 (15)**†† 65.0 (13)**†† 
Ramipril equivalent dose (mg) 4.8 ± 1.2 8.8 ± 1.3 5.7 ± 0.8 7.7 ± 0.9 
Beta-blocker use [% (n)] 25.0 (5) 41.2 (7) 95.0 (19)**†† 85.0 (17)**† 
Bisoprolol equivalent dose 
(mg) 
3.8 ± 0.8 2.9 ± 0.6 5.2 ± 0.7 6.8 ± 0.9 
Loop diuretic use [% (n)] 15.0 (3) 17.6 (3) 45.0 (9)*† 75.0 (15)**†† 
Furosemide equivalent dose 
(mg) 
66.7 ± 13.3 33.3 ± 6.7 44.4 ± 6.5 82.9 ± 13.2 
ARB use [% (n)]   10.0 (2) 15.0 (3) 
Candesartan equivalent dose 
(mg) 
 (mg) 
      6.0 ± 2.0 17.3 ± 8.1 
Aldosterone antagonist use [% 
(n)] 
  45.0 (9) 60.0 (12) 
Aldosterone antagonist dose 
(mg) 
      23.6 ± 1.4 31.8 ± 7.4 
Statin use [% (n)] 65.0 (13) (13) 75.0 (15) 65.0 (13) 
Statin dose (mg) 35.0 ± 10.4 34.6 ± 5.9 39.2 ± 4.6 50.0 ± 7.7 
Aspirin use [% (n)] 30.0 (6) 11.8 (2) 45.0 (9) 30.0 (6) 
Metformin use [% (n)]  29.4 (5)  45.0 (9) 
Insulin use [% (n)]  17.6 (3)  10.0 (2) 
Device therapy             
PPM [% (n)] 95.0 (19) 94.1 (16)   
ICD [% (n)] 5.0 (1) 5.9 (1) 20.0 (4) 5.0 (1) 
CRT [% (n)]   80. (16) 95.0 (19) 
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; PPM, permanent pacemaker; ICD, implantable 
cardioverter defibrillator; CRT, cardiac resynchronisation therapy. *P < 0.05 vs. CON; **P < 0.01 vs. CON; †P < 0.05 vs. DM; ††P < 0.01 
vs. DM.  
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6.3.3 Gene expression 
Figure 6.1 illustrates the relative (to the control cohort) mRNA expression of the 
6 genes of interest included in this study. PGC-1α expression was 31%, 13% 
and 24% lower in DM, CHF, and D-HF compared to CON, respectively, but did 
not reach significance (P > 0.05). Compared to CON, SOD2 expression was not 
different in DM and CHF (P > 0.05); however, it was reduced by 42% in D-HF (P 
= 0.036; Figure 6.1B) and tended to be 36% lower compared to CHF (P = 0.087). 
NDUFS1 expression was lower by 55% (P = 0.031) and 49% (P = 0.037; Figure 
6.1C) in D-HF compared to CON and CHF, respectively. NDUFS1 expression 
also tended to be 49% lower in D-HF compared to DM (P = 0.072). In contrast, 
no differences were found between groups for the gene expression of NDUFS3, 
FIS1or OPA1 (all P > 0.05; Figure 6.1E-F).  
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Figure 6.1. Relative mRNA expression of key mitochondrial genes. SOD2 and 
NDUFS1 were both lower in D-HF patients. The data displayed above are given 
as mean ± SEM. *P < 0.05 using independent samples Student t-tests.  
 
6.3.4 High-resolution respirometry with H2O2 production 
Figure 6.2 illustrates the relative H2O2 production across the different respiratory 
states. D-HF resulted in an ~8-fold and ~7-fold higher H2O2 production with 
complex I substrates in the Leak state (LI) compared to CON (P = 0.007) and 
DM (P = 0.011), respectively (Figure 6.2). During complex I OXPHOS (PI), H2O2 
production was ~14-fold, ~12-fold, and ~4-fold higher compared to CON (P < 
0.0001), DM (P = 0.0001), and CHF (P = 0.0009), respectively (Figure 6.2). 
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During simultaneous electron flow with complex I and II substrates (PI+II), H2O2 
production was ~6-fold and ~4-fold higher in D-HF compared to CON (P = 0.016) 
and DM (P = 0.041), respectively (Figure 6.2). Following uncoupling with these 
substrates still present (EI+II), H2O2 production was ~7-fold, ~6-fold and ~3-fold 
higher in D-HF compared to CON (P = 0.0002), DM (P = 0.0005), and CHF (P = 
0.0018), respectively (Figure 6.2). This same trend continued even after 
inhibiting complex I (EII) with H2O2 production being ~8-fold, ~11-fold and ~5-fold 
higher in D-HF compared to CON, DM, and CHF, respectively (All P < 0.0001; 
Figure 6.2). Figure 6.3 displays the relationship between complex I H2O2 
production and complex I function.  
 
Figure 6.2. Relative fold changes in mitochondrial H2O2-emission across different 
respiratory states during simultaneous high-resolution respirometry. The data 
displayed above are given as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001 using Tukey’s multiple comparisons post-hoc tests following 
significant one-way ANOVAs.  
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Figure 6.3. The relationship between complex I H2O2 production and complex I 
function in terms of O2 flux (A) and the flux control ratio (B).  
 
6.3.5 Muscle isoform composition and fibre cross-sectional area 
Figure 6.4 shows the mean fibre-specific cross-sectional area (i.e., FCSA). Mean 
FCSA in D-HF patients was 44% and 30% smaller than CON (P = 0.001) and 
CHF (P = 0.044), respectively (Figure 6.4). Type I FCSA did not differ between 
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groups; however, type IIa FCSA was 39% smaller in DM compared to CON (P = 
0.009; Figure 6.4) and there was a trend for CHF to have smaller type IIa fibres 
compared to CON (P = 0.115). Type IIa FCSA was also 53% and 39% smaller 
in D-HF compared to CON (P < 0.0001) and CHF (P = 0.001), respectively 
(Figure 6.4). Type IIx fibres were 50% smaller in DM compared to CON (P = 
0.015; Figure 6.4). Furthermore, type IIx FCSA was 65% and 52% smaller in D-
HF compared to CON (P = 0.0003) and CHF (P = 0.014), respectively (Figure 
6.4).  
 
Figure 6.4. Mean fibre cross-sectional area (µm2) across each cohort according 
to fibre type. The data displayed above are given as mean ± SEM. *P < 0.05; **P 
< 0.01; ***P < 0.001; ****P < 0.0001 using Tukey’s multiple comparisons post-
hoc tests following significant one-way ANOVAs.  
 
Figure 6.5 shows the numerical and areal densities for each fibre type within 
each of the cohorts. CHF had a higher areal density of type IIx fibres compared 
to DM (P = 0.040) and D-HF (P = 0.035), respectively (Figure 6.5). D-HF also 
had a higher areal density of type I fibres compared to CHF (P = 0.014; Figure 
6.5). 
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Figure 6.5. Fibre numerical and areal densities for each fibre type according to 
the respective cohorts. The data displayed above are given as mean ± SEM. *P 
< 0.05 vs. CHF for corresponding fibre type using Tukey’s multiple comparisons 
post-hoc tests following significant one-way ANOVAs.  
 
Figure 6.6 shows the individual (A-C) and composite (D) images obtained from 
a serial transverse cryo-section stained for capillaries, basal membrane, and 
type I MHC isoform, while representative composite images from each patient 
cohort are presented in Figure 6.7. 
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Figure 6.6. Staining protocol for determining capillaries and fibre types. Individual 
(A-C) and composite (D) images obtained from a serial transverse cryo-section 
stained for capillaries (A), basal membrane (B), and type I MHC isoform (C). 
†Shows corresponding type I fibres in each image. *Shows corresponding type 
II fibres in each image. Scale bar represents 200 µm.  
 
Figure 6.7. Representative composite images of histological staining obtained 
from CON (A), DM (B), CHF (C), and D-HF patients (D). Type I MHC fibres are 
stained red; type II MHC fibres are stained green; the basal membrane is stained 
blue. Scale bar represents 200 µm.  
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6.3.6 Skeletal muscle capillarisation 
Figure 6.8 displays both the global and localised (fibre type-specific) indices of 
capillarity as well as the capillary domain area and heterogeneity of capillary 
distribution. Although there were no significant differences in the capillary-to-fibre 
ratio, the LCFR was significantly lower in D-HF patients in both IIa and IIx fibres, 
with LCFR for IIa fibres 34% lower in D-HF compared to CON (P = 0.011; Figure 
6.8C). Additionally, the LCFRs for IIx fibres were 40% and 55% lower in DM (P 
= 0.023) and D-HF (P = 0.0003) compared to CON (Figure 6.8C). Conversely, 
capillary density and LCD were both higher in D-HF fibres compared to CON and 
CHF. Capillary density was 63% and 37% higher in D-HF compared to CON (P 
= 0.007) and CHF (P = 0.034), respectively (Figure 6.8B). The LCD was 46% (P 
= 0.023), 62% (P = 0.021), and 49% (P = 0.029) higher in D-HF compared to 
CON for type I, type IIa and type IIx fibres, respectively (Figure 6.8D). 
Furthermore, the LCD was 41% (P = 0.0499) and 45% (P = 0.0174) higher in D-
HF compared to CHF for type IIa and type IIx fibres, respectively (Figure 6.8D). 
These differences in LCD and CD likely reflect the previous findings of atrophy 
in these corresponding fibre types (Figure 6.4). The capillary domain area was 
also lower across the cohorts according to the one-way ANOVA (P = 0.040) but 
there were no significant pairwise comparisons in the post-hoc tests with a trend 
for a lower capillary domain area in D-HF compared to CON (P = 0.052; Figure 
6.8E). There were no differences in the heterogeneity of capillary distribution 
between cohorts (Figure 6.8F).  
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Figure 6.8. Global and localised indices of capillarisation. D-HF was associated 
with a lower LCFR yet higher capillary density and LCD. The data displayed 
above are given as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001 using 
Tukey’s multiple comparisons post-hoc tests following significant one-way 
ANOVAs. 
 
6.4 Discussion 
The primary findings of this study are that in skeletal muscle from D-HF patients 
there is: 1) a lower expression of the key mitochondrial regulatory genes SOD2 
and NDUFS1; 2) a substantial increase in mitochondrial-derived ROS; 3) 
significant fibre atrophy; and 4) impairments to capillarity including a lower local 
capillary-to-fibre ratio (LCFR). Overall, therefore, these findings provide novel 
data on various mechanisms that may contribute to the severe skeletal muscle 
mitochondrial pathology (and exercise intolerance) demonstrated by D-HF 
patients.  
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6.4.1 Mitochondrial related genes  
The current study observed that both the SOD2 and NDUFS1 genes were 
downregulated in skeletal muscle tissue from D-HF patients. Whether these 
represent potential therapeutic targets in D-HF to treat mitochondrial dysfunction, 
remains an exciting future avenue. The SOD2 gene encodes for the 
MnSOD/SOD2 enzyme, which is the SOD isoform residing within the 
mitochondrial matrix and is a primary antioxidant combating mitochondrial ROS 
(Murphy, 2009). SOD2 dismutates O2·-, produced primarily at complexes I and 
III, to generate H2O2. Previous studies have shown that CHF and DM are 
associated with a lower SOD and SOD2 skeletal muscle gene expression, 
protein content and enzyme activity levels (Linke et al., 2005; Rush et al., 2005; 
Holmstrom et al., 2012; Ramirez-Sanchez et al., 2013; Mangner et al., 2015; 
Martinez et al., 2015). Further evidence comes from murine studies, where 
SOD2 genetic deletion confirmed its causal role in the development of 
mitochondrial dysfunction and subsequent CHF pathology (Nojiri et al., 2006), 
while SOD2 overexpression prevented high-fat diet induced insulin resistance 
(Boden et al., 2012). Collectively, these data support the inference that a low 
expression of SOD2 could contribute to the severe mitochondrial pathology and 
disease severity observed in D-HF patients. Further research is therefore 
required to determine the exact role of SOD2 in D-HF. 
 
Few studies in either CHF or DM have assessed the expression of genes 
encoding for core mitochondrial subunits of complex I, such as NDUFS1 and 
NDUFS3. NDUFS1 is the largest (75 kDa) subunit of complex I and forms a 
component of the 8 iron-sulphur chains involved in transferring electrons from 
NADH oxidation at the flavin mononucleotide to the ubiquinone binding site 
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where the electron acceptor, ubiquinone, is reduced to ubiquinol (Hirst, 2013; 
Zhu et al., 2016). In line with the current study, one previous study has shown 
that several genes encoding for the subunits of complex I, including NDUFS1, 
are downregulated in skeletal muscle samples from DM patients (Wu et al., 
2017). Thus it remains plausible that a lower expression of the NDUFS1 gene 
could impact NDUFS1 protein expression or function to consequently impair 
complex I respiration (and even increase the formation of O2·-). Further research 
is thus required to confirm whether low NDUFS1 expression impacts 
mitochondrial function in D-HF.  
 
6.4.2 Mitochondrial ROS  
To further characterise the functional consequences of the lower SOD2 and 
NDUFS1 gene expression, we determined mitochondrial H2O2 production 
simultaneously with O2 flux measurements in order to provide a marker of 
mitochondrial-derived ROS (Krumschnabel et al., 2015b; Makrecka-Kuka et al., 
2015). This method highlighted that permeabilized skeletal muscle fibres from D-
HF patients have a substantially higher mitochondrial ROS production compared 
to CON, DM and CHF patients, and in particularly at complex I. This novel finding 
supports previous data where both CHF and DM have been associated with 
increased global markers of ROS in skeletal muscle (Tsutsui et al., 2001; Rush 
et al., 2005; Coirault et al., 2007; Bonnard et al., 2008; Anderson et al., 2009). 
The mechanisms underlying this elevated mitochondrial ROS in D-HF remain 
unclear, but it could be related to hyperlipidaemia and hyperglycaemia, as these 
conditions have been shown to be associated with increased mitochondrial ROS 
production that result in mitochondrial dysfunction (Bonnard et al., 2008; 
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Anderson et al., 2009; Yokota et al., 2009; Bravard et al., 2011). Likewise, animal 
models of CHF (Tsutsui et al., 2001; Rush et al., 2005; Coirault et al., 2007; 
Supinski & Callahan, 2007; Martinez et al., 2015; Laitano et al., 2016; Mangner 
et al., 2016) and CHF patients (Guzman Mentesana et al., 2014) also exhibit 
enhanced skeletal muscle ROS production and oxidative stress (Ohta et al., 
2011). Several studies have shown that treatment with mitochondrial-specific 
antioxidants, including SOD2, in addition to exercise training, are able to 
ameliorate oxidative stress in skeletal muscle and this is linked to improved 
mitochondrial function and insulin sensitivity in both CHF (Ennezat et al., 2001; 
Gielen et al., 2005; Linke et al., 2005; Supinski & Callahan, 2005; Okutsu et al., 
2014; Gomes et al., 2016; Mangner et al., 2016) and DM (Yokota et al., 2009; 
Hey-Mogensen et al., 2010; Brinkmann et al., 2012; de Oliveira et al., 2012; 
Barbosa et al., 2013; Takada et al., 2015; Mason et al., 2016). Overall, these 
data provide strong support for mitochondrial-derived ROS playing a key role in 
the pathogenesis of the reduced muscle mitochondrial function in D-HF patients.  
 
6.4.3 Skeletal muscle isoform and atrophy 
Given that previous studies have documented a fibre type shift from type I to type 
IIx fibres in both CHF (Sullivan et al., 1990; Schaufelberger et al., 1995; Simonini 
et al., 1996; Schaufelberger et al., 1997; Sullivan et al., 1997; Middlekauff et al., 
2013) and DM (Marin et al., 1994; Nyholm et al., 1997; Oberbach et al., 2006), 
and this isoform is associated with an increase in mitochondrial H2O2 production 
(Anderson & Neufer, 2006), we decided to determine if D-HF patients exhibit a 
fibre type shift. However, we did not find any differences between patient cohorts 
and controls in terms of numerical fibre density. Nevertheless, we did observe 
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differences in fibre areal densities between CHF patients and the two DM 
cohorts. However, as areal density is influenced by changes in FCSA (Egginton, 
1990a), these differences were likely driven by the observation of a greater 
atrophy of both type IIa and IIx fibres in DM and D-HF patients in the presence 
of a preserved FCSA of type I fibres in all patient cohorts.  
 
We also observed a trend for type IIa fibres to atrophy in CHF patients. These 
findings support previous studies indicating fibre type-specific atrophy of 
glycolytic type II fibres in CHF (Sullivan et al., 1990; Xu et al., 1998; Li et al., 
2007; Yu et al., 2008), DM (Almond & Enser, 1984; Kemp et al., 2009), and 
ageing skeletal muscle (Deschenes, 2004; Brunner et al., 2007; Picard et al., 
2011a; Nilwik et al., 2013; Murgia et al., 2017). The functional consequence of 
this fibre atrophy includes reduced muscle mass, which in turn decreases muscle 
strength (dynapenia), thereby contributing to a vicious cycle of inactivity and 
exercise intolerance that ultimately increases mortality risk in CHF and DM 
(Anker et al., 1997; Park et al., 2006; Park et al., 2009; Kim et al., 2010; Leenders 
et al., 2013; Kim et al., 2014). While the exact mechanisms mediating this fibre-
type specific atrophy are still being uncovered, it is believed that increased 
inflammation, oxidative stress, and angiotensin II concentrations as well as 
reduced Akt (protein kinase b) activation and PGC-1α expression all can promote 
protein degradation while inhibiting protein synthesis in CHF and DM (Li et al., 
1998; Li et al., 2003b; Cai et al., 2004; Wang et al., 2006; Geng et al., 2011; 
Ostler et al., 2014; Du Bois et al., 2015). As such, in the current study our D-HF 
group may be characterized by elevated proteolysis (i.e. increased activation of 
ubiquitin-proteasome, autophagy-lysosomal, and caspase-3 pathways) and/or a 
down-regulation in anabolic signalling, such as the IGF1-Akt-mTOR pathway 
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(Perry et al., 2016). Interestingly, elevated mitochondrial ROS has been shown 
to directly induce atrophy in animal models of wasting (Fulle et al., 2004). As 
such, further work is therefore warranted to confirm whether impairments in 
protein homeostasis contribute to the greater fibre atrophy in D-HF and whether 
increased mitochondrial ROS is playing a causal role.  
 
6.4.4 Skeletal muscle capillarisation 
To provide greater insight into potential O2 delivery limitations in D-HF, the 
current study also employed state-of-the-art computational capillarity modelling 
(Al-Shammari et al., 2014). Impairments in capillarity can reduce convective and 
diffusive O2 delivery to mitochondria, thus limiting mitochondrial function. 
Interestingly, we observed an increase in capillary density (CD) in D-HF patients, 
which was matched by comparable increases in the fibre-type specific measure 
of LCD. However, using the scale-independent measure of LCFR, we were able 
to detect significant fibre-type specific capillary rarefaction in both type II fibres 
in D-HF patients as well as type IIx fibres in DM patients. It is interesting to note 
that these differences were not evident when the global measure of capillary-to-
fibre ratio (CF) was quantified. Thus the increased sensitivity of the LCFR 
method was sufficient to identify significant differences that may have otherwise 
been undetected. Although an increase in CD has also been previously observed 
in both CHF (Mancini et al., 1989) and insulin-resistant subjects (Eriksson et al., 
1994), the majority of studies have shown a decrease in CD and C:F (Marin et 
al., 1994; Schaufelberger et al., 1995; Schaufelberger et al., 1997; Duscha et al., 
1999; Nusz et al., 2003; Williams et al., 2004; Groen et al., 2014). Our divergent 
responses may partly be explained by the greater atrophy of type II fibres in D-
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HF patients. Thus, even with an increased CD within a particular region of 
interest, the LCFR is still decreased due to a higher number of fibres within the 
region.  
 
Previous studies measuring LCFR, have shown that it is reduced in both fibre 
types in DM patients (Groen et al., 2014). Similarly, a decreased number of 
capillaries contacting both type I and IIx fibres has been reported in CHF patients 
(Williams et al., 2004). However, some studies have shown that CHF reduces 
the capillary-to-fibre ratio specifically in type II muscle fibres (Xu et al., 1998). 
Although we did not explore the exact mechanisms contributing to the fibre type-
specific reduction in LCFR in D-HF patients, it is possible to speculate on some. 
In the context of insulin resistance, it has been shown that a decreased 
expression of vascular endothelial growth factor induces capillary rarefaction in 
skeletal muscle (Bonner et al., 2013). Similarly, intramuscular VEGF 
overexpression has been shown to increase capillarity in an animal model of 
CHF (Zisa et al., 2009). Thus VEGF may be considered a potential therapeutic 
target for ameliorating capillary rarefaction in D-HF patients. A reduced LCFR 
may even decrease O2 delivery to individual fibres such that a hypoxic state is 
induced. Therefore it seems reasonable to speculate that severe impairments to 
microvascular O2 delivery in D-HF patient may render some areas of the muscle 
hypoxic, which is well known to promote complex I deactivation (Galkin et al., 
2009). As such, this may be another mechanism contributing to the low 
mitochondrial function in D-HF patients. This may even be exacerbated by 
endothelial dysfunction, which is known to occur in DM (Bauer et al., 2007; 
Muniyappa & Sowers, 2013) and CHF (Hambrecht et al., 1999b).  
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6.4.5 Limitations 
One possible limitation of the current study was the limited analysis of gene 
expression aside from genes encoding for mitochondrial complex I proteins. 
However, given that gene expression analyses are time-consuming and 
expensive, the current study had to be selective in the gene targets included. 
Therefore, given that the previous two chapters had identified complex I as a 
dysfunctional mitochondrial protein in D-HF patients, the current chapter decided 
to focus on genes encoding for this enzyme. An additional drawback is the 
inability to confidently exclude other potential sources of superoxide anion 
production within the cell which may have contributed to the elevated H2O2 
production levels observed in D-HF patients. Indeed, the activity and expression 
of NADPH oxidase, a membrane-bound enzyme which produces superoxide 
anion in the process of regenerating the NADP+ pool, is upregulated with 
hyperglycaemia and angiotensin II overactivation, both of which characterise the 
D-HF phenotype. Therefore future studies may wish to isolate the effects of 
mitochondrial and other cellular sources of superoxide anion production. Finally, 
this study also draws into question the utility of the capillary:fibre ratio as a useful 
marker of morphological adaptations within the muscle. As this global measure 
only quantifies the ratio between these two indices, it does not provide an 
indication of how each of these variables are changing alone and therefore often 
lacks the sensitivity to identify localised changes within the redistribution of 
capillaries around individual fibres of different isoforms. Therefore future studies 
may wish to incorporate the LCFR, as in the current chapter, to better identify 
changes within the redistribution of capillaries around individual fibres. Finally, 
this study also failed to measure any plasma concentrations of pro-inflammatory 
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cytokines or angiotensin II as possible markers mediating the systemic complex 
I dysfunction observed in Results III. Therefore future studies should include 
blood samples to measures these variables and provide a more conclusive 
understanding of the potential mechanisms mediating complex I dysfunction.  
 
6.5 Conclusions 
In summary, the current study elucidated several novel mechanisms that may 
contribute to the severe skeletal muscle mitochondrial dysfunction and exercise 
intolerance demonstrated in D-HF patients. Evidence included low expression of 
key mitochondrial genes (i.e. SOD2 and NDUFS1), elevated mitochondrial-
derived ROS, fibre atrophy, and impaired capillarity. As such, these may 
represent viable therapeutic targets for attenuating muscle mitochondrial 
impairments in patients with D-HF.  
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Chapter 7 General discussion 
Chronic heart failure (CHF) and type 2 diabetes mellitus (DM) remain two major 
primary causes of mortality and morbidity (Kannel & McGee, 1979; Metra & 
Teerlink, 2017). Importantly, recent evidence shows a disturbing trend indicating 
an increased prevalence of both conditions in combination, which is termed 
diabetic heart failure (D-HF) (Lehrke & Marx, 2017). Estimates indicate that ~25-
30% of CHF patients have DM (MacDonald et al., 2008a; MacDonald et al., 
2008b; Cubbon et al., 2013; van Deursen et al., 2014; Dei Cas et al., 2015; 
Seferovic et al., 2018), yet despite this large, and increasingly growing, 
population there are no targeted therapeutic treatments for D-HF patients, which 
is somewhat surprising given that these patients have a significantly worse 
prognosis than CHF alone (Shindler et al., 1996; de Groote et al., 2004; 
Gustafsson et al., 2004; Cubbon et al., 2013; Dauriz et al., 2017; Seferovic et al., 
2018). We hypothesised that, as mortality is strongly determined by exercise 
capacity (Myers et al., 2002) and D-HF patients have a worse exercise 
intolerance than CHF (Guazzi et al., 2002; Tibb et al., 2005; Ingle et al., 2006), 
that an improved understanding of the mechanisms limiting exercise capacity in 
D-HF may uncover potential therapeutic targets to ameliorate symptoms and 
improve outcomes in this population. To this end, the present thesis focused on 
improving our understanding of exercise intolerance, and in particular skeletal 
muscle alterations, in D-HF patients.  
 
7.1 Summary of key findings 
The first study (Results I) of this thesis employed a novel CPX test (termed the 
RISE-95) in a clinical hospital to better evaluate exercise intolerance in the 
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general CHF population, but with an added focus on the response of D-HF 
patients. This study confirmed previous clinical findings indicating that V̇O2peak 
and exercise capacity are reduced by ~20% in D-HF patients compared to typical 
CHF patients (Guazzi et al., 2002; Tibb et al., 2005; Ingle et al., 2006). 
Furthermore this chapter also extended the findings of a previous pilot study 
performed in the research laboratory, showing that around 20% of CHF patients 
can access an “aerobic reserve” that allows them to increase V̇O2peak by a 
clinically-important threshold (Bowen et al., 2012a). Interestingly, this “aerobic 
reserve” was still evident in the D-HF population. 
 
To further elucidate the potential mechanisms contributing to exercise 
intolerance in D-HF patients, the second study (Results II) investigated skeletal 
muscle mitochondrial dysfunction in age-matched control, DM, CHF and D-HF 
patients. This study exploited the opportunity to extract muscle biopsies from the 
pectoralis major muscle of patients undergoing routine pacemaker and ICD/CRT 
device implantations. The major finding from this study was that D-HF patients 
demonstrated more severe reductions in skeletal muscle mitochondrial 
respiration compared to either CHF or DM patients. Interestingly, after 
normalizing the data to account for differences in mitochondrial content, we 
identified a specific complex I myopathy. Therefore it was concluded that D-HF 
induces both qualitative as well as quantitative impairments to mitochondria. To 
corroborate these findings and validate chest muscle sampling, the next study 
(Results III) examined skeletal muscle mitochondrial dysfunction in leg vastus 
lateralis biopsies, obtained from the same patients. Again, this study confirmed 
the previous observation that D-HF induces both quantitative and qualitative 
mitochondrial impairments, with the latter residing at complex I. That these 
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alterations were present in both upper and lower limb muscles suggest a 
systemic effect is acting in D-HF to induce mitochondrial deficits.  
 
The final study of this thesis (Results IV) aimed to further characterise the 
potential mechanisms contributing to skeletal muscle mitochondrial impairments 
in D-HF, and uncovered several contributory factors likely involved, such as an 
increased mitochondrial ROS production and downregulated expression of key 
mitochondrial genes. Furthermore this study revealed that D-HF patients exhibit 
a type II fibre-specific atrophy and capillary rarefaction, which may also 
contribute to mitochondrial impairments. Collectively, these findings expand our 
current knowledge regarding how D-HF impacts skeletal muscle and identifies 
potential therapeutic targets (i.e. the mitochondria) by which exercise intolerance 
may be ameliorated in these patients.  
 
7.2 Why is exercise intolerance exacerbated in D-HF patients? 
The Results I chapter of this thesis confirmed several previous studies (Guazzi 
et al., 2002; Tibb et al., 2005; Ingle et al., 2006), which indicated that exercise 
intolerance (i.e. V̇O2peak), is reduced in D-HF compared to CHF. Notably, the 
novel finding from this study was that around half of both CHF and D-HF patients 
exhibit an “aerobic reserve” that permits them to increase V̇O2peak in the step-
exercise (SE) phase of the RISE-95 protocol. Collectively, 46% of patients 
statistically increased their V̇O2peak in the SE phase of the test by an average of 
1.6 mL·kg⁻1·min⁻1, or 11%, as compared to the “gold-standard” ramp-
incremental protocol (Table 3.5). In comparison to the other 54% of patients who 
did not display this “aerobic reserve”, this 11% increase in V̇O2peak in the SE 
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phase translated to a higher peak work rate and exercise duration, respectively. 
While these findings may be somewhat surprising considering the only previous 
study in CHF patients using the RISE-95 protocol found that only ~20% of 
patients increased V̇O2peak by an average of 1.3 mL·kg⁻1·min⁻1 (Bowen et al., 
2012a), this study was performed under research laboratory settings from a 
small sample size (n = 24). The substantial improvements in exercise tolerance 
and functional capacity seen in the present study are clinically significant, given 
that a 6% higher V̇O2peak is associated with a 7% lower risk of all-cause mortality 
in CHF patients (Swank et al., 2012). As this response is rarely seen in healthy 
subjects performing similar exercise protocols (Day et al., 2003; Rossiter et al., 
2006), this raises two intriguing questions that remain to be addressed: 1) Is it 
possible to better direct treatment and predict prognosis in these individuals that 
exhibit (or not) an “aerobic reserve”?; and 2) What physiological mechanisms 
exist in some, but not all, CHF patients that allow them to access this “aerobic 
reserve”? (Azevedo et al., 2018). 
 
To address the first question, whether improved findings from the RISE-95 can 
better direct treatment and predict prognosis in individuals that exhibit an 
“aerobic reserve”, we compared the clinical characteristics of “responders” to 
“non-responders” from the RISE-95 test. Despite being younger and having less 
severe symptoms, as evidenced by a lower NYHA classification, “responders”, 
who exhibited an “aerobic reserve”, had more hospitalisations in the follow-up 
period. Therefore it would appear paradoxically that this “aerobic reserve” is 
actually predictive of a poorer prognosis. As such, these initial data would 
indicate “responder” patients to the RISE-95 test would require more urgent and 
aggressive clinical treatment and management. 
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To help answer the second question, we can simply probe the question whether 
some CHF and D-HF patients exhibit a limitation to exercise that may be acutely 
alleviated. This limitation may be of central origin (thereby reducing convective 
O2 delivery), or a peripheral mechanism (thus reducing microvascular O2 
diffusion and/or mitochondria O2 utilization). Therefore a better understanding of 
the mechanisms underpinning this limitation could potentially yield novel 
therapeutic targets to treat exercise intolerance in these patients. To provide 
insight into this, the RISE-95 test showed that “responder” and “non-responder” 
patients exhibited several divergent cardiopulmonary responses between the 
two exercise phases. In particular, the “responders” increased both peak HR and 
O2 pulse in the SE phase of the protocol (Table 3.5), which provides evidence 
that these patients probably increase both skeletal muscle O2 delivery and 
extraction. The increase in O2 pulse indicates that, even with an increased peak 
HR, O2 consumption for each heartbeat also increased, possibly due to 
increased stroke volume, improved convective O2 delivery and/or increased 
mitochondrial O2 extraction and utilisation. Interestingly, even when all patients 
were assessed, there was a significant increase in O2 pulse between the two 
phases of the test despite no change in peak HR, and this may have contributed 
to a modest yet significant 0.5 mL·kg⁻1·min⁻1 increase in V̇O2peak (Table 3.2). 
Hence, these data support the hypothesis that exercise intolerance in CHF 
patients may be limited by varying mechanisms, including an intramuscular 
limitation in O2 extraction (Bowen et al., 2012b).  
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To further investigate an intramuscular limitation to O2 extraction in some 
patients, we compared 12 patients that had completed the RISE-95 test where 
we had obtained pectoralis major muscle biopsies. Interestingly, our findings 
revealed that patients with an “aerobic reserve” tended to exhibit mitochondrial 
dysfunction, as evidenced by a lower complex I-supported O2 flux (Figure 7.1). 
While speculative, these data provide initial evidence that a mitochondrial 
limitation residing at complex I may be overcome following the first RI exercise 
phase, thus allowing patients to access their “aerobic reserve” and achieve a 
higher V̇O2peak during the second SE bout. Therefore an improved understanding 
of the physiological mechanisms allowing access to this “aerobic reserve” in 
some patients would likely reveal therapeutic targets to reduce exercise 
intolerance. 
 
Figure 7.1. The relationship between complex I O2 flux and ΔV̇O2peak between 
the SE and RI phases of the RISE-95 test tended to be inversely correlated, 
thereby suggesting that patients with an “aerobic reserve” may be limited by a 
complex I-specific impairment.  
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7.3 What mechanisms contribute to skeletal muscle 
maladaptations in D-HF patients? 
To provide detailed insight into the potential mechanisms limiting skeletal muscle 
O2 extraction and/or O2 utilization in CHF and D-HF patients, direct pectoralis 
major muscle sampling was performed during routine pacemaker and ICD/CRT 
device implantations (Results II). We anticipated upper limb sampling would 
better mitigate against the potential confounding influences of detraining that 
often impact lower limb skeletal muscle in patients with CHF (Olsen et al., 2005; 
Reynolds et al., 2007; Rehn et al., 2012). Using high-resolution respirometry, we 
demonstrated that skeletal muscle mitochondrial respiration was significantly 
lower in D-HF patients compared to control, CHF and DM patients. However, the 
majority of these differences were negated after normalizing to mitochondrial 
content with the exception of complex I-supported OXPHOS. Consequently, we 
concluded that D-HF induces both qualitative as well as quantitative impairments 
to mitochondrial function. The respiratory control ratio (RCR), a measure of 
mitochondrial coupling at complex I, was also impaired in D-HF compared to 
CHF patients. Complex I-supported O2 flux closely correlated with V̇O2peak, which 
provided the first evidence of a novel mechanism that may mediate exercise 
intolerance in D-HF patients. We reinforced these finding in Results III, where we 
demonstrated that D-HF patients also exhibit similar mitochondrial impairments 
in the vastus lateralis muscle of the leg. As these mitochondrial impairments were 
of a similar degree and well correlated to the chest muscle and V̇O2peak, we 
concluded that a systemic mechanism is likely acting to limit whole-body exercise 
tolerance via reduced mitochondrial content and a complex I-specific myopathy.  
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7.3.1 Mitochondrial dysfunction 
7.3.1.1 Reduced mitochondrial content 
V̇O2peak measured at the limit of tolerance is dictated by the capacity of several 
integrative whole-body organ systems to uptake, transport, extract, and utilise 
atmospheric O2 for cellular ATP resynthesis that provides the necessary energy 
for repeated skeletal muscle contractions. In its most simplistic form, V̇O2peak is 
determined by the two products of the Fick equation: cardiac output (Q̇) and 
skeletal muscle O2 extraction. In healthy individuals, V̇O2peak is primarily limited 
by Q̇ and convective O2 delivery to the muscles (Mortensen et al., 2005; Saltin & 
Calbet, 2006) and therefore the capacity for skeletal muscle oxidative 
phosphorylation exceeds the capacity for O2 delivery (Boushel et al., 2011). 
However, diffusive O2 delivery (Roca et al., 1989) and mitochondrial O2 utilisation 
(McAllister & Terjung, 1990) have also been shown to significantly impact V̇O2peak 
in health, with both thought to provide a major limitation to exercise tolerance in 
CHF patients (Poole et al., 2018). Indeed this is supported by 31P MRS studies 
demonstrating that CHF patients have an impaired in vivo mitochondrial 
oxidative capacity (Wilson et al., 1985; Wiener et al., 1986; Massie et al., 1987a; 
Massie et al., 1987b; Rajagopalan et al., 1988; Mancini et al., 1989; Mancini et 
al., 1990; Stratton et al., 1994; van der Ent et al., 1998; Okita et al., 2001; Nakae 
et al., 2005). As similar findings have been reported in DM patients (Petersen et 
al., 2004; Schrauwen-Hinderling et al., 2007; Phielix et al., 2008; Bajpeyi et al., 
2011; Tecilazich et al., 2013), and given the current findings from this thesis, it 
may be speculated that a reduction in mitochondrial content represents a 
potential limitation to exercise tolerance in D-HF patients (i.e. by impairing O2 
extraction and limiting myocyte O2 diffusion/and or consumption). This is 
supported by the strong correlation between skeletal muscle mitochondrial 
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content and V̇O2peak (Holloszy & Coyle, 1984). Similarly, we also observed a 
significant positive correlation between a validated marker of mitochondrial 
content (i.e. complex IV activity (Larsen et al., 2012a)) and V̇O2peak (Figure 2.8). 
Given that mitochondrial OXPHOS is the primary pathway of aerobic ATP 
resynthesis, a reduction in mitochondrial content would be expected to reduce 
V̇O2peak.  
 
To further elucidate the mechanisms contributing to reduced mitochondrial 
content, we probed muscle fibre type isoforms as well as the mRNA expression 
of PGC-1α (Results IV). As previous studies have shown a shift in phenotype 
from mitochondria-rich type I oxidative fibres to type II glycolytic fibres in both 
CHF and DM (Sullivan et al., 1990; Schaufelberger et al., 1995; Massie et al., 
1996; Schaufelberger et al., 1997; Sullivan et al., 1997; Oberbach et al., 2006; 
Mogensen et al., 2007), we hypothesized that this fibre type switch may be an 
underlying pathway mediating reduced mitochondrial content in D-HF patients. 
Furthermore we also hypothesized that D-HF patients may have a reduced 
expression of the transcriptional coactivator PGC-1α, as this regulates 
mitochondrial biogenesis and is reduced in both CHF (Garnier et al., 2003; Zoll 
et al., 2006; Seiler et al., 2016) and DM (Sreekumar et al., 2002; Yang et al., 
2002; Mootha et al., 2003; Patti et al., 2003). Surprisingly, however, while this 
study did not observe a consistent fibre type shift to type II fibres, there was a 
tendency for PGC-1α expression to be reduced across the patient cohorts by 
~25%. Therefore further studies are required to elucidate the specific 
mechanisms contributing to reduced mitochondrial content in D-HF patients.  
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7.3.1.2 Complex I mitochondrial dysfunction 
Complex I and complex II are the two initial electron-accepting enzymes which 
enable ATP resynthesis via oxidative phosphorylation. Both of these complexes 
facilitate redox reactions that result in electrons being transported to complex IV, 
where O2 acts as the final electron acceptor. Of these two complexes, complex I 
has a higher phosphate-to-oxygen ratio, thus it resynthesizes more ATP per 
molecule O2 consumed (Hinkle, 2005). As such, complex I has a higher capacity 
for ATP resynthesis and any limitation in electron flow from complex I to complex 
IV has the potential to reduce proton translocation across the inner mitochondrial 
membrane and decrease the proton-motive force required for ATP resynthesis 
at complex V. Therefore an impairment in complex I is likely to reduce ATP 
resynthesis and limit exercise tolerance. Aside from a quantitative decrease in 
mitochondrial content, this thesis also observed a decrease in qualitative 
complex I function in D-HF patients, thereby suggesting that electron flow is 
impaired through this complex. Thereafter, we measured the gene expression of 
two key subunits of complex I (NDUFS1 and NDUFS3) that are involved in 
transporting electrons following NADH oxidation to the electron carrier 
ubiquinone. Of these, we found a lower gene expression of NDUFS1, which is 
the largest subunit of complex I (Hirst, 2013). Hence, it may be postulated that 
D-HF impairs complex I function, possibly by impacting NDUFS1, which 
subsequently decreases electron flow and oxidative ATP resynthesis to limit 
exercise tolerance.  
 
 
207 
 
7.3.2 Atrophy 
Several previous studies have shown that skeletal muscle mass is reduced in 
CHF and DM (Anker et al., 1997; Park et al., 2006; Park et al., 2009; Kim et al., 
2010; Leenders et al., 2013; Kim et al., 2014) and this contributes to exercise 
intolerance, in terms of reduced muscle strength and endurance (Minotti et al., 
1993; Cetinus et al., 2005; Park et al., 2006; Park et al., 2007; Fulster et al., 
2013; Almurdhi et al., 2016; Almurdhi et al., 2017). This reduction in muscle mass 
has been attributed to fibre atrophy i.e. a reduction in the fibre cross-sectional 
area in both CHF and DM (Almond & Enser, 1984; Lipkin et al., 1988; Mancini et 
al., 1989; Sullivan et al., 1990; Massie et al., 1996; Delp et al., 1997; Xu et al., 
1998; Larsen et al., 2002; Li et al., 2007; Yu et al., 2008; Kemp et al., 2009). 
Importantly, skeletal muscle wasting and weakness are associated with reduced 
V̇O2peak (Fulster et al., 2013), insulin resistance (Park et al., 2006; Doehner et al., 
2015) as well as an increased risk for hospitalisations and mortality (Anker et al., 
1997; Anker et al., 2003; Rossignol et al., 2015). In the current thesis, we 
identified that fibre atrophy was type II specific in D-HF patients (Results IV). This 
finding has been previously reported in both CHF (Sullivan et al., 1990; Xu et al., 
1998; Li et al., 2007; Yu et al., 2008) and DM (Almond & Enser, 1984; Kemp et 
al., 2009). As type II fibres are larger and primarily support fast rapid contractions 
(Schiaffino & Reggiani, 2011), a type II fibre-specific atrophy likely contributes to 
muscle wasting and reduced skeletal muscle power and force generating 
capacity observed in both CHF and DM (Buller et al., 1991; Minotti et al., 1991; 
Minotti et al., 1992; Harrington et al., 1997; Sayer et al., 2005; Park et al., 2006; 
Park et al., 2007; Toth et al., 2010; Volpato et al., 2012; Leenders et al., 2013; 
Almurdhi et al., 2016). Indeed, during the ageing process, type II fibre atrophy 
has been implicated in the decline of functional capacity (Deschenes, 2004; 
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Brunner et al., 2007; Picard et al., 2011a; Nilwik et al., 2013; Murgia et al., 2017). 
Therefore type II fibre-specific atrophy likely contributes to the greater exercise 
intolerance observed in D-HF patients. Nevertheless, future studies are required 
to examine how D-HF impacts upon the numerous pathways involved in muscle 
protein synthesis and degradation.  
 
7.3.3 Capillary rarefaction 
In addition to type II fibre atrophy, we also observed a type II fibre-specific 
capillary rarefaction (Results IV). This reduction in capillarity has the potential to 
reduce both convective and diffusive O2 delivery to the mitochondria, thereby 
potentially decreasing V̇O2peak, as previously shown (Roca et al., 1989). Several 
previous studies have shown a reduced skeletal muscle capillarisation in both 
CHF and DM (Marin et al., 1994; Schaufelberger et al., 1995; Schaufelberger et 
al., 1997; Duscha et al., 1999; Nusz et al., 2003; Williams et al., 2004; Groen et 
al., 2014). However, the majority of these studies have relied on global indices 
of capillarity that are not as sensitive as localised indices, which give an 
indication of fibre-type specific O2 delivery (Al-Shammari et al., 2014). This 
reduction in capillarity, possibly in combination with endothelial dysfunction and 
sympathetic vasoconstriction, which both occur in the microvasculature of DM 
and CHF patients (Bauer et al., 2007; Muniyappa & Sowers, 2013; Piepoli & 
Crisafulli, 2014; Poole et al., 2018), may impair O2 delivery further. This localised 
tissue hypoxic is known to deactivate complex I (Galkin et al., 2009) and may 
also contribute to the mitochondrial complex I impairments we observed in the 
D-HF patients. Nevertheless further research is required to ascertain if a fibre 
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type-specific capillary rarefaction does actually induce localised tissue hypoxia 
and deactivate complex I in D-HF.  
 
7.4 What upstream pathways possibly contribute to 
mitochondrial dysfunction and fibre atrophy? 
Several studies have implicated oxidative stress in both fibre atrophy and 
mitochondrial dysfunction in both CHF and DM (Bonnard et al., 2008; Koves et 
al., 2008; Anderson et al., 2009; Ohta et al., 2011). Therefore we determined 
mitochondrial ROS production and mitochondrial antioxidant enzyme gene 
expression in Results IV. This demonstrated that D-HF patients exhibit increased 
mitochondrial ROS generation and a reduced gene expression of manganese 
SOD2, a matrix-specific antioxidant. Several distinct pathways involved in CHF 
and DM are known to induce oxidative stress, atrophy and mitochondrial 
dysfunction. Given that these pathways represent potential therapeutic targets 
in D-HF patients, each of these warrant further discussion.  
 
7.4.1 Does oxidative stress contribute to complex I mitochondrial 
dysfunction? 
One hypothesis generated from this thesis is that increased oxidative stress 
induces a mitochondrial complex I specific myopathy in D-HF. Given that 
complex I function, the respiratory control ratio (RCR), and NDUFS1 gene 
expression were all lower in parallel to elevated mitochondrial ROS production 
in D-HF compared to CHF, it may be speculated that increased mitochondrial 
ROS production damages the large complex I subunit NDUFS1. NDUFS1 
damage would be predicted to limit the capacity of the iron-sulphur chains of 
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complex I to transfer electrons from NADH oxidation to the ubiquinone binding 
site and electrons may react with O2 instead to form superoxide anion (O2·-). In 
theory, this could create a vicious cycle between complex I damage and 
increased mitochondrial ROS production. Indeed complex I inhibition has 
previously been shown to increase mitochondrial ROS production (Li et al., 
2003a). Furthermore, our finding that ROS production was greatest with complex 
I substrates supports such a process and this is consistent with the finding that 
increased ROS production is associated with a decreased protein abundance of 
complex I subunits in insulin-resistant individuals (Lefort et al., 2010). Given that 
many previous studies in DM and CHF have demonstrated that increased 
circulating angiotensin II, inflammation, hyperglycaemia- and hyperlipidaemia-
induced substrate overload all contribute to oxidative stress, mitochondrial 
dysfunction and fibre atrophy, it is worth discussing how each of these pathways 
may interact in D-HF patients.  
 
7.4.2 Role of circulating pro-inflammatory cytokines in D-HF 
Both CHF and DM are associated with a chronically increased concentration of 
circulating and muscle pro-inflammatory cytokines, including tumour necrosis 
factor-α (TNF-α) and the interleukins (IL), IL-1β and IL-6 (Gielen et al., 2003; 
Donath & Shoelson, 2011; Fulster et al., 2013; Esser et al., 2014; Lackey & 
Olefsky, 2016; Seiler et al., 2016; Lavine & Sierra, 2017; von Haehling et al., 
2017). These inflammatory cytokines induce oxidative stress by increasing ROS 
production in mitochondria as well as via NADPH oxidase and NOS (Supinski & 
Callahan, 2007). Additionally, inflammation and oxidative stress promote atrophy 
via the ubiquitin-proteasome system, which is activated by the nuclear factor-κB 
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(NF-κB)-inhibitor of κB kinase (IκK) signalling pathway (Li et al., 1998; Reid et 
al., 2002; Li et al., 2003b; Cai et al., 2004; Hunter & Kandarian, 2004; Tantiwong 
et al., 2010; Jackman et al., 2013) as well as the p38 mitogen activated protein 
kinase pathway (Li et al., 2005). This ubiquitin-proteasome pathway is 
coordinated by some key E3 ubiquitin-ligases, which include muscle RING finger 
1 (MuRF1) and muscle atrophy F-box (MAFbx)/Atrogin1 (Bodine et al., 2001; 
Gomes et al., 2001). These E3 ligases, which are upregulated by the forkhead 
box O1 (FOXO1) and FOXO3 transcription factors (Kamei et al., 2004; Sandri et 
al., 2004), promote muscle catabolism by increasing ubiquitin conjugation to 
muscle proteins that are to be degraded by the proteasome pathway (Bodine & 
Baehr, 2014). In CHF and DM, there is evidence that inflammation and oxidative 
stress upregulate the ubiquitin-proteasome system and promote atrophy (Fulster 
et al., 2013; Bechara et al., 2014; Cleasby et al., 2016; Seiler et al., 2016). 
Furthermore, inducible NOS (iNOS) promotes atrophy via apoptosis and this is 
associated with exercise intolerance in CHF (Adams et al., 1997; Adams et al., 
1999; Hambrecht et al., 1999a; Vescovo et al., 2000). Finally, CHF and DM have 
also been associated with a reduced expression of several catabolic protein 
synthesis pathways, including insulin-like growth factor-1 (Hambrecht et al., 
2002) and AKT phosphorylation (Wang et al., 2006). Collectively, therefore, it 
may be postulated that increased inflammation and oxidative stress in D-HF 
patients contribute to mitochondrial dysfunction and fibre atrophy.  
 
7.4.3 Role of hyperglycaemia and hyperlipidaemia in D-HF 
It has been suggested that the chronic hyperlipidaemia and hyperglycaemia 
associated with DM and insulin-resistant states promotes mitochondrial 
212 
 
substrate overload, which results in electrons being diverted towards O2·- 
formation (Muoio, 2014). Such excessive O2·- formation, in combination with a 
decrease in antioxidant defences, as evidenced by a decreased SOD2 gene 
expression in this thesis, may explain the greater ROS production and 
mitochondrial dysfunction observed in the D-HF patients. Indeed, it has been 
demonstrated that diet-induced substrate overload promotes mitochondrial 
dysfunction and oxidative stress which interfere with insulin signalling pathways 
(Bonnard et al., 2008; Koves et al., 2008; Anderson et al., 2009). The prevailing 
hypothesis is that mitochondrial dysfunction and oxidative stress precede insulin 
resistance by reducing the capacity to oxidize free fatty acids, which 
subsequently leads to the accumulation of ectopic intramyocellular lipids (IMCLs) 
that interfere with insulin signalling pathways (Schrauwen-Hinderling et al., 2007; 
Muoio, 2010; Szendroedi et al., 2011; Hoeks & Schrauwen, 2012). This inhibition 
of the insulin signalling pathway downregulates muscle glucose transport and 
phosphorylation thereby promoting insulin resistance (Roden et al., 1996). 
Recent studies in D-HF patients have shown that this pathway may be involved, 
as evidenced from lower SOD2 enzyme activity levels accompanied with 
increased markers of oxidative stress, including protein carbonylation and 
nitrotyrosine residue formation (Ramirez-Sanchez et al., 2013).  
 
In addition to mitochondrial dysfunction, impaired insulin signalling has been 
implicated in skeletal muscle atrophy. For instance, suppression of the insulin 
signalling pathway in a db/db mouse model has been shown to phosphorylate 
FOXO transcriptions factors and increase the expression of MuRF1 and MAFbx 
(Wang et al., 2006). Furthermore, in CHF patients, insulin resistance alone is 
associated with reduced muscle strength (Doehner et al., 2015). Therefore, 
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given that mitochondrial ROS production is increased in type II fibres (Anderson 
& Neufer, 2006), and oxidative stress is implicated in impaired insulin signalling 
and atrophy, it may be hypothesised that the type II fibre-specific atrophy 
observed in D-HF patients in the current study was induced by ROS.  
 
The chronic hyperglycaemia associated with D-HF also likely exerts several 
deleterious effects on many of the integrative pathways involved in skeletal 
muscle mitochondrial oxygen consumption. Aside from potentially interfering with 
intracellular metabolic pathways, hyperglycaemia is known to impair micro- and 
macrovascular function. In particular, hyperglycaemia is known to induce 
endothelial dysfunction, which subsequently impairs vasodilation to peripheral 
tissues and decreases glucose uptake. Furthermore endothelial dysfunction is 
associated with microvascular complications, such as retinopathy and 
neuropathy, as well as the macrovascular development of atherosclerosis. 
However, there is currently limited research into how hyperglycaemia-induced 
endothelial dysfunction impacts upon the microvasculature and skeletal muscle 
mitochondrial function in D-HF patients. Therefore further research is warranted 
to assess the role of endothelial dysfunction in the pathogenesis of D-HF.  
 
7.4.4 Role of angiotensin II in D-HF 
One potentially unifying mechanism by which both CHF and DM may contribute 
to oxidative stress, mitochondrial dysfunction and fibre atrophy is the overactivity 
of the renin-angiotensin aldosterone system (RAAS) seen in these conditions 
(Henriksen et al., 2011; Tsutsui et al., 2011). CHF increases both peripheral and 
central angiotensin II (Ang II) expression and plasma renin activity to modulate 
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sympathetic activity (Zucker et al., 2004) whilst Ang II is also increased in DM by 
hyperglycaemia-induced oxidative stress (Dikalov & Nazarewicz, 2013). In each 
case, Ang II binds to receptors on the skeletal muscle membrane to activate 
NADPH oxidase, which produces O2·- by the one-electron reduction of O2 and 
oxidation of NADPH (Wei et al., 2006; Dikalov & Nazarewicz, 2013). This 
pathway decreases insulin signalling in myotubes, a process which was negated 
by the AT1R and NADPH oxidase inhibitors, losartan and apocynin, and with 
small interfering RNA (siRNA) targeted against p47phox, a cytosolic subunit of 
NADPH oxidase (Wei et al., 2006). Interestingly, this same pathway has been 
implicated in diaphragm muscle contractile dysfunction (Ahn et al., 2015; Bost et 
al., 2015) as well as mitochondrial dysfunction (Ohta et al., 2011) in animal 
models of CHF. In two of these studies, RAAS overactivation enhanced skeletal 
muscle oxidative stress by increased NADPH oxidase activity, which 
subsequently decreased insulin-stimulated serine phosphorylation of Akt and 
glucose transporter-4 translocation to the cell membrane, resulting in insulin 
resistance (Wei et al., 2006; Ohta et al., 2011). Furthermore, Ang II inhibition with 
olmesartan has also been shown to improve exercise capacity in DM mice by 
attenuating mitochondrial dysfunction induced by oxidative stress (Takada et al., 
2013).  
 
Additionally, Ang II is known to promote muscle atrophy via FOXO increased 
expression of MuRF1 and MAFbx (Sukhanov et al., 2011; Yoshida et al., 2013; 
Du Bois et al., 2015; Yoshida & Delafontaine, 2015). Indeed, Ang II 
administration to mice has also been shown to induce mitochondrial dysfunction, 
including reduced complex I and citrate synthase activities, in addition to fibre 
atrophy (Kadoguchi et al., 2015). Collectively, these studies suggest that 
215 
 
increased concentrations of circulating Ang II may play a role in mitochondrial 
dysfunction, increased ROS and fibre atrophy, all of which were observed in the 
current study in D-HF patients.  
 
7.4.5 Is ROS-mediated complex I dysfunction caused by hypoxic 
deactivation of the enzyme? 
ROS can directly inhibit complex I when it has undergone a structural 
conformational change from the active to deactive form of the enzyme (Clementi 
et al., 1998; Gostimskaya et al., 2006; Galkin & Moncada, 2007). Prolonged 
hypoxia has been shown to induce deactivation (Galkin et al., 2009) by exposing 
a cysteine residue, Cys39, located within a hydrophilic loop connecting two 
transmembrane helices on the matrix side of the mitochondrially encoded ND3 
subunit of complex I (Galkin et al., 2008). This exposure renders complex I 
susceptible to covalent modifications by ROS products (Galkin et al., 2008). It 
has been hypothesised that these modifications produce a shift in the ND3 
subunit loop which disrupts the quinone binding site, where electrons are 
accepted by ubiquinone, reducing it to ubiquinol (Galkin & Moncada, 2017). As 
this redox reaction is catalytically coupled with proton translocation (Ripple et al., 
2013), this deactivation of complex I reduces electron flow and the mitochondrial 
membrane potential, which consequently decrease O2 flux and ATP resynthesis. 
It may be hypothesised that the decreased type II fibre-specific capillarity 
observed in D-HF patients in the current thesis may promote hypoxia, thus 
encouraging the active-deactive transition of complex I. Therefore it may be 
postulated that diffusive skeletal muscle O2 delivery may be compromised in D-
HF patients, reducing tissue O2 levels and deactivating complex I. Figure 7.2 
provides an overview of the potential pathways that may contribute to 
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mitochondrial dysfunction, oxidative stress, fibre atrophy, and, ultimately, 
exercise intolerance in D-HF patients.  
 
Figure 7.2. General overview of putative pathways that may mediate exercise 
intolerance in D-HF patients, as derived from the data collected in this thesis. 
See text for expanded details.  
 
7.5 Experimental considerations and limitations 
7.5.1 Methodology 
Ex vivo measures of mitochondrial function using high-resolution respirometry 
are thought to reflect mitochondrial function and metabolism in vivo. Previous 
studies have validated this assumption by showing that in vivo measurements of 
mitochondrial function strongly correlate with ex vivo measurements obtained 
from high-resolution respirometry using both isolated mitochondria (Lanza et al., 
2011) and saponin-permeabilized muscle fibres (Ryan et al., 2014). 
Nevertheless, it may be argued that the artificial hyperoxygenated environment 
and substrate saturation protocol employed in this current thesis is not reflective 
of in vivo mitochondrial function. Of particular relevance is the bolus saturating 
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concentration of ADP (2.5 mM), which is not accurately reflective of in vivo 
function where ADP concentrations are in constant flux as dictated by the 
demand for ATP resynthesis. Therefore future experiments, as recently 
demonstrated (Gonzalez-Freire et al., 2018), may wish to incorporate several 
titrations of ADP that cover a spectrum of more physiologically-relevant ADP 
concentrations seen in vivo. Nevertheless, given that our methodology was 
consistent across all patient groups, the finding of reduced complex I OXPHOS 
is still of significance. Indeed, previous studies have shown that in situ 
mitochondrial respiration in the presence of saturating ADP significantly 
correlates with V̇O2peak across a range of athletic abilities (Zoll et al., 2002). To 
corroborate the current findings, future studies should assess in vivo skeletal 
muscle mitochondrial function using 31P MRS in D-HF patients. 
 
7.5.2 Patients 
Clinical human research is often impacted by marked heterogeneity between 
patients. This limits studies, such as the current thesis, to observational 
evidence, which can demonstrate associations but not prove causality. As with 
all human studies, we aimed to match the four patient cohorts as best as 
possible, in terms of age, sex and weight, to ameliorate the confounding effects 
that each of these are known to have on skeletal muscle mitochondrial function 
(Trounce et al., 1989; Duscha et al., 2001; Lesnefsky & Hoppel, 2006; 
Karakelides et al., 2010; Murgia et al., 2017). Nevertheless, future studies may 
wish to employ animal models to acquire better mechanistic insights in to the 
effects of D-HF on skeletal muscle mitochondrial function, atrophy, capillarisation 
and oxidative stress. 
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7.5.3 Drug therapy 
Medications administered to patients always have potential to confound research 
findings. Of particular note in the current thesis is the drug metformin, which has 
been shown to inhibit complex I (Owen et al., 2000; Brunmair et al., 2004a; 
Brunmair et al., 2004b) and reduce in vivo and ex vivo skeletal muscle oxidative 
capacity in a rat model of DM (Wessels et al., 2014). However, human studies 
with DM patients have shown that metformin does not inhibit complex I (Larsen 
et al., 2012b). In patients that provided pectoralis major samples, metformin use 
did not affect complex I O2 flux in either the DM or D-HF cohorts (both P > 0.05; 
Figure 7.3). As such, these provide strong evidence that metformin cannot 
explain the severe mitochondrial deficits we observed in D-HF patients.  
 
 
Figure 7.3. Metformin use did not affect complex I O2 flux in either DM or D-HF 
patients. P > 0.05 using unpaired Student’s t-tests.  
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7.6 Clinical implications and future directions 
The first study of this thesis demonstrated the efficacy of a novel exercise 
protocol that arguably should be used in clinical settings in CHF patients. Firstly, 
the RISE-95 protocol is a more accurate method for confirming V̇O2max in CHF 
patients. This is of significant clinical importance as V̇O2max can accurately inform 
on the prognosis/symptomatic status of the patient and guide future therapeutic 
treatment(s) and/or clinical intervention(s). Secondly, this test may be used to 
delineate patients that have an “aerobic reserve”.  
 
Further research is required to identify the pathways that contribute to 
mitochondrial impairments and how these may be ameliorated. Exercise training 
remains a significant therapy for increasing mitochondrial content via contractile-
induced upregulation of mitochondrial biogenesis pathways (Essig, 1996; Baar 
et al., 2002). Several studies have shown the beneficial effects of regular aerobic 
exercise training on skeletal muscle mitochondrial function and content as well 
as metabolic flexibility and insulin sensitivity in DM patients (Toledo et al., 2007; 
Meex et al., 2010; Phielix et al., 2010; Little et al., 2011). Similarly, in CHF 
patients, exercise training can improve mitochondrial function (Hambrecht et al., 
1995; Hambrecht et al., 1997; Santoro et al., 2002; Williams et al., 2007; Esposito 
et al., 2011) and improve outcomes in terms of mortality and hospitalisations 
(O’Connor et al., 2009). These improvements have been associated with 
exercise-induced anti-inflammatory (Gielen et al., 2003; Gielen et al., 2005), anti-
oxidative (Linke et al., 2005; Brinkmann et al., 2012; de Oliveira et al., 2012), and 
anti-atrophic (Lenk et al., 2012) effects. Exercise training can also increase 
V̇O2peak in D-HF patients, although this is comparably blunted compared to CHF 
patients (Banks et al., 2016).  
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Given the close associations between Ang II and oxidative stress with 
mitochondrial dysfunction and fibre atrophy, previous studies in CHF and DM 
animal models have demonstrated that inhibiting these pathways can improve 
exercise tolerance (Ohta et al., 2011; Takada et al., 2013; Okutsu et al., 2014). 
Therefore future studies may wish to investigate the effects of antioxidant 
treatments on skeletal muscle mitochondrial function and exercise intolerance in 
D-HF patients. However, antioxidant supplements should be used cautiously to 
avoid inhibiting the exercise training adaptations that low levels of ROS are 
known to induce (Gomez-Cabrera et al., 2008; Mankowski et al., 2015).  
 
In addition to these interventional studies, future studies in animal models are 
required to further elucidate the mechanisms of mitochondrial dysfunction in D-
HF, particularly in terms of identifying the pathways reducing complex I function, 
as this may be considered a potential therapeutic target. Additionally, it may be 
possible to determine the aetiology and pathophysiology behind the 
development of D-HF by inducing both DM and CHF in separate animal groups 
and chronicling the development and incidence of the other condition. This may 
potentially uncover what mechanisms drive the close association between these 
two conditions.  
 
7.7 Thesis conclusions 
The studies outlined in this thesis have revealed novel findings related to the 
aetiology of diabetic heart failure. In the first study, a novel exercise protocol 
(RISE-95) was employed to demonstrate that nearly half of CHF and D-HF 
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patients have an “aerobic reserve”, but surprisingly these patients were 
characterised by a poorer prognosis. An improved understanding of the 
mechanisms underlying this “aerobic reserve” may potentially lead to the 
development of pharmacological treatments that can acutely increase V̇O2peak in 
order to ameliorate symptoms of exercise intolerance in these patients.  
 
Given that patients tested in the first study exhibited evidence of intramuscular 
impairments, the second and third studies of this thesis obtained skeletal muscle 
biopsies to identify that D-HF patients present with both quantitative and 
qualitative mitochondrial impairments, the latter of which resides at complex I. 
Comparable impairments were observed in both leg and chest muscle, 
suggesting that a systemic factor may be mediating these effects. Importantly, 
these mitochondrial impairments correlated with V̇O2peak, thereby suggesting that 
mitochondrial dysfunction may underlie the exacerbated exercise intolerance in 
D-HF patients.  
 
The final study of this thesis assessed potential mechanisms underlying 
mitochondrial dysfunction in D-HF. This study identified that D-HF patients have 
type II fibre-specific atrophy and capillary rarefaction as well as an increase in 
mitochondrial ROS production. Furthermore this study also identified 
decrements in the expression of complex I and a mitochondrial antioxidant gene 
in D-HF patients. These findings suggest that certain pathways involved in both 
CHF and DM, such as chronic inflammation, elevated Ang II concentrations, and 
substrate overload may coalesce to increase oxidative stress, mitochondrial 
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dysfunction and fibre atrophy, all of which likely contribute to exercise intolerance 
(Figure 7.2).  
 
Collectively, the evidence obtained from these studies demonstrate that D-HF 
patients exhibit various skeletal muscle impairments, many of which likely 
contribute to exercise intolerance. It is now of paramount importance to further 
elucidate the mechanisms and pathways contributing to these impairments such 
that effective therapeutic treatments can be developed to improve the symptoms, 
prognosis and outcomes in the growing population of D-HF patients
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